"","Sample ID","Gene","Variant1","Variant2","Variant3","allele_count","Drug","Affected Subgroups+","Description of Gene-Drug Interaction","data.name","data.chr.name"
"1","R208","SLCO1B1","*5","g.37041T>C","0",1,"Simvastatin","521 TC or 521 CC (intermediate or poor function transporters)","Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.","solute carrier organic anion transporter family member 1B1","chr12"
"2","R208","SLCO1B1","*5","g.37041T>C","0",1,"Elagolix","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"3","R208","SLCO1B1","*5","g.37041T>C","0",1,"Rosuvastatin","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"4","R231","SLCO1B1","*5","g.37041T>C","0",1,"Simvastatin","521 TC or 521 CC (intermediate or poor function transporters)","Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.","solute carrier organic anion transporter family member 1B1","chr12"
"5","R231","SLCO1B1","*5","g.37041T>C","0",1,"Elagolix","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"6","R231","SLCO1B1","*5","g.37041T>C","0",1,"Rosuvastatin","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"7","R232","SLCO1B1","*5","g.37041T>C","0",1,"Simvastatin","521 TC or 521 CC (intermediate or poor function transporters)","Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.","solute carrier organic anion transporter family member 1B1","chr12"
"8","R232","SLCO1B1","*5","g.37041T>C","0",1,"Elagolix","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"9","R232","SLCO1B1","*5","g.37041T>C","0",1,"Rosuvastatin","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"10","R233","SLCO1B1","*5","g.37041T>C","0",1,"Simvastatin","521 TC or 521 CC (intermediate or poor function transporters)","Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.","solute carrier organic anion transporter family member 1B1","chr12"
"11","R233","SLCO1B1","*5","g.37041T>C","0",1,"Elagolix","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"12","R233","SLCO1B1","*5","g.37041T>C","0",1,"Rosuvastatin","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"13","R70","SLCO1B1","*5","g.37041T>C","0",1,"Simvastatin","521 TC or 521 CC (intermediate or poor function transporters)","Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.","solute carrier organic anion transporter family member 1B1","chr12"
"14","R70","SLCO1B1","*5","g.37041T>C","0",1,"Elagolix","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"15","R70","SLCO1B1","*5","g.37041T>C","0",1,"Rosuvastatin","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"16","R83","SLCO1B1","*5","g.37041T>C","0",1,"Simvastatin","521 TC or 521 CC (intermediate or poor function transporters)","Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.","solute carrier organic anion transporter family member 1B1","chr12"
"17","R83","SLCO1B1","*5","g.37041T>C","0",1,"Elagolix","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"18","R83","SLCO1B1","*5","g.37041T>C","0",1,"Rosuvastatin","521 CC (poor function transporters)","Results in higher systemic concentrations.","solute carrier organic anion transporter family member 1B1","chr12"
"19","H47","CYP3A5","*7","g.27131_27132insT","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"20","R217","CYP3A5","*7","g.27131_27132insT","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"21","R63","CYP3A5","*7","g.27131_27132insT","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"22","R81","CYP3A5","*7","g.27131_27132insT","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"23","V151","CYP3A5","*7","g.27131_27132insT","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"24","V154","CYP3A5","*7","g.27131_27132insT","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"25","H46","CYP3A5","*7","g.27131_27132insT","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"26","R206","CYP2D6","*4","*10","g.100C>T",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"27","R206","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"28","R206","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"29","R206","CYP2D6","*4","*10","g.100C>T",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"30","R206","CYP2D6","*4","*10","g.100C>T",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"31","R206","CYP2D6","*4","*10","g.100C>T",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"32","R206","CYP2D6","*4","*10","g.100C>T",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"33","R206","CYP2D6","*4","*10","g.100C>T",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"34","R206","CYP2D6","*4","*10","g.100C>T",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"35","R206","CYP2D6","*4","*10","g.100C>T",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"36","R206","CYP2D6","*4","*10","g.100C>T",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"37","R206","CYP2D6","*4","*10","g.100C>T",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"38","R206","CYP2D6","*4","*10","g.100C>T",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"39","R206","CYP2D6","*4","*10","g.100C>T",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"40","R206","CYP2D6","*4","*10","g.100C>T",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"41","R206","CYP2D6","*4","*10","g.100C>T",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"42","R206","CYP2D6","*4","*10","g.100C>T",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"43","R206","CYP2D6","*4","*10","g.100C>T",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"44","R206","CYP2D6","*4","*10","g.100C>T",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"45","R206","CYP2D6","*4","*10","g.100C>T",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"46","R206","CYP2D6","*4","*10","g.100C>T",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"47","R206","CYP2D6","*4","*10","g.100C>T",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"48","R206","CYP2D6","*4","*10","g.100C>T",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"49","R206","CYP2D6","*4","*10","g.100C>T",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"50","R206","CYP2D6","*4","*10","g.100C>T",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"51","R206","CYP2D6","*4","*10","g.100C>T",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"52","R206","CYP2D6","*4","*10","g.100C>T",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"53","R206","CYP2D6","*4","*10","g.100C>T",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"54","R206","CYP2D6","*4","*10","g.100C>T",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"55","R206","CYP2D6","*4","*10","g.100C>T",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"56","R206","CYP2D6","*4","*10","g.100C>T",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"57","R206","CYP2D6","*4","*10","g.100C>T",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"58","R206","CYP2D6","*4","*10","g.100C>T",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"59","R206","CYP2D6","*4","*10","g.100C>T",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"60","R206","CYP2D6","*4","*10","g.100C>T",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"61","R206","CYP2D6","*4","*10","g.100C>T",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"62","R206","CYP2D6","*4","*10","g.100C>T",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"63","R206","CYP2D6","*4","*10","g.100C>T",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"64","R206","CYP2D6","*4","*10","g.100C>T",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"65","R206","CYP2D6","*4","*10","g.100C>T",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"66","R206","CYP2D6","*4","*10","g.100C>T",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"67","R206","CYP2D6","*4","*10","g.100C>T",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"68","R206","CYP2D6","*4","*10","g.100C>T",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"69","R206","CYP2D6","*4","*10","g.100C>T",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"70","R206","CYP2D6","*4","*10","g.100C>T",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"71","R206","CYP2D6","*4","*10","g.100C>T",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"72","R206","CYP2D6","*4","*10","g.100C>T",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"73","R206","CYP2D6","*4","*10","g.100C>T",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"74","R206","CYP2D6","*4","*10","g.100C>T",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"75","R211","CYP2D6","*4","*10","g.100C>T",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"76","R211","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"77","R211","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"78","R211","CYP2D6","*4","*10","g.100C>T",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"79","R211","CYP2D6","*4","*10","g.100C>T",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"80","R211","CYP2D6","*4","*10","g.100C>T",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"81","R211","CYP2D6","*4","*10","g.100C>T",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"82","R211","CYP2D6","*4","*10","g.100C>T",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"83","R211","CYP2D6","*4","*10","g.100C>T",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"84","R211","CYP2D6","*4","*10","g.100C>T",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"85","R211","CYP2D6","*4","*10","g.100C>T",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"86","R211","CYP2D6","*4","*10","g.100C>T",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"87","R211","CYP2D6","*4","*10","g.100C>T",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"88","R211","CYP2D6","*4","*10","g.100C>T",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"89","R211","CYP2D6","*4","*10","g.100C>T",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"90","R211","CYP2D6","*4","*10","g.100C>T",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"91","R211","CYP2D6","*4","*10","g.100C>T",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"92","R211","CYP2D6","*4","*10","g.100C>T",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"93","R211","CYP2D6","*4","*10","g.100C>T",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"94","R211","CYP2D6","*4","*10","g.100C>T",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"95","R211","CYP2D6","*4","*10","g.100C>T",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"96","R211","CYP2D6","*4","*10","g.100C>T",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"97","R211","CYP2D6","*4","*10","g.100C>T",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"98","R211","CYP2D6","*4","*10","g.100C>T",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"99","R211","CYP2D6","*4","*10","g.100C>T",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"100","R211","CYP2D6","*4","*10","g.100C>T",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"101","R211","CYP2D6","*4","*10","g.100C>T",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"102","R211","CYP2D6","*4","*10","g.100C>T",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"103","R211","CYP2D6","*4","*10","g.100C>T",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"104","R211","CYP2D6","*4","*10","g.100C>T",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"105","R211","CYP2D6","*4","*10","g.100C>T",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"106","R211","CYP2D6","*4","*10","g.100C>T",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"107","R211","CYP2D6","*4","*10","g.100C>T",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"108","R211","CYP2D6","*4","*10","g.100C>T",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"109","R211","CYP2D6","*4","*10","g.100C>T",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"110","R211","CYP2D6","*4","*10","g.100C>T",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"111","R211","CYP2D6","*4","*10","g.100C>T",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"112","R211","CYP2D6","*4","*10","g.100C>T",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"113","R211","CYP2D6","*4","*10","g.100C>T",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"114","R211","CYP2D6","*4","*10","g.100C>T",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"115","R211","CYP2D6","*4","*10","g.100C>T",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"116","R211","CYP2D6","*4","*10","g.100C>T",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"117","R211","CYP2D6","*4","*10","g.100C>T",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"118","R211","CYP2D6","*4","*10","g.100C>T",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"119","R211","CYP2D6","*4","*10","g.100C>T",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"120","R211","CYP2D6","*4","*10","g.100C>T",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"121","R211","CYP2D6","*4","*10","g.100C>T",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"122","R211","CYP2D6","*4","*10","g.100C>T",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"123","R211","CYP2D6","*4","*10","g.100C>T",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"124","R212","CYP2D6","*4","*10","g.100C>T",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"125","R212","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"126","R212","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"127","R212","CYP2D6","*4","*10","g.100C>T",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"128","R212","CYP2D6","*4","*10","g.100C>T",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"129","R212","CYP2D6","*4","*10","g.100C>T",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"130","R212","CYP2D6","*4","*10","g.100C>T",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"131","R212","CYP2D6","*4","*10","g.100C>T",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"132","R212","CYP2D6","*4","*10","g.100C>T",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"133","R212","CYP2D6","*4","*10","g.100C>T",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"134","R212","CYP2D6","*4","*10","g.100C>T",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"135","R212","CYP2D6","*4","*10","g.100C>T",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"136","R212","CYP2D6","*4","*10","g.100C>T",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"137","R212","CYP2D6","*4","*10","g.100C>T",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"138","R212","CYP2D6","*4","*10","g.100C>T",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"139","R212","CYP2D6","*4","*10","g.100C>T",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"140","R212","CYP2D6","*4","*10","g.100C>T",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"141","R212","CYP2D6","*4","*10","g.100C>T",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"142","R212","CYP2D6","*4","*10","g.100C>T",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"143","R212","CYP2D6","*4","*10","g.100C>T",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"144","R212","CYP2D6","*4","*10","g.100C>T",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"145","R212","CYP2D6","*4","*10","g.100C>T",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"146","R212","CYP2D6","*4","*10","g.100C>T",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"147","R212","CYP2D6","*4","*10","g.100C>T",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"148","R212","CYP2D6","*4","*10","g.100C>T",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"149","R212","CYP2D6","*4","*10","g.100C>T",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"150","R212","CYP2D6","*4","*10","g.100C>T",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"151","R212","CYP2D6","*4","*10","g.100C>T",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"152","R212","CYP2D6","*4","*10","g.100C>T",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"153","R212","CYP2D6","*4","*10","g.100C>T",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"154","R212","CYP2D6","*4","*10","g.100C>T",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"155","R212","CYP2D6","*4","*10","g.100C>T",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"156","R212","CYP2D6","*4","*10","g.100C>T",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"157","R212","CYP2D6","*4","*10","g.100C>T",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"158","R212","CYP2D6","*4","*10","g.100C>T",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"159","R212","CYP2D6","*4","*10","g.100C>T",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"160","R212","CYP2D6","*4","*10","g.100C>T",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"161","R212","CYP2D6","*4","*10","g.100C>T",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"162","R212","CYP2D6","*4","*10","g.100C>T",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"163","R212","CYP2D6","*4","*10","g.100C>T",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"164","R212","CYP2D6","*4","*10","g.100C>T",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"165","R212","CYP2D6","*4","*10","g.100C>T",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"166","R212","CYP2D6","*4","*10","g.100C>T",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"167","R212","CYP2D6","*4","*10","g.100C>T",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"168","R212","CYP2D6","*4","*10","g.100C>T",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"169","R212","CYP2D6","*4","*10","g.100C>T",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"170","R212","CYP2D6","*4","*10","g.100C>T",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"171","R212","CYP2D6","*4","*10","g.100C>T",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"172","R212","CYP2D6","*4","*10","g.100C>T",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"173","R213","CYP2D6","*4","*10","g.100C>T",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"174","R213","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"175","R213","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"176","R213","CYP2D6","*4","*10","g.100C>T",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"177","R213","CYP2D6","*4","*10","g.100C>T",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"178","R213","CYP2D6","*4","*10","g.100C>T",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"179","R213","CYP2D6","*4","*10","g.100C>T",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"180","R213","CYP2D6","*4","*10","g.100C>T",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"181","R213","CYP2D6","*4","*10","g.100C>T",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"182","R213","CYP2D6","*4","*10","g.100C>T",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"183","R213","CYP2D6","*4","*10","g.100C>T",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"184","R213","CYP2D6","*4","*10","g.100C>T",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"185","R213","CYP2D6","*4","*10","g.100C>T",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"186","R213","CYP2D6","*4","*10","g.100C>T",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"187","R213","CYP2D6","*4","*10","g.100C>T",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"188","R213","CYP2D6","*4","*10","g.100C>T",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"189","R213","CYP2D6","*4","*10","g.100C>T",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"190","R213","CYP2D6","*4","*10","g.100C>T",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"191","R213","CYP2D6","*4","*10","g.100C>T",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"192","R213","CYP2D6","*4","*10","g.100C>T",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"193","R213","CYP2D6","*4","*10","g.100C>T",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"194","R213","CYP2D6","*4","*10","g.100C>T",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"195","R213","CYP2D6","*4","*10","g.100C>T",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"196","R213","CYP2D6","*4","*10","g.100C>T",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"197","R213","CYP2D6","*4","*10","g.100C>T",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"198","R213","CYP2D6","*4","*10","g.100C>T",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"199","R213","CYP2D6","*4","*10","g.100C>T",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"200","R213","CYP2D6","*4","*10","g.100C>T",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"201","R213","CYP2D6","*4","*10","g.100C>T",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"202","R213","CYP2D6","*4","*10","g.100C>T",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"203","R213","CYP2D6","*4","*10","g.100C>T",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"204","R213","CYP2D6","*4","*10","g.100C>T",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"205","R213","CYP2D6","*4","*10","g.100C>T",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"206","R213","CYP2D6","*4","*10","g.100C>T",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"207","R213","CYP2D6","*4","*10","g.100C>T",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"208","R213","CYP2D6","*4","*10","g.100C>T",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"209","R213","CYP2D6","*4","*10","g.100C>T",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"210","R213","CYP2D6","*4","*10","g.100C>T",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"211","R213","CYP2D6","*4","*10","g.100C>T",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"212","R213","CYP2D6","*4","*10","g.100C>T",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"213","R213","CYP2D6","*4","*10","g.100C>T",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"214","R213","CYP2D6","*4","*10","g.100C>T",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"215","R213","CYP2D6","*4","*10","g.100C>T",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"216","R213","CYP2D6","*4","*10","g.100C>T",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"217","R213","CYP2D6","*4","*10","g.100C>T",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"218","R213","CYP2D6","*4","*10","g.100C>T",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"219","R213","CYP2D6","*4","*10","g.100C>T",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"220","R213","CYP2D6","*4","*10","g.100C>T",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"221","R213","CYP2D6","*4","*10","g.100C>T",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"222","R218","CYP2D6","*4","*10","g.100C>T",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"223","R218","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"224","R218","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"225","R218","CYP2D6","*4","*10","g.100C>T",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"226","R218","CYP2D6","*4","*10","g.100C>T",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"227","R218","CYP2D6","*4","*10","g.100C>T",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"228","R218","CYP2D6","*4","*10","g.100C>T",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"229","R218","CYP2D6","*4","*10","g.100C>T",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"230","R218","CYP2D6","*4","*10","g.100C>T",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"231","R218","CYP2D6","*4","*10","g.100C>T",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"232","R218","CYP2D6","*4","*10","g.100C>T",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"233","R218","CYP2D6","*4","*10","g.100C>T",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"234","R218","CYP2D6","*4","*10","g.100C>T",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"235","R218","CYP2D6","*4","*10","g.100C>T",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"236","R218","CYP2D6","*4","*10","g.100C>T",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"237","R218","CYP2D6","*4","*10","g.100C>T",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"238","R218","CYP2D6","*4","*10","g.100C>T",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"239","R218","CYP2D6","*4","*10","g.100C>T",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"240","R218","CYP2D6","*4","*10","g.100C>T",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"241","R218","CYP2D6","*4","*10","g.100C>T",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"242","R218","CYP2D6","*4","*10","g.100C>T",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"243","R218","CYP2D6","*4","*10","g.100C>T",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"244","R218","CYP2D6","*4","*10","g.100C>T",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"245","R218","CYP2D6","*4","*10","g.100C>T",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"246","R218","CYP2D6","*4","*10","g.100C>T",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"247","R218","CYP2D6","*4","*10","g.100C>T",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"248","R218","CYP2D6","*4","*10","g.100C>T",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"249","R218","CYP2D6","*4","*10","g.100C>T",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"250","R218","CYP2D6","*4","*10","g.100C>T",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"251","R218","CYP2D6","*4","*10","g.100C>T",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"252","R218","CYP2D6","*4","*10","g.100C>T",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"253","R218","CYP2D6","*4","*10","g.100C>T",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"254","R218","CYP2D6","*4","*10","g.100C>T",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"255","R218","CYP2D6","*4","*10","g.100C>T",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"256","R218","CYP2D6","*4","*10","g.100C>T",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"257","R218","CYP2D6","*4","*10","g.100C>T",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"258","R218","CYP2D6","*4","*10","g.100C>T",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"259","R218","CYP2D6","*4","*10","g.100C>T",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"260","R218","CYP2D6","*4","*10","g.100C>T",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"261","R218","CYP2D6","*4","*10","g.100C>T",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"262","R218","CYP2D6","*4","*10","g.100C>T",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"263","R218","CYP2D6","*4","*10","g.100C>T",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"264","R218","CYP2D6","*4","*10","g.100C>T",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"265","R218","CYP2D6","*4","*10","g.100C>T",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"266","R218","CYP2D6","*4","*10","g.100C>T",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"267","R218","CYP2D6","*4","*10","g.100C>T",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"268","R218","CYP2D6","*4","*10","g.100C>T",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"269","R218","CYP2D6","*4","*10","g.100C>T",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"270","R218","CYP2D6","*4","*10","g.100C>T",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"271","R58","CYP2D6","*4","*10","g.100C>T",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"272","R58","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"273","R58","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"274","R58","CYP2D6","*4","*10","g.100C>T",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"275","R58","CYP2D6","*4","*10","g.100C>T",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"276","R58","CYP2D6","*4","*10","g.100C>T",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"277","R58","CYP2D6","*4","*10","g.100C>T",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"278","R58","CYP2D6","*4","*10","g.100C>T",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"279","R58","CYP2D6","*4","*10","g.100C>T",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"280","R58","CYP2D6","*4","*10","g.100C>T",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"281","R58","CYP2D6","*4","*10","g.100C>T",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"282","R58","CYP2D6","*4","*10","g.100C>T",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"283","R58","CYP2D6","*4","*10","g.100C>T",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"284","R58","CYP2D6","*4","*10","g.100C>T",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"285","R58","CYP2D6","*4","*10","g.100C>T",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"286","R58","CYP2D6","*4","*10","g.100C>T",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"287","R58","CYP2D6","*4","*10","g.100C>T",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"288","R58","CYP2D6","*4","*10","g.100C>T",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"289","R58","CYP2D6","*4","*10","g.100C>T",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"290","R58","CYP2D6","*4","*10","g.100C>T",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"291","R58","CYP2D6","*4","*10","g.100C>T",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"292","R58","CYP2D6","*4","*10","g.100C>T",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"293","R58","CYP2D6","*4","*10","g.100C>T",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"294","R58","CYP2D6","*4","*10","g.100C>T",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"295","R58","CYP2D6","*4","*10","g.100C>T",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"296","R58","CYP2D6","*4","*10","g.100C>T",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"297","R58","CYP2D6","*4","*10","g.100C>T",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"298","R58","CYP2D6","*4","*10","g.100C>T",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"299","R58","CYP2D6","*4","*10","g.100C>T",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"300","R58","CYP2D6","*4","*10","g.100C>T",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"301","R58","CYP2D6","*4","*10","g.100C>T",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"302","R58","CYP2D6","*4","*10","g.100C>T",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"303","R58","CYP2D6","*4","*10","g.100C>T",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"304","R58","CYP2D6","*4","*10","g.100C>T",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"305","R58","CYP2D6","*4","*10","g.100C>T",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"306","R58","CYP2D6","*4","*10","g.100C>T",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"307","R58","CYP2D6","*4","*10","g.100C>T",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"308","R58","CYP2D6","*4","*10","g.100C>T",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"309","R58","CYP2D6","*4","*10","g.100C>T",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"310","R58","CYP2D6","*4","*10","g.100C>T",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"311","R58","CYP2D6","*4","*10","g.100C>T",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"312","R58","CYP2D6","*4","*10","g.100C>T",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"313","R58","CYP2D6","*4","*10","g.100C>T",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"314","R58","CYP2D6","*4","*10","g.100C>T",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"315","R58","CYP2D6","*4","*10","g.100C>T",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"316","R58","CYP2D6","*4","*10","g.100C>T",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"317","R58","CYP2D6","*4","*10","g.100C>T",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"318","R58","CYP2D6","*4","*10","g.100C>T",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"319","R58","CYP2D6","*4","*10","g.100C>T",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"320","R61","CYP2D6","*4","*10","g.100C>T",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"321","R61","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"322","R61","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"323","R61","CYP2D6","*4","*10","g.100C>T",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"324","R61","CYP2D6","*4","*10","g.100C>T",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"325","R61","CYP2D6","*4","*10","g.100C>T",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"326","R61","CYP2D6","*4","*10","g.100C>T",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"327","R61","CYP2D6","*4","*10","g.100C>T",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"328","R61","CYP2D6","*4","*10","g.100C>T",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"329","R61","CYP2D6","*4","*10","g.100C>T",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"330","R61","CYP2D6","*4","*10","g.100C>T",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"331","R61","CYP2D6","*4","*10","g.100C>T",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"332","R61","CYP2D6","*4","*10","g.100C>T",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"333","R61","CYP2D6","*4","*10","g.100C>T",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"334","R61","CYP2D6","*4","*10","g.100C>T",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"335","R61","CYP2D6","*4","*10","g.100C>T",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"336","R61","CYP2D6","*4","*10","g.100C>T",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"337","R61","CYP2D6","*4","*10","g.100C>T",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"338","R61","CYP2D6","*4","*10","g.100C>T",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"339","R61","CYP2D6","*4","*10","g.100C>T",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"340","R61","CYP2D6","*4","*10","g.100C>T",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"341","R61","CYP2D6","*4","*10","g.100C>T",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"342","R61","CYP2D6","*4","*10","g.100C>T",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"343","R61","CYP2D6","*4","*10","g.100C>T",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"344","R61","CYP2D6","*4","*10","g.100C>T",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"345","R61","CYP2D6","*4","*10","g.100C>T",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"346","R61","CYP2D6","*4","*10","g.100C>T",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"347","R61","CYP2D6","*4","*10","g.100C>T",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"348","R61","CYP2D6","*4","*10","g.100C>T",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"349","R61","CYP2D6","*4","*10","g.100C>T",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"350","R61","CYP2D6","*4","*10","g.100C>T",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"351","R61","CYP2D6","*4","*10","g.100C>T",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"352","R61","CYP2D6","*4","*10","g.100C>T",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"353","R61","CYP2D6","*4","*10","g.100C>T",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"354","R61","CYP2D6","*4","*10","g.100C>T",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"355","R61","CYP2D6","*4","*10","g.100C>T",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"356","R61","CYP2D6","*4","*10","g.100C>T",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"357","R61","CYP2D6","*4","*10","g.100C>T",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"358","R61","CYP2D6","*4","*10","g.100C>T",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"359","R61","CYP2D6","*4","*10","g.100C>T",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"360","R61","CYP2D6","*4","*10","g.100C>T",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"361","R61","CYP2D6","*4","*10","g.100C>T",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"362","R61","CYP2D6","*4","*10","g.100C>T",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"363","R61","CYP2D6","*4","*10","g.100C>T",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"364","R61","CYP2D6","*4","*10","g.100C>T",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"365","R61","CYP2D6","*4","*10","g.100C>T",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"366","R61","CYP2D6","*4","*10","g.100C>T",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"367","R61","CYP2D6","*4","*10","g.100C>T",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"368","R61","CYP2D6","*4","*10","g.100C>T",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"369","R81","CYP2D6","*4","*10","g.100C>T",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"370","R81","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"371","R81","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"372","R81","CYP2D6","*4","*10","g.100C>T",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"373","R81","CYP2D6","*4","*10","g.100C>T",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"374","R81","CYP2D6","*4","*10","g.100C>T",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"375","R81","CYP2D6","*4","*10","g.100C>T",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"376","R81","CYP2D6","*4","*10","g.100C>T",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"377","R81","CYP2D6","*4","*10","g.100C>T",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"378","R81","CYP2D6","*4","*10","g.100C>T",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"379","R81","CYP2D6","*4","*10","g.100C>T",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"380","R81","CYP2D6","*4","*10","g.100C>T",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"381","R81","CYP2D6","*4","*10","g.100C>T",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"382","R81","CYP2D6","*4","*10","g.100C>T",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"383","R81","CYP2D6","*4","*10","g.100C>T",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"384","R81","CYP2D6","*4","*10","g.100C>T",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"385","R81","CYP2D6","*4","*10","g.100C>T",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"386","R81","CYP2D6","*4","*10","g.100C>T",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"387","R81","CYP2D6","*4","*10","g.100C>T",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"388","R81","CYP2D6","*4","*10","g.100C>T",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"389","R81","CYP2D6","*4","*10","g.100C>T",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"390","R81","CYP2D6","*4","*10","g.100C>T",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"391","R81","CYP2D6","*4","*10","g.100C>T",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"392","R81","CYP2D6","*4","*10","g.100C>T",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"393","R81","CYP2D6","*4","*10","g.100C>T",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"394","R81","CYP2D6","*4","*10","g.100C>T",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"395","R81","CYP2D6","*4","*10","g.100C>T",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"396","R81","CYP2D6","*4","*10","g.100C>T",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"397","R81","CYP2D6","*4","*10","g.100C>T",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"398","R81","CYP2D6","*4","*10","g.100C>T",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"399","R81","CYP2D6","*4","*10","g.100C>T",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"400","R81","CYP2D6","*4","*10","g.100C>T",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"401","R81","CYP2D6","*4","*10","g.100C>T",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"402","R81","CYP2D6","*4","*10","g.100C>T",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"403","R81","CYP2D6","*4","*10","g.100C>T",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"404","R81","CYP2D6","*4","*10","g.100C>T",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"405","R81","CYP2D6","*4","*10","g.100C>T",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"406","R81","CYP2D6","*4","*10","g.100C>T",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"407","R81","CYP2D6","*4","*10","g.100C>T",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"408","R81","CYP2D6","*4","*10","g.100C>T",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"409","R81","CYP2D6","*4","*10","g.100C>T",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"410","R81","CYP2D6","*4","*10","g.100C>T",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"411","R81","CYP2D6","*4","*10","g.100C>T",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"412","R81","CYP2D6","*4","*10","g.100C>T",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"413","R81","CYP2D6","*4","*10","g.100C>T",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"414","R81","CYP2D6","*4","*10","g.100C>T",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"415","R81","CYP2D6","*4","*10","g.100C>T",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"416","R81","CYP2D6","*4","*10","g.100C>T",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"417","R81","CYP2D6","*4","*10","g.100C>T",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"418","V152","CYP2D6","*4","*10","g.100C>T",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"419","V152","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"420","V152","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"421","V152","CYP2D6","*4","*10","g.100C>T",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"422","V152","CYP2D6","*4","*10","g.100C>T",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"423","V152","CYP2D6","*4","*10","g.100C>T",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"424","V152","CYP2D6","*4","*10","g.100C>T",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"425","V152","CYP2D6","*4","*10","g.100C>T",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"426","V152","CYP2D6","*4","*10","g.100C>T",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"427","V152","CYP2D6","*4","*10","g.100C>T",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"428","V152","CYP2D6","*4","*10","g.100C>T",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"429","V152","CYP2D6","*4","*10","g.100C>T",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"430","V152","CYP2D6","*4","*10","g.100C>T",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"431","V152","CYP2D6","*4","*10","g.100C>T",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"432","V152","CYP2D6","*4","*10","g.100C>T",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"433","V152","CYP2D6","*4","*10","g.100C>T",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"434","V152","CYP2D6","*4","*10","g.100C>T",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"435","V152","CYP2D6","*4","*10","g.100C>T",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"436","V152","CYP2D6","*4","*10","g.100C>T",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"437","V152","CYP2D6","*4","*10","g.100C>T",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"438","V152","CYP2D6","*4","*10","g.100C>T",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"439","V152","CYP2D6","*4","*10","g.100C>T",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"440","V152","CYP2D6","*4","*10","g.100C>T",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"441","V152","CYP2D6","*4","*10","g.100C>T",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"442","V152","CYP2D6","*4","*10","g.100C>T",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"443","V152","CYP2D6","*4","*10","g.100C>T",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"444","V152","CYP2D6","*4","*10","g.100C>T",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"445","V152","CYP2D6","*4","*10","g.100C>T",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"446","V152","CYP2D6","*4","*10","g.100C>T",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"447","V152","CYP2D6","*4","*10","g.100C>T",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"448","V152","CYP2D6","*4","*10","g.100C>T",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"449","V152","CYP2D6","*4","*10","g.100C>T",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"450","V152","CYP2D6","*4","*10","g.100C>T",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"451","V152","CYP2D6","*4","*10","g.100C>T",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"452","V152","CYP2D6","*4","*10","g.100C>T",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"453","V152","CYP2D6","*4","*10","g.100C>T",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"454","V152","CYP2D6","*4","*10","g.100C>T",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"455","V152","CYP2D6","*4","*10","g.100C>T",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"456","V152","CYP2D6","*4","*10","g.100C>T",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"457","V152","CYP2D6","*4","*10","g.100C>T",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"458","V152","CYP2D6","*4","*10","g.100C>T",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"459","V152","CYP2D6","*4","*10","g.100C>T",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"460","V152","CYP2D6","*4","*10","g.100C>T",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"461","V152","CYP2D6","*4","*10","g.100C>T",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"462","V152","CYP2D6","*4","*10","g.100C>T",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"463","V152","CYP2D6","*4","*10","g.100C>T",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"464","V152","CYP2D6","*4","*10","g.100C>T",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"465","V152","CYP2D6","*4","*10","g.100C>T",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"466","V152","CYP2D6","*4","*10","g.100C>T",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"467","R208","CYP2D6","*4","*10","g.100C>T",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"468","R208","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"469","R208","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"470","R208","CYP2D6","*4","*10","g.100C>T",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"471","R208","CYP2D6","*4","*10","g.100C>T",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"472","R208","CYP2D6","*4","*10","g.100C>T",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"473","R208","CYP2D6","*4","*10","g.100C>T",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"474","R208","CYP2D6","*4","*10","g.100C>T",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"475","R208","CYP2D6","*4","*10","g.100C>T",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"476","R208","CYP2D6","*4","*10","g.100C>T",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"477","R208","CYP2D6","*4","*10","g.100C>T",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"478","R208","CYP2D6","*4","*10","g.100C>T",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"479","R208","CYP2D6","*4","*10","g.100C>T",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"480","R208","CYP2D6","*4","*10","g.100C>T",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"481","R208","CYP2D6","*4","*10","g.100C>T",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"482","R208","CYP2D6","*4","*10","g.100C>T",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"483","R208","CYP2D6","*4","*10","g.100C>T",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"484","R208","CYP2D6","*4","*10","g.100C>T",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"485","R208","CYP2D6","*4","*10","g.100C>T",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"486","R208","CYP2D6","*4","*10","g.100C>T",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"487","R208","CYP2D6","*4","*10","g.100C>T",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"488","R208","CYP2D6","*4","*10","g.100C>T",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"489","R208","CYP2D6","*4","*10","g.100C>T",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"490","R208","CYP2D6","*4","*10","g.100C>T",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"491","R208","CYP2D6","*4","*10","g.100C>T",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"492","R208","CYP2D6","*4","*10","g.100C>T",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"493","R208","CYP2D6","*4","*10","g.100C>T",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"494","R208","CYP2D6","*4","*10","g.100C>T",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"495","R208","CYP2D6","*4","*10","g.100C>T",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"496","R208","CYP2D6","*4","*10","g.100C>T",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"497","R208","CYP2D6","*4","*10","g.100C>T",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"498","R208","CYP2D6","*4","*10","g.100C>T",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"499","R208","CYP2D6","*4","*10","g.100C>T",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"500","R208","CYP2D6","*4","*10","g.100C>T",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"501","R208","CYP2D6","*4","*10","g.100C>T",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"502","R208","CYP2D6","*4","*10","g.100C>T",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"503","R208","CYP2D6","*4","*10","g.100C>T",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"504","R208","CYP2D6","*4","*10","g.100C>T",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"505","R208","CYP2D6","*4","*10","g.100C>T",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"506","R208","CYP2D6","*4","*10","g.100C>T",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"507","R208","CYP2D6","*4","*10","g.100C>T",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"508","R208","CYP2D6","*4","*10","g.100C>T",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"509","R208","CYP2D6","*4","*10","g.100C>T",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"510","R208","CYP2D6","*4","*10","g.100C>T",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"511","R208","CYP2D6","*4","*10","g.100C>T",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"512","R208","CYP2D6","*4","*10","g.100C>T",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"513","R208","CYP2D6","*4","*10","g.100C>T",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"514","R208","CYP2D6","*4","*10","g.100C>T",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"515","R208","CYP2D6","*4","*10","g.100C>T",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"516","R214","CYP2D6","*4","*10","g.100C>T",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"517","R214","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"518","R214","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"519","R214","CYP2D6","*4","*10","g.100C>T",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"520","R214","CYP2D6","*4","*10","g.100C>T",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"521","R214","CYP2D6","*4","*10","g.100C>T",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"522","R214","CYP2D6","*4","*10","g.100C>T",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"523","R214","CYP2D6","*4","*10","g.100C>T",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"524","R214","CYP2D6","*4","*10","g.100C>T",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"525","R214","CYP2D6","*4","*10","g.100C>T",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"526","R214","CYP2D6","*4","*10","g.100C>T",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"527","R214","CYP2D6","*4","*10","g.100C>T",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"528","R214","CYP2D6","*4","*10","g.100C>T",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"529","R214","CYP2D6","*4","*10","g.100C>T",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"530","R214","CYP2D6","*4","*10","g.100C>T",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"531","R214","CYP2D6","*4","*10","g.100C>T",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"532","R214","CYP2D6","*4","*10","g.100C>T",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"533","R214","CYP2D6","*4","*10","g.100C>T",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"534","R214","CYP2D6","*4","*10","g.100C>T",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"535","R214","CYP2D6","*4","*10","g.100C>T",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"536","R214","CYP2D6","*4","*10","g.100C>T",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"537","R214","CYP2D6","*4","*10","g.100C>T",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"538","R214","CYP2D6","*4","*10","g.100C>T",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"539","R214","CYP2D6","*4","*10","g.100C>T",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"540","R214","CYP2D6","*4","*10","g.100C>T",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"541","R214","CYP2D6","*4","*10","g.100C>T",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"542","R214","CYP2D6","*4","*10","g.100C>T",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"543","R214","CYP2D6","*4","*10","g.100C>T",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"544","R214","CYP2D6","*4","*10","g.100C>T",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"545","R214","CYP2D6","*4","*10","g.100C>T",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"546","R214","CYP2D6","*4","*10","g.100C>T",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"547","R214","CYP2D6","*4","*10","g.100C>T",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"548","R214","CYP2D6","*4","*10","g.100C>T",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"549","R214","CYP2D6","*4","*10","g.100C>T",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"550","R214","CYP2D6","*4","*10","g.100C>T",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"551","R214","CYP2D6","*4","*10","g.100C>T",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"552","R214","CYP2D6","*4","*10","g.100C>T",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"553","R214","CYP2D6","*4","*10","g.100C>T",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"554","R214","CYP2D6","*4","*10","g.100C>T",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"555","R214","CYP2D6","*4","*10","g.100C>T",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"556","R214","CYP2D6","*4","*10","g.100C>T",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"557","R214","CYP2D6","*4","*10","g.100C>T",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"558","R214","CYP2D6","*4","*10","g.100C>T",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"559","R214","CYP2D6","*4","*10","g.100C>T",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"560","R214","CYP2D6","*4","*10","g.100C>T",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"561","R214","CYP2D6","*4","*10","g.100C>T",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"562","R214","CYP2D6","*4","*10","g.100C>T",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"563","R214","CYP2D6","*4","*10","g.100C>T",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"564","R214","CYP2D6","*4","*10","g.100C>T",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"565","H46","CYP2D6","*4","*10","g.100C>T",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"566","H46","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"567","H46","CYP2D6","*4","*10","g.100C>T",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"568","H46","CYP2D6","*4","*10","g.100C>T",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"569","H46","CYP2D6","*4","*10","g.100C>T",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"570","H46","CYP2D6","*4","*10","g.100C>T",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"571","H46","CYP2D6","*4","*10","g.100C>T",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"572","H46","CYP2D6","*4","*10","g.100C>T",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"573","H46","CYP2D6","*4","*10","g.100C>T",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"574","H46","CYP2D6","*4","*10","g.100C>T",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"575","H46","CYP2D6","*4","*10","g.100C>T",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"576","H46","CYP2D6","*4","*10","g.100C>T",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"577","H46","CYP2D6","*4","*10","g.100C>T",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"578","H46","CYP2D6","*4","*10","g.100C>T",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"579","H46","CYP2D6","*4","*10","g.100C>T",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"580","H46","CYP2D6","*4","*10","g.100C>T",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"581","H46","CYP2D6","*4","*10","g.100C>T",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"582","H46","CYP2D6","*4","*10","g.100C>T",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"583","H46","CYP2D6","*4","*10","g.100C>T",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"584","H46","CYP2D6","*4","*10","g.100C>T",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"585","H46","CYP2D6","*4","*10","g.100C>T",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"586","H46","CYP2D6","*4","*10","g.100C>T",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"587","H46","CYP2D6","*4","*10","g.100C>T",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"588","H46","CYP2D6","*4","*10","g.100C>T",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"589","H46","CYP2D6","*4","*10","g.100C>T",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"590","H46","CYP2D6","*4","*10","g.100C>T",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"591","H46","CYP2D6","*4","*10","g.100C>T",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"592","H46","CYP2D6","*4","*10","g.100C>T",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"593","H46","CYP2D6","*4","*10","g.100C>T",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"594","H46","CYP2D6","*4","*10","g.100C>T",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"595","H46","CYP2D6","*4","*10","g.100C>T",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"596","H46","CYP2D6","*4","*10","g.100C>T",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"597","H46","CYP2D6","*4","*10","g.100C>T",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"598","H46","CYP2D6","*4","*10","g.100C>T",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"599","H46","CYP2D6","*4","*10","g.100C>T",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"600","H46","CYP2D6","*4","*10","g.100C>T",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"601","H46","CYP2D6","*4","*10","g.100C>T",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"602","H46","CYP2D6","*4","*10","g.100C>T",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"603","H46","CYP2D6","*4","*10","g.100C>T",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"604","H46","CYP2D6","*4","*10","g.100C>T",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"605","H46","CYP2D6","*4","*10","g.100C>T",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"606","H46","CYP2D6","*4","*10","g.100C>T",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"607","H46","CYP2D6","*4","*10","g.100C>T",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"608","H46","CYP2D6","*4","*10","g.100C>T",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"609","H46","CYP2D6","*4","*10","g.100C>T",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"610","H46","CYP2D6","*4","*10","g.100C>T",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"611","H46","CYP2D6","*4","*10","g.100C>T",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"612","H46","CYP2D6","*4","*10","g.100C>T",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"613","H46","CYP2D6","*4","*10","g.100C>T",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"614","R75","CYP2D6","*4","*10","g.100C>T",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"615","R75","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"616","R75","CYP2D6","*4","*10","g.100C>T",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"617","R75","CYP2D6","*4","*10","g.100C>T",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"618","R75","CYP2D6","*4","*10","g.100C>T",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"619","R75","CYP2D6","*4","*10","g.100C>T",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"620","R75","CYP2D6","*4","*10","g.100C>T",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"621","R75","CYP2D6","*4","*10","g.100C>T",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"622","R75","CYP2D6","*4","*10","g.100C>T",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"623","R75","CYP2D6","*4","*10","g.100C>T",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"624","R75","CYP2D6","*4","*10","g.100C>T",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"625","R75","CYP2D6","*4","*10","g.100C>T",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"626","R75","CYP2D6","*4","*10","g.100C>T",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"627","R75","CYP2D6","*4","*10","g.100C>T",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"628","R75","CYP2D6","*4","*10","g.100C>T",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"629","R75","CYP2D6","*4","*10","g.100C>T",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"630","R75","CYP2D6","*4","*10","g.100C>T",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"631","R75","CYP2D6","*4","*10","g.100C>T",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"632","R75","CYP2D6","*4","*10","g.100C>T",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"633","R75","CYP2D6","*4","*10","g.100C>T",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"634","R75","CYP2D6","*4","*10","g.100C>T",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"635","R75","CYP2D6","*4","*10","g.100C>T",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"636","R75","CYP2D6","*4","*10","g.100C>T",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"637","R75","CYP2D6","*4","*10","g.100C>T",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"638","R75","CYP2D6","*4","*10","g.100C>T",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"639","R75","CYP2D6","*4","*10","g.100C>T",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"640","R75","CYP2D6","*4","*10","g.100C>T",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"641","R75","CYP2D6","*4","*10","g.100C>T",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"642","R75","CYP2D6","*4","*10","g.100C>T",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"643","R75","CYP2D6","*4","*10","g.100C>T",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"644","R75","CYP2D6","*4","*10","g.100C>T",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"645","R75","CYP2D6","*4","*10","g.100C>T",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"646","R75","CYP2D6","*4","*10","g.100C>T",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"647","R75","CYP2D6","*4","*10","g.100C>T",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"648","R75","CYP2D6","*4","*10","g.100C>T",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"649","R75","CYP2D6","*4","*10","g.100C>T",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"650","R75","CYP2D6","*4","*10","g.100C>T",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"651","R75","CYP2D6","*4","*10","g.100C>T",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"652","R75","CYP2D6","*4","*10","g.100C>T",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"653","R75","CYP2D6","*4","*10","g.100C>T",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"654","R75","CYP2D6","*4","*10","g.100C>T",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"655","R75","CYP2D6","*4","*10","g.100C>T",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"656","R75","CYP2D6","*4","*10","g.100C>T",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"657","R75","CYP2D6","*4","*10","g.100C>T",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"658","R75","CYP2D6","*4","*10","g.100C>T",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"659","R75","CYP2D6","*4","*10","g.100C>T",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"660","R75","CYP2D6","*4","*10","g.100C>T",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"661","R75","CYP2D6","*4","*10","g.100C>T",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"662","R75","CYP2D6","*4","*10","g.100C>T",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"663","H47","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"664","R05","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"665","R202","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"666","R203","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"667","R206","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"668","R210","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"669","R211","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"670","R212","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"671","R213","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"672","R215","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"673","R218","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"674","R220","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"675","R221","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"676","R222","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"677","R223","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"678","R228","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"679","R58","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"680","R59","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"681","R60","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"682","R61","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"683","R64","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"684","R71","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"685","R73","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"686","R74","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"687","R82","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"688","R86","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"689","V152","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"690","V155","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"691","R208","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"692","R231","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"693","R232","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"694","R233","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"695","R70","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"696","R83","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"697","R214","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"698","R66","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"699","r69","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"700","R207","CYP3A4","*1B"," g.-392A>G","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"701","R65","CYP3A4","*1B"," g.-392A>G","0",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"702","R208","CYP2D6","*6","g.1707delT","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"703","R208","CYP2D6","*6","g.1707delT","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"704","R208","CYP2D6","*6","g.1707delT","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"705","R208","CYP2D6","*6","g.1707delT","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"706","R208","CYP2D6","*6","g.1707delT","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"707","R208","CYP2D6","*6","g.1707delT","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"708","R208","CYP2D6","*6","g.1707delT","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"709","R208","CYP2D6","*6","g.1707delT","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"710","R208","CYP2D6","*6","g.1707delT","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"711","R208","CYP2D6","*6","g.1707delT","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"712","R208","CYP2D6","*6","g.1707delT","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"713","R208","CYP2D6","*6","g.1707delT","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"714","R208","CYP2D6","*6","g.1707delT","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"715","R208","CYP2D6","*6","g.1707delT","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"716","R208","CYP2D6","*6","g.1707delT","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"717","R208","CYP2D6","*6","g.1707delT","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"718","R208","CYP2D6","*6","g.1707delT","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"719","R208","CYP2D6","*6","g.1707delT","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"720","R208","CYP2D6","*6","g.1707delT","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"721","R208","CYP2D6","*6","g.1707delT","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"722","R208","CYP2D6","*6","g.1707delT","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"723","R208","CYP2D6","*6","g.1707delT","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"724","R208","CYP2D6","*6","g.1707delT","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"725","R208","CYP2D6","*6","g.1707delT","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"726","R208","CYP2D6","*6","g.1707delT","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"727","R208","CYP2D6","*6","g.1707delT","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"728","R208","CYP2D6","*6","g.1707delT","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"729","R208","CYP2D6","*6","g.1707delT","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"730","R208","CYP2D6","*6","g.1707delT","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"731","R208","CYP2D6","*6","g.1707delT","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"732","R208","CYP2D6","*6","g.1707delT","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"733","R208","CYP2D6","*6","g.1707delT","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"734","R208","CYP2D6","*6","g.1707delT","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"735","R208","CYP2D6","*6","g.1707delT","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"736","R208","CYP2D6","*6","g.1707delT","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"737","R208","CYP2D6","*6","g.1707delT","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"738","R208","CYP2D6","*6","g.1707delT","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"739","R208","CYP2D6","*6","g.1707delT","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"740","R208","CYP2D6","*6","g.1707delT","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"741","R208","CYP2D6","*6","g.1707delT","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"742","R208","CYP2D6","*6","g.1707delT","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"743","R208","CYP2D6","*6","g.1707delT","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"744","R208","CYP2D6","*6","g.1707delT","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"745","R208","CYP2D6","*6","g.1707delT","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"746","R208","CYP2D6","*6","g.1707delT","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"747","R208","CYP2D6","*6","g.1707delT","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"748","R208","CYP2D6","*6","g.1707delT","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"749","R208","CYP2D6","*6","g.1707delT","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"750","R208","CYP2D6","*6","g.1707delT","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"751","R63","CYP2C9","*6","c.818delA","g.10601delA",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"752","R63","CYP2C9","*6","c.818delA","g.10601delA",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"753","R63","CYP2C9","*6","c.818delA","g.10601delA",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"754","R63","CYP2C9","*6","c.818delA","g.10601delA",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"755","R63","CYP2C9","*6","c.818delA","g.10601delA",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"756","R63","CYP2C9","*6","c.818delA","g.10601delA",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"757","R63","CYP2C9","*6","c.818delA","g.10601delA",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"758","R63","CYP2C9","*6","c.818delA","g.10601delA",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"759","V152","CYP2C9","*6","c.818delA","g.10601delA",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"760","V152","CYP2C9","*6","c.818delA","g.10601delA",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"761","V152","CYP2C9","*6","c.818delA","g.10601delA",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"762","V152","CYP2C9","*6","c.818delA","g.10601delA",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"763","V152","CYP2C9","*6","c.818delA","g.10601delA",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"764","V152","CYP2C9","*6","c.818delA","g.10601delA",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"765","V152","CYP2C9","*6","c.818delA","g.10601delA",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"766","V152","CYP2C9","*6","c.818delA","g.10601delA",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"767","H47","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"768","H47","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"769","H47","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"770","H47","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"771","H47","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"772","H47","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"773","H47","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"774","H47","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"775","H47","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"776","H47","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"777","H47","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"778","H47","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"779","H47","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"780","H47","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"781","H47","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"782","H48","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"783","H48","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"784","H48","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"785","H48","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"786","H48","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"787","H48","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"788","H48","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"789","H48","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"790","H48","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"791","H48","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"792","H48","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"793","H48","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"794","H48","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"795","H48","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"796","H48","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"797","H49","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"798","H49","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"799","H49","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"800","H49","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"801","H49","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"802","H49","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"803","H49","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"804","H49","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"805","H49","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"806","H49","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"807","H49","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"808","H49","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"809","H49","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"810","H49","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"811","H49","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"812","R206","CYP2C19","*17","g.-806C>T","0",2,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"813","R206","CYP2C19","*17","g.-806C>T","0",2,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"814","R206","CYP2C19","*17","g.-806C>T","0",2,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"815","R206","CYP2C19","*17","g.-806C>T","0",2,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"816","R206","CYP2C19","*17","g.-806C>T","0",2,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"817","R206","CYP2C19","*17","g.-806C>T","0",2,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"818","R206","CYP2C19","*17","g.-806C>T","0",2,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"819","R206","CYP2C19","*17","g.-806C>T","0",2,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"820","R206","CYP2C19","*17","g.-806C>T","0",2,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"821","R206","CYP2C19","*17","g.-806C>T","0",2,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"822","R206","CYP2C19","*17","g.-806C>T","0",2,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"823","R206","CYP2C19","*17","g.-806C>T","0",2,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"824","R206","CYP2C19","*17","g.-806C>T","0",2,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"825","R206","CYP2C19","*17","g.-806C>T","0",2,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"826","R206","CYP2C19","*17","g.-806C>T","0",2,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"827","R211","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"828","R211","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"829","R211","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"830","R211","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"831","R211","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"832","R211","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"833","R211","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"834","R211","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"835","R211","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"836","R211","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"837","R211","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"838","R211","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"839","R211","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"840","R211","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"841","R211","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"842","R218","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"843","R218","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"844","R218","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"845","R218","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"846","R218","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"847","R218","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"848","R218","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"849","R218","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"850","R218","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"851","R218","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"852","R218","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"853","R218","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"854","R218","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"855","R218","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"856","R218","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"857","R220","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"858","R220","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"859","R220","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"860","R220","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"861","R220","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"862","R220","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"863","R220","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"864","R220","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"865","R220","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"866","R220","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"867","R220","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"868","R220","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"869","R220","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"870","R220","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"871","R220","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"872","R223","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"873","R223","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"874","R223","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"875","R223","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"876","R223","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"877","R223","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"878","R223","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"879","R223","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"880","R223","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"881","R223","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"882","R223","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"883","R223","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"884","R223","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"885","R223","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"886","R223","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"887","R228","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"888","R228","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"889","R228","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"890","R228","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"891","R228","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"892","R228","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"893","R228","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"894","R228","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"895","R228","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"896","R228","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"897","R228","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"898","R228","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"899","R228","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"900","R228","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"901","R228","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"902","R57","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"903","R57","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"904","R57","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"905","R57","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"906","R57","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"907","R57","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"908","R57","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"909","R57","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"910","R57","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"911","R57","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"912","R57","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"913","R57","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"914","R57","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"915","R57","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"916","R57","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"917","R59","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"918","R59","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"919","R59","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"920","R59","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"921","R59","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"922","R59","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"923","R59","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"924","R59","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"925","R59","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"926","R59","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"927","R59","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"928","R59","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"929","R59","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"930","R59","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"931","R59","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"932","R60","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"933","R60","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"934","R60","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"935","R60","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"936","R60","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"937","R60","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"938","R60","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"939","R60","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"940","R60","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"941","R60","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"942","R60","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"943","R60","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"944","R60","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"945","R60","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"946","R60","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"947","R61","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"948","R61","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"949","R61","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"950","R61","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"951","R61","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"952","R61","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"953","R61","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"954","R61","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"955","R61","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"956","R61","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"957","R61","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"958","R61","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"959","R61","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"960","R61","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"961","R61","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"962","R71","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"963","R71","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"964","R71","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"965","R71","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"966","R71","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"967","R71","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"968","R71","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"969","R71","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"970","R71","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"971","R71","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"972","R71","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"973","R71","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"974","R71","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"975","R71","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"976","R71","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"977","R72","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"978","R72","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"979","R72","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"980","R72","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"981","R72","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"982","R72","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"983","R72","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"984","R72","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"985","R72","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"986","R72","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"987","R72","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"988","R72","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"989","R72","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"990","R72","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"991","R72","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"992","R80","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"993","R80","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"994","R80","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"995","R80","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"996","R80","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"997","R80","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"998","R80","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"999","R80","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1000","R80","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1001","R80","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1002","R80","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1003","R80","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1004","R80","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1005","R80","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1006","R80","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1007","R81","CYP2C19","*17","g.-806C>T","0",2,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1008","R81","CYP2C19","*17","g.-806C>T","0",2,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1009","R81","CYP2C19","*17","g.-806C>T","0",2,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1010","R81","CYP2C19","*17","g.-806C>T","0",2,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1011","R81","CYP2C19","*17","g.-806C>T","0",2,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1012","R81","CYP2C19","*17","g.-806C>T","0",2,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1013","R81","CYP2C19","*17","g.-806C>T","0",2,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1014","R81","CYP2C19","*17","g.-806C>T","0",2,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1015","R81","CYP2C19","*17","g.-806C>T","0",2,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1016","R81","CYP2C19","*17","g.-806C>T","0",2,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1017","R81","CYP2C19","*17","g.-806C>T","0",2,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1018","R81","CYP2C19","*17","g.-806C>T","0",2,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1019","R81","CYP2C19","*17","g.-806C>T","0",2,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1020","R81","CYP2C19","*17","g.-806C>T","0",2,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1021","R81","CYP2C19","*17","g.-806C>T","0",2,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1022","V151","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1023","V151","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1024","V151","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1025","V151","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1026","V151","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1027","V151","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1028","V151","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1029","V151","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1030","V151","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1031","V151","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1032","V151","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1033","V151","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1034","V151","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1035","V151","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1036","V151","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1037","V155","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1038","V155","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1039","V155","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1040","V155","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1041","V155","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1042","V155","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1043","V155","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1044","V155","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1045","V155","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1046","V155","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1047","V155","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1048","V155","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1049","V155","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1050","V155","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1051","V155","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1052","R208","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1053","R208","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1054","R208","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1055","R208","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1056","R208","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1057","R208","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1058","R208","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1059","R208","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1060","R208","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1061","R208","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1062","R208","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1063","R208","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1064","R208","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1065","R208","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1066","R208","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1067","R231","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1068","R231","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1069","R231","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1070","R231","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1071","R231","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1072","R231","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1073","R231","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1074","R231","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1075","R231","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1076","R231","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1077","R231","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1078","R231","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1079","R231","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1080","R231","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1081","R231","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1082","R232","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1083","R232","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1084","R232","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1085","R232","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1086","R232","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1087","R232","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1088","R232","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1089","R232","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1090","R232","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1091","R232","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1092","R232","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1093","R232","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1094","R232","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1095","R232","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1096","R232","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1097","R70","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1098","R70","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1099","R70","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1100","R70","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1101","R70","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1102","R70","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1103","R70","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1104","R70","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1105","R70","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1106","R70","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1107","R70","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1108","R70","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1109","R70","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1110","R70","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1111","R70","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1112","R83","CYP2C19","*17","g.-806C>T","0",2,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1113","R83","CYP2C19","*17","g.-806C>T","0",2,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1114","R83","CYP2C19","*17","g.-806C>T","0",2,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1115","R83","CYP2C19","*17","g.-806C>T","0",2,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1116","R83","CYP2C19","*17","g.-806C>T","0",2,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1117","R83","CYP2C19","*17","g.-806C>T","0",2,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1118","R83","CYP2C19","*17","g.-806C>T","0",2,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1119","R83","CYP2C19","*17","g.-806C>T","0",2,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1120","R83","CYP2C19","*17","g.-806C>T","0",2,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1121","R83","CYP2C19","*17","g.-806C>T","0",2,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1122","R83","CYP2C19","*17","g.-806C>T","0",2,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1123","R83","CYP2C19","*17","g.-806C>T","0",2,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1124","R83","CYP2C19","*17","g.-806C>T","0",2,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1125","R83","CYP2C19","*17","g.-806C>T","0",2,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1126","R83","CYP2C19","*17","g.-806C>T","0",2,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1127","R216","CYP2C19","*17","g.-806C>T","0",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1128","R216","CYP2C19","*17","g.-806C>T","0",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1129","R216","CYP2C19","*17","g.-806C>T","0",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1130","R216","CYP2C19","*17","g.-806C>T","0",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1131","R216","CYP2C19","*17","g.-806C>T","0",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1132","R216","CYP2C19","*17","g.-806C>T","0",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1133","R216","CYP2C19","*17","g.-806C>T","0",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1134","R216","CYP2C19","*17","g.-806C>T","0",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1135","R216","CYP2C19","*17","g.-806C>T","0",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1136","R216","CYP2C19","*17","g.-806C>T","0",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1137","R216","CYP2C19","*17","g.-806C>T","0",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1138","R216","CYP2C19","*17","g.-806C>T","0",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1139","R216","CYP2C19","*17","g.-806C>T","0",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1140","R216","CYP2C19","*17","g.-806C>T","0",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1141","R216","CYP2C19","*17","g.-806C>T","0",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"1142","R203","VKORC1","c.-1639G>A","0","0",2,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1143","R206","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1144","R211","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1145","R212","VKORC1","c.-1639G>A","0","0",2,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1146","R218","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1147","R220","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1148","R222","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1149","R62","VKORC1","c.-1639G>A","0","0",2,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1150","R71","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1151","R82","VKORC1","c.-1639G>A","0","0",2,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1152","R86","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1153","V154","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1154","R208","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1155","R232","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1156","R233","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1157","R70","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1158","R214","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1159","R66","VKORC1","c.-1639G>A","0","0",2,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1160","r69","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1161","R207","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1162","R75","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1163","R65","VKORC1","c.-1639G>A","0","0",1,"Warfarin","-1639G>A variant carriers","Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","vitamin K epoxide reductase complex subunit 1","chr16"
"1164","R05","CYP1A2","*1","g.-739T>G","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1165","R209","CYP1A2","*1","g.-739T>G","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1166","R215","CYP1A2","*1","g.-739T>G","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1167","R58","CYP1A2","*1","g.-739T>G","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1168","R74","CYP1A2","*1","g.-739T>G","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1169","V152","CYP1A2","*1","g.-739T>G","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1170","R75","CYP1A2","*1","g.-739T>G","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1171","R224","CYP3A4","*12","c.1117C>T","g.21896C>T",1,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"1172","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1173","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1174","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1175","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1176","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1177","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1178","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1179","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1180","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1181","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1182","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1183","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1184","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1185","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1186","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1187","R76","CYP2C9","*5","c.1080C>G","g.42619C>G",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"1188","H47","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1189","R202","CYP1A2","*1","g.-3860G>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1190","R203","CYP1A2","*1","g.-3860G>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1191","R209","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1192","R210","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1193","R211","CYP1A2","*1","g.-3860G>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1194","R213","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1195","R221","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1196","R59","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1197","R61","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1198","R62","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1199","R63","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1200","R72","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1201","R73","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1202","R79","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1203","R82","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1204","V152","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1205","V153","CYP1A2","*1","g.-3860G>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1206","R76","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1207","R76","CYP1A2","*1","g.-3860G>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1208","R65","CYP1A2","*1","g.-3860G>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"1209","H48","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1210","H48","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1211","H48","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1212","H48","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1213","H48","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1214","H48","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1215","H48","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1216","H48","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1217","H48","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1218","H48","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1219","H48","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1220","H48","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1221","H48","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1222","H48","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1223","H48","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1224","H48","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1225","H48","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1226","H48","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1227","H48","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1228","H48","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1229","H48","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1230","H48","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1231","H48","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1232","H48","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1233","H48","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1234","H48","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1235","H48","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1236","H48","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1237","H48","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1238","H48","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1239","H48","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1240","H48","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1241","H48","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1242","H48","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1243","H48","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1244","H48","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1245","H48","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1246","H48","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1247","H48","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1248","H48","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1249","H48","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1250","H48","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1251","H48","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1252","H48","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1253","H48","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1254","H48","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1255","H48","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1256","H48","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1257","H48","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1258","H49","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1259","H49","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1260","H49","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1261","H49","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1262","H49","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1263","H49","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1264","H49","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1265","H49","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1266","H49","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1267","H49","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1268","H49","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1269","H49","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1270","H49","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1271","H49","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1272","H49","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1273","H49","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1274","H49","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1275","H49","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1276","H49","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1277","H49","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1278","H49","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1279","H49","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1280","H49","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1281","H49","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1282","H49","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1283","H49","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1284","H49","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1285","H49","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1286","H49","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1287","H49","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1288","H49","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1289","H49","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1290","H49","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1291","H49","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1292","H49","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1293","H49","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1294","H49","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1295","H49","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1296","H49","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1297","H49","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1298","H49","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1299","H49","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1300","H49","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1301","H49","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1302","H49","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1303","H49","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1304","H49","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1305","H49","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1306","H49","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1307","R206","CYP2D6","g.2850C>T","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1308","R206","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1309","R206","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1310","R206","CYP2D6","g.2850C>T","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1311","R206","CYP2D6","g.2850C>T","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1312","R206","CYP2D6","g.2850C>T","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1313","R206","CYP2D6","g.2850C>T","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1314","R206","CYP2D6","g.2850C>T","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1315","R206","CYP2D6","g.2850C>T","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1316","R206","CYP2D6","g.2850C>T","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1317","R206","CYP2D6","g.2850C>T","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1318","R206","CYP2D6","g.2850C>T","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1319","R206","CYP2D6","g.2850C>T","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1320","R206","CYP2D6","g.2850C>T","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1321","R206","CYP2D6","g.2850C>T","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1322","R206","CYP2D6","g.2850C>T","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1323","R206","CYP2D6","g.2850C>T","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1324","R206","CYP2D6","g.2850C>T","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1325","R206","CYP2D6","g.2850C>T","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1326","R206","CYP2D6","g.2850C>T","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1327","R206","CYP2D6","g.2850C>T","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1328","R206","CYP2D6","g.2850C>T","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1329","R206","CYP2D6","g.2850C>T","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1330","R206","CYP2D6","g.2850C>T","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1331","R206","CYP2D6","g.2850C>T","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1332","R206","CYP2D6","g.2850C>T","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1333","R206","CYP2D6","g.2850C>T","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1334","R206","CYP2D6","g.2850C>T","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1335","R206","CYP2D6","g.2850C>T","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1336","R206","CYP2D6","g.2850C>T","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1337","R206","CYP2D6","g.2850C>T","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1338","R206","CYP2D6","g.2850C>T","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1339","R206","CYP2D6","g.2850C>T","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1340","R206","CYP2D6","g.2850C>T","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1341","R206","CYP2D6","g.2850C>T","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1342","R206","CYP2D6","g.2850C>T","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1343","R206","CYP2D6","g.2850C>T","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1344","R206","CYP2D6","g.2850C>T","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1345","R206","CYP2D6","g.2850C>T","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1346","R206","CYP2D6","g.2850C>T","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1347","R206","CYP2D6","g.2850C>T","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1348","R206","CYP2D6","g.2850C>T","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1349","R206","CYP2D6","g.2850C>T","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1350","R206","CYP2D6","g.2850C>T","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1351","R206","CYP2D6","g.2850C>T","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1352","R206","CYP2D6","g.2850C>T","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1353","R206","CYP2D6","g.2850C>T","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1354","R206","CYP2D6","g.2850C>T","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1355","R206","CYP2D6","g.2850C>T","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1356","R209","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1357","R209","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1358","R209","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1359","R209","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1360","R209","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1361","R209","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1362","R209","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1363","R209","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1364","R209","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1365","R209","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1366","R209","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1367","R209","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1368","R209","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1369","R209","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1370","R209","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1371","R209","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1372","R209","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1373","R209","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1374","R209","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1375","R209","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1376","R209","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1377","R209","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1378","R209","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1379","R209","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1380","R209","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1381","R209","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1382","R209","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1383","R209","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1384","R209","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1385","R209","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1386","R209","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1387","R209","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1388","R209","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1389","R209","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1390","R209","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1391","R209","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1392","R209","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1393","R209","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1394","R209","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1395","R209","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1396","R209","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1397","R209","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1398","R209","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1399","R209","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1400","R209","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1401","R209","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1402","R209","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1403","R209","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1404","R209","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1405","R211","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1406","R211","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1407","R211","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1408","R211","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1409","R211","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1410","R211","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1411","R211","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1412","R211","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1413","R211","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1414","R211","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1415","R211","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1416","R211","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1417","R211","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1418","R211","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1419","R211","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1420","R211","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1421","R211","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1422","R211","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1423","R211","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1424","R211","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1425","R211","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1426","R211","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1427","R211","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1428","R211","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1429","R211","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1430","R211","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1431","R211","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1432","R211","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1433","R211","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1434","R211","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1435","R211","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1436","R211","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1437","R211","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1438","R211","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1439","R211","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1440","R211","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1441","R211","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1442","R211","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1443","R211","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1444","R211","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1445","R211","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1446","R211","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1447","R211","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1448","R211","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1449","R211","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1450","R211","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1451","R211","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1452","R211","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1453","R211","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1454","R212","CYP2D6","g.2850C>T","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1455","R212","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1456","R212","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1457","R212","CYP2D6","g.2850C>T","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1458","R212","CYP2D6","g.2850C>T","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1459","R212","CYP2D6","g.2850C>T","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1460","R212","CYP2D6","g.2850C>T","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1461","R212","CYP2D6","g.2850C>T","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1462","R212","CYP2D6","g.2850C>T","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1463","R212","CYP2D6","g.2850C>T","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1464","R212","CYP2D6","g.2850C>T","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1465","R212","CYP2D6","g.2850C>T","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1466","R212","CYP2D6","g.2850C>T","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1467","R212","CYP2D6","g.2850C>T","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1468","R212","CYP2D6","g.2850C>T","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1469","R212","CYP2D6","g.2850C>T","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1470","R212","CYP2D6","g.2850C>T","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1471","R212","CYP2D6","g.2850C>T","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1472","R212","CYP2D6","g.2850C>T","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1473","R212","CYP2D6","g.2850C>T","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1474","R212","CYP2D6","g.2850C>T","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1475","R212","CYP2D6","g.2850C>T","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1476","R212","CYP2D6","g.2850C>T","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1477","R212","CYP2D6","g.2850C>T","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1478","R212","CYP2D6","g.2850C>T","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1479","R212","CYP2D6","g.2850C>T","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1480","R212","CYP2D6","g.2850C>T","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1481","R212","CYP2D6","g.2850C>T","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1482","R212","CYP2D6","g.2850C>T","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1483","R212","CYP2D6","g.2850C>T","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1484","R212","CYP2D6","g.2850C>T","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1485","R212","CYP2D6","g.2850C>T","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1486","R212","CYP2D6","g.2850C>T","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1487","R212","CYP2D6","g.2850C>T","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1488","R212","CYP2D6","g.2850C>T","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1489","R212","CYP2D6","g.2850C>T","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1490","R212","CYP2D6","g.2850C>T","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1491","R212","CYP2D6","g.2850C>T","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1492","R212","CYP2D6","g.2850C>T","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1493","R212","CYP2D6","g.2850C>T","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1494","R212","CYP2D6","g.2850C>T","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1495","R212","CYP2D6","g.2850C>T","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1496","R212","CYP2D6","g.2850C>T","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1497","R212","CYP2D6","g.2850C>T","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1498","R212","CYP2D6","g.2850C>T","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1499","R212","CYP2D6","g.2850C>T","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1500","R212","CYP2D6","g.2850C>T","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1501","R212","CYP2D6","g.2850C>T","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1502","R212","CYP2D6","g.2850C>T","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1503","R213","CYP2D6","g.2850C>T","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1504","R213","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1505","R213","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1506","R213","CYP2D6","g.2850C>T","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1507","R213","CYP2D6","g.2850C>T","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1508","R213","CYP2D6","g.2850C>T","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1509","R213","CYP2D6","g.2850C>T","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1510","R213","CYP2D6","g.2850C>T","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1511","R213","CYP2D6","g.2850C>T","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1512","R213","CYP2D6","g.2850C>T","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1513","R213","CYP2D6","g.2850C>T","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1514","R213","CYP2D6","g.2850C>T","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1515","R213","CYP2D6","g.2850C>T","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1516","R213","CYP2D6","g.2850C>T","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1517","R213","CYP2D6","g.2850C>T","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1518","R213","CYP2D6","g.2850C>T","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1519","R213","CYP2D6","g.2850C>T","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1520","R213","CYP2D6","g.2850C>T","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1521","R213","CYP2D6","g.2850C>T","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1522","R213","CYP2D6","g.2850C>T","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1523","R213","CYP2D6","g.2850C>T","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1524","R213","CYP2D6","g.2850C>T","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1525","R213","CYP2D6","g.2850C>T","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1526","R213","CYP2D6","g.2850C>T","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1527","R213","CYP2D6","g.2850C>T","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1528","R213","CYP2D6","g.2850C>T","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1529","R213","CYP2D6","g.2850C>T","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1530","R213","CYP2D6","g.2850C>T","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1531","R213","CYP2D6","g.2850C>T","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1532","R213","CYP2D6","g.2850C>T","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1533","R213","CYP2D6","g.2850C>T","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1534","R213","CYP2D6","g.2850C>T","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1535","R213","CYP2D6","g.2850C>T","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1536","R213","CYP2D6","g.2850C>T","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1537","R213","CYP2D6","g.2850C>T","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1538","R213","CYP2D6","g.2850C>T","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1539","R213","CYP2D6","g.2850C>T","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1540","R213","CYP2D6","g.2850C>T","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1541","R213","CYP2D6","g.2850C>T","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1542","R213","CYP2D6","g.2850C>T","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1543","R213","CYP2D6","g.2850C>T","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1544","R213","CYP2D6","g.2850C>T","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1545","R213","CYP2D6","g.2850C>T","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1546","R213","CYP2D6","g.2850C>T","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1547","R213","CYP2D6","g.2850C>T","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1548","R213","CYP2D6","g.2850C>T","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1549","R213","CYP2D6","g.2850C>T","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1550","R213","CYP2D6","g.2850C>T","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1551","R213","CYP2D6","g.2850C>T","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1552","R215","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1553","R215","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1554","R215","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1555","R215","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1556","R215","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1557","R215","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1558","R215","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1559","R215","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1560","R215","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1561","R215","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1562","R215","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1563","R215","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1564","R215","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1565","R215","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1566","R215","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1567","R215","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1568","R215","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1569","R215","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1570","R215","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1571","R215","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1572","R215","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1573","R215","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1574","R215","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1575","R215","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1576","R215","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1577","R215","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1578","R215","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1579","R215","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1580","R215","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1581","R215","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1582","R215","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1583","R215","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1584","R215","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1585","R215","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1586","R215","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1587","R215","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1588","R215","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1589","R215","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1590","R215","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1591","R215","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1592","R215","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1593","R215","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1594","R215","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1595","R215","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1596","R215","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1597","R215","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1598","R215","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1599","R215","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1600","R215","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1601","R218","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1602","R218","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1603","R218","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1604","R218","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1605","R218","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1606","R218","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1607","R218","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1608","R218","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1609","R218","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1610","R218","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1611","R218","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1612","R218","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1613","R218","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1614","R218","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1615","R218","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1616","R218","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1617","R218","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1618","R218","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1619","R218","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1620","R218","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1621","R218","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1622","R218","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1623","R218","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1624","R218","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1625","R218","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1626","R218","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1627","R218","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1628","R218","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1629","R218","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1630","R218","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1631","R218","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1632","R218","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1633","R218","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1634","R218","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1635","R218","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1636","R218","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1637","R218","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1638","R218","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1639","R218","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1640","R218","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1641","R218","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1642","R218","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1643","R218","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1644","R218","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1645","R218","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1646","R218","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1647","R218","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1648","R218","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1649","R218","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1650","R220","CYP2D6","g.2850C>T","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1651","R220","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1652","R220","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1653","R220","CYP2D6","g.2850C>T","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1654","R220","CYP2D6","g.2850C>T","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1655","R220","CYP2D6","g.2850C>T","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1656","R220","CYP2D6","g.2850C>T","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1657","R220","CYP2D6","g.2850C>T","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1658","R220","CYP2D6","g.2850C>T","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1659","R220","CYP2D6","g.2850C>T","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1660","R220","CYP2D6","g.2850C>T","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1661","R220","CYP2D6","g.2850C>T","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1662","R220","CYP2D6","g.2850C>T","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1663","R220","CYP2D6","g.2850C>T","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1664","R220","CYP2D6","g.2850C>T","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1665","R220","CYP2D6","g.2850C>T","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1666","R220","CYP2D6","g.2850C>T","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1667","R220","CYP2D6","g.2850C>T","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1668","R220","CYP2D6","g.2850C>T","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1669","R220","CYP2D6","g.2850C>T","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1670","R220","CYP2D6","g.2850C>T","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1671","R220","CYP2D6","g.2850C>T","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1672","R220","CYP2D6","g.2850C>T","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1673","R220","CYP2D6","g.2850C>T","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1674","R220","CYP2D6","g.2850C>T","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1675","R220","CYP2D6","g.2850C>T","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1676","R220","CYP2D6","g.2850C>T","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1677","R220","CYP2D6","g.2850C>T","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1678","R220","CYP2D6","g.2850C>T","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1679","R220","CYP2D6","g.2850C>T","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1680","R220","CYP2D6","g.2850C>T","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1681","R220","CYP2D6","g.2850C>T","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1682","R220","CYP2D6","g.2850C>T","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1683","R220","CYP2D6","g.2850C>T","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1684","R220","CYP2D6","g.2850C>T","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1685","R220","CYP2D6","g.2850C>T","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1686","R220","CYP2D6","g.2850C>T","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1687","R220","CYP2D6","g.2850C>T","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1688","R220","CYP2D6","g.2850C>T","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1689","R220","CYP2D6","g.2850C>T","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1690","R220","CYP2D6","g.2850C>T","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1691","R220","CYP2D6","g.2850C>T","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1692","R220","CYP2D6","g.2850C>T","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1693","R220","CYP2D6","g.2850C>T","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1694","R220","CYP2D6","g.2850C>T","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1695","R220","CYP2D6","g.2850C>T","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1696","R220","CYP2D6","g.2850C>T","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1697","R220","CYP2D6","g.2850C>T","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1698","R220","CYP2D6","g.2850C>T","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1699","R221","CYP2D6","g.2850C>T","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1700","R221","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1701","R221","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1702","R221","CYP2D6","g.2850C>T","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1703","R221","CYP2D6","g.2850C>T","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1704","R221","CYP2D6","g.2850C>T","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1705","R221","CYP2D6","g.2850C>T","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1706","R221","CYP2D6","g.2850C>T","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1707","R221","CYP2D6","g.2850C>T","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1708","R221","CYP2D6","g.2850C>T","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1709","R221","CYP2D6","g.2850C>T","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1710","R221","CYP2D6","g.2850C>T","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1711","R221","CYP2D6","g.2850C>T","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1712","R221","CYP2D6","g.2850C>T","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1713","R221","CYP2D6","g.2850C>T","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1714","R221","CYP2D6","g.2850C>T","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1715","R221","CYP2D6","g.2850C>T","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1716","R221","CYP2D6","g.2850C>T","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1717","R221","CYP2D6","g.2850C>T","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1718","R221","CYP2D6","g.2850C>T","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1719","R221","CYP2D6","g.2850C>T","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1720","R221","CYP2D6","g.2850C>T","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1721","R221","CYP2D6","g.2850C>T","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1722","R221","CYP2D6","g.2850C>T","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1723","R221","CYP2D6","g.2850C>T","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1724","R221","CYP2D6","g.2850C>T","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1725","R221","CYP2D6","g.2850C>T","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1726","R221","CYP2D6","g.2850C>T","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1727","R221","CYP2D6","g.2850C>T","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1728","R221","CYP2D6","g.2850C>T","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1729","R221","CYP2D6","g.2850C>T","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1730","R221","CYP2D6","g.2850C>T","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1731","R221","CYP2D6","g.2850C>T","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1732","R221","CYP2D6","g.2850C>T","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1733","R221","CYP2D6","g.2850C>T","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1734","R221","CYP2D6","g.2850C>T","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1735","R221","CYP2D6","g.2850C>T","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1736","R221","CYP2D6","g.2850C>T","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1737","R221","CYP2D6","g.2850C>T","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1738","R221","CYP2D6","g.2850C>T","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1739","R221","CYP2D6","g.2850C>T","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1740","R221","CYP2D6","g.2850C>T","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1741","R221","CYP2D6","g.2850C>T","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1742","R221","CYP2D6","g.2850C>T","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1743","R221","CYP2D6","g.2850C>T","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1744","R221","CYP2D6","g.2850C>T","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1745","R221","CYP2D6","g.2850C>T","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1746","R221","CYP2D6","g.2850C>T","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1747","R221","CYP2D6","g.2850C>T","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1748","R222","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1749","R222","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1750","R222","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1751","R222","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1752","R222","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1753","R222","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1754","R222","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1755","R222","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1756","R222","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1757","R222","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1758","R222","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1759","R222","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1760","R222","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1761","R222","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1762","R222","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1763","R222","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1764","R222","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1765","R222","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1766","R222","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1767","R222","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1768","R222","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1769","R222","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1770","R222","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1771","R222","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1772","R222","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1773","R222","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1774","R222","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1775","R222","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1776","R222","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1777","R222","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1778","R222","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1779","R222","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1780","R222","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1781","R222","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1782","R222","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1783","R222","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1784","R222","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1785","R222","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1786","R222","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1787","R222","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1788","R222","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1789","R222","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1790","R222","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1791","R222","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1792","R222","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1793","R222","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1794","R222","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1795","R222","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1796","R222","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1797","R57","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1798","R57","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1799","R57","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1800","R57","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1801","R57","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1802","R57","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1803","R57","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1804","R57","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1805","R57","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1806","R57","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1807","R57","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1808","R57","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1809","R57","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1810","R57","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1811","R57","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1812","R57","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1813","R57","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1814","R57","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1815","R57","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1816","R57","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1817","R57","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1818","R57","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1819","R57","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1820","R57","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1821","R57","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1822","R57","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1823","R57","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1824","R57","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1825","R57","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1826","R57","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1827","R57","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1828","R57","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1829","R57","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1830","R57","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1831","R57","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1832","R57","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1833","R57","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1834","R57","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1835","R57","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1836","R57","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1837","R57","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1838","R57","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1839","R57","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1840","R57","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1841","R57","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1842","R57","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1843","R57","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1844","R57","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1845","R57","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1846","R58","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1847","R58","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1848","R58","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1849","R58","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1850","R58","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1851","R58","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1852","R58","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1853","R58","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1854","R58","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1855","R58","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1856","R58","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1857","R58","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1858","R58","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1859","R58","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1860","R58","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1861","R58","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1862","R58","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1863","R58","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1864","R58","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1865","R58","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1866","R58","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1867","R58","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1868","R58","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1869","R58","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1870","R58","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1871","R58","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1872","R58","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1873","R58","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1874","R58","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1875","R58","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1876","R58","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1877","R58","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1878","R58","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1879","R58","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1880","R58","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1881","R58","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1882","R58","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1883","R58","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1884","R58","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1885","R58","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1886","R58","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1887","R58","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1888","R58","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1889","R58","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1890","R58","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1891","R58","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1892","R58","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1893","R58","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1894","R58","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1895","R60","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1896","R60","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1897","R60","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1898","R60","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1899","R60","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1900","R60","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1901","R60","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1902","R60","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1903","R60","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1904","R60","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1905","R60","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1906","R60","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1907","R60","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1908","R60","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1909","R60","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1910","R60","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1911","R60","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1912","R60","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1913","R60","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1914","R60","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1915","R60","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1916","R60","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1917","R60","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1918","R60","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1919","R60","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1920","R60","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1921","R60","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1922","R60","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1923","R60","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1924","R60","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1925","R60","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1926","R60","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1927","R60","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1928","R60","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1929","R60","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1930","R60","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1931","R60","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1932","R60","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1933","R60","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1934","R60","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1935","R60","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1936","R60","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1937","R60","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1938","R60","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1939","R60","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1940","R60","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1941","R60","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1942","R60","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1943","R60","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1944","R61","CYP2D6","g.2850C>T","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1945","R61","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1946","R61","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1947","R61","CYP2D6","g.2850C>T","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1948","R61","CYP2D6","g.2850C>T","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1949","R61","CYP2D6","g.2850C>T","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1950","R61","CYP2D6","g.2850C>T","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1951","R61","CYP2D6","g.2850C>T","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1952","R61","CYP2D6","g.2850C>T","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1953","R61","CYP2D6","g.2850C>T","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1954","R61","CYP2D6","g.2850C>T","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1955","R61","CYP2D6","g.2850C>T","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1956","R61","CYP2D6","g.2850C>T","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1957","R61","CYP2D6","g.2850C>T","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1958","R61","CYP2D6","g.2850C>T","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1959","R61","CYP2D6","g.2850C>T","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1960","R61","CYP2D6","g.2850C>T","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1961","R61","CYP2D6","g.2850C>T","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1962","R61","CYP2D6","g.2850C>T","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1963","R61","CYP2D6","g.2850C>T","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1964","R61","CYP2D6","g.2850C>T","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1965","R61","CYP2D6","g.2850C>T","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1966","R61","CYP2D6","g.2850C>T","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1967","R61","CYP2D6","g.2850C>T","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1968","R61","CYP2D6","g.2850C>T","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1969","R61","CYP2D6","g.2850C>T","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1970","R61","CYP2D6","g.2850C>T","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"1971","R61","CYP2D6","g.2850C>T","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1972","R61","CYP2D6","g.2850C>T","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1973","R61","CYP2D6","g.2850C>T","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1974","R61","CYP2D6","g.2850C>T","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1975","R61","CYP2D6","g.2850C>T","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1976","R61","CYP2D6","g.2850C>T","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1977","R61","CYP2D6","g.2850C>T","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1978","R61","CYP2D6","g.2850C>T","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1979","R61","CYP2D6","g.2850C>T","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1980","R61","CYP2D6","g.2850C>T","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1981","R61","CYP2D6","g.2850C>T","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1982","R61","CYP2D6","g.2850C>T","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1983","R61","CYP2D6","g.2850C>T","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1984","R61","CYP2D6","g.2850C>T","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1985","R61","CYP2D6","g.2850C>T","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1986","R61","CYP2D6","g.2850C>T","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1987","R61","CYP2D6","g.2850C>T","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1988","R61","CYP2D6","g.2850C>T","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1989","R61","CYP2D6","g.2850C>T","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1990","R61","CYP2D6","g.2850C>T","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1991","R61","CYP2D6","g.2850C>T","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1992","R61","CYP2D6","g.2850C>T","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1993","R63","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1994","R63","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1995","R63","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1996","R63","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1997","R63","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1998","R63","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"1999","R63","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2000","R63","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2001","R63","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2002","R63","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2003","R63","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2004","R63","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2005","R63","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2006","R63","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2007","R63","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2008","R63","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2009","R63","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2010","R63","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2011","R63","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2012","R63","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2013","R63","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2014","R63","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2015","R63","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2016","R63","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2017","R63","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2018","R63","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2019","R63","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2020","R63","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2021","R63","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2022","R63","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2023","R63","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2024","R63","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2025","R63","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2026","R63","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2027","R63","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2028","R63","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2029","R63","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2030","R63","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2031","R63","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2032","R63","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2033","R63","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2034","R63","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2035","R63","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2036","R63","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2037","R63","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2038","R63","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2039","R63","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2040","R63","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2041","R63","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2042","R71","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2043","R71","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2044","R71","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2045","R71","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2046","R71","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2047","R71","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2048","R71","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2049","R71","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2050","R71","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2051","R71","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2052","R71","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2053","R71","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2054","R71","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2055","R71","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2056","R71","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2057","R71","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2058","R71","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2059","R71","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2060","R71","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2061","R71","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2062","R71","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2063","R71","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2064","R71","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2065","R71","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2066","R71","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2067","R71","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2068","R71","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2069","R71","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2070","R71","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2071","R71","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2072","R71","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2073","R71","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2074","R71","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2075","R71","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2076","R71","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2077","R71","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2078","R71","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2079","R71","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2080","R71","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2081","R71","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2082","R71","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2083","R71","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2084","R71","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2085","R71","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2086","R71","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2087","R71","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2088","R71","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2089","R71","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2090","R71","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2091","R72","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2092","R72","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2093","R72","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2094","R72","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2095","R72","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2096","R72","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2097","R72","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2098","R72","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2099","R72","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2100","R72","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2101","R72","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2102","R72","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2103","R72","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2104","R72","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2105","R72","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2106","R72","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2107","R72","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2108","R72","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2109","R72","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2110","R72","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2111","R72","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2112","R72","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2113","R72","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2114","R72","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2115","R72","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2116","R72","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2117","R72","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2118","R72","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2119","R72","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2120","R72","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2121","R72","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2122","R72","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2123","R72","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2124","R72","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2125","R72","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2126","R72","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2127","R72","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2128","R72","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2129","R72","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2130","R72","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2131","R72","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2132","R72","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2133","R72","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2134","R72","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2135","R72","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2136","R72","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2137","R72","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2138","R72","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2139","R72","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2140","R79","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2141","R79","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2142","R79","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2143","R79","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2144","R79","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2145","R79","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2146","R79","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2147","R79","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2148","R79","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2149","R79","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2150","R79","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2151","R79","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2152","R79","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2153","R79","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2154","R79","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2155","R79","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2156","R79","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2157","R79","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2158","R79","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2159","R79","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2160","R79","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2161","R79","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2162","R79","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2163","R79","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2164","R79","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2165","R79","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2166","R79","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2167","R79","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2168","R79","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2169","R79","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2170","R79","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2171","R79","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2172","R79","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2173","R79","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2174","R79","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2175","R79","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2176","R79","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2177","R79","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2178","R79","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2179","R79","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2180","R79","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2181","R79","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2182","R79","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2183","R79","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2184","R79","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2185","R79","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2186","R79","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2187","R79","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2188","R79","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2189","R80","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2190","R80","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2191","R80","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2192","R80","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2193","R80","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2194","R80","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2195","R80","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2196","R80","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2197","R80","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2198","R80","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2199","R80","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2200","R80","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2201","R80","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2202","R80","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2203","R80","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2204","R80","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2205","R80","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2206","R80","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2207","R80","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2208","R80","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2209","R80","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2210","R80","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2211","R80","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2212","R80","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2213","R80","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2214","R80","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2215","R80","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2216","R80","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2217","R80","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2218","R80","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2219","R80","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2220","R80","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2221","R80","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2222","R80","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2223","R80","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2224","R80","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2225","R80","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2226","R80","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2227","R80","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2228","R80","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2229","R80","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2230","R80","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2231","R80","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2232","R80","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2233","R80","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2234","R80","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2235","R80","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2236","R80","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2237","R80","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2238","R81","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2239","R81","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2240","R81","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2241","R81","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2242","R81","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2243","R81","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2244","R81","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2245","R81","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2246","R81","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2247","R81","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2248","R81","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2249","R81","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2250","R81","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2251","R81","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2252","R81","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2253","R81","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2254","R81","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2255","R81","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2256","R81","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2257","R81","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2258","R81","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2259","R81","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2260","R81","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2261","R81","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2262","R81","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2263","R81","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2264","R81","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2265","R81","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2266","R81","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2267","R81","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2268","R81","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2269","R81","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2270","R81","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2271","R81","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2272","R81","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2273","R81","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2274","R81","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2275","R81","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2276","R81","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2277","R81","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2278","R81","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2279","R81","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2280","R81","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2281","R81","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2282","R81","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2283","R81","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2284","R81","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2285","R81","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2286","R81","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2287","R82","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2288","R82","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2289","R82","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2290","R82","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2291","R82","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2292","R82","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2293","R82","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2294","R82","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2295","R82","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2296","R82","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2297","R82","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2298","R82","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2299","R82","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2300","R82","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2301","R82","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2302","R82","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2303","R82","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2304","R82","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2305","R82","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2306","R82","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2307","R82","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2308","R82","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2309","R82","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2310","R82","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2311","R82","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2312","R82","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2313","R82","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2314","R82","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2315","R82","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2316","R82","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2317","R82","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2318","R82","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2319","R82","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2320","R82","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2321","R82","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2322","R82","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2323","R82","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2324","R82","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2325","R82","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2326","R82","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2327","R82","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2328","R82","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2329","R82","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2330","R82","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2331","R82","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2332","R82","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2333","R82","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2334","R82","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2335","R82","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2336","R84","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2337","R84","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2338","R84","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2339","R84","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2340","R84","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2341","R84","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2342","R84","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2343","R84","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2344","R84","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2345","R84","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2346","R84","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2347","R84","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2348","R84","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2349","R84","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2350","R84","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2351","R84","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2352","R84","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2353","R84","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2354","R84","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2355","R84","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2356","R84","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2357","R84","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2358","R84","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2359","R84","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2360","R84","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2361","R84","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2362","R84","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2363","R84","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2364","R84","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2365","R84","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2366","R84","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2367","R84","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2368","R84","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2369","R84","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2370","R84","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2371","R84","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2372","R84","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2373","R84","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2374","R84","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2375","R84","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2376","R84","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2377","R84","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2378","R84","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2379","R84","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2380","R84","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2381","R84","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2382","R84","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2383","R84","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2384","R84","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2385","V152","CYP2D6","g.2850C>T","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2386","V152","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2387","V152","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2388","V152","CYP2D6","g.2850C>T","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2389","V152","CYP2D6","g.2850C>T","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2390","V152","CYP2D6","g.2850C>T","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2391","V152","CYP2D6","g.2850C>T","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2392","V152","CYP2D6","g.2850C>T","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2393","V152","CYP2D6","g.2850C>T","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2394","V152","CYP2D6","g.2850C>T","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2395","V152","CYP2D6","g.2850C>T","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2396","V152","CYP2D6","g.2850C>T","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2397","V152","CYP2D6","g.2850C>T","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2398","V152","CYP2D6","g.2850C>T","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2399","V152","CYP2D6","g.2850C>T","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2400","V152","CYP2D6","g.2850C>T","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2401","V152","CYP2D6","g.2850C>T","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2402","V152","CYP2D6","g.2850C>T","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2403","V152","CYP2D6","g.2850C>T","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2404","V152","CYP2D6","g.2850C>T","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2405","V152","CYP2D6","g.2850C>T","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2406","V152","CYP2D6","g.2850C>T","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2407","V152","CYP2D6","g.2850C>T","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2408","V152","CYP2D6","g.2850C>T","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2409","V152","CYP2D6","g.2850C>T","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2410","V152","CYP2D6","g.2850C>T","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2411","V152","CYP2D6","g.2850C>T","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2412","V152","CYP2D6","g.2850C>T","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2413","V152","CYP2D6","g.2850C>T","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2414","V152","CYP2D6","g.2850C>T","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2415","V152","CYP2D6","g.2850C>T","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2416","V152","CYP2D6","g.2850C>T","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2417","V152","CYP2D6","g.2850C>T","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2418","V152","CYP2D6","g.2850C>T","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2419","V152","CYP2D6","g.2850C>T","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2420","V152","CYP2D6","g.2850C>T","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2421","V152","CYP2D6","g.2850C>T","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2422","V152","CYP2D6","g.2850C>T","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2423","V152","CYP2D6","g.2850C>T","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2424","V152","CYP2D6","g.2850C>T","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2425","V152","CYP2D6","g.2850C>T","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2426","V152","CYP2D6","g.2850C>T","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2427","V152","CYP2D6","g.2850C>T","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2428","V152","CYP2D6","g.2850C>T","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2429","V152","CYP2D6","g.2850C>T","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2430","V152","CYP2D6","g.2850C>T","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2431","V152","CYP2D6","g.2850C>T","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2432","V152","CYP2D6","g.2850C>T","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2433","V152","CYP2D6","g.2850C>T","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2434","R208","CYP2D6","g.2850C>T","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2435","R208","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2436","R208","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2437","R208","CYP2D6","g.2850C>T","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2438","R208","CYP2D6","g.2850C>T","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2439","R208","CYP2D6","g.2850C>T","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2440","R208","CYP2D6","g.2850C>T","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2441","R208","CYP2D6","g.2850C>T","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2442","R208","CYP2D6","g.2850C>T","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2443","R208","CYP2D6","g.2850C>T","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2444","R208","CYP2D6","g.2850C>T","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2445","R208","CYP2D6","g.2850C>T","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2446","R208","CYP2D6","g.2850C>T","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2447","R208","CYP2D6","g.2850C>T","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2448","R208","CYP2D6","g.2850C>T","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2449","R208","CYP2D6","g.2850C>T","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2450","R208","CYP2D6","g.2850C>T","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2451","R208","CYP2D6","g.2850C>T","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2452","R208","CYP2D6","g.2850C>T","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2453","R208","CYP2D6","g.2850C>T","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2454","R208","CYP2D6","g.2850C>T","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2455","R208","CYP2D6","g.2850C>T","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2456","R208","CYP2D6","g.2850C>T","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2457","R208","CYP2D6","g.2850C>T","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2458","R208","CYP2D6","g.2850C>T","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2459","R208","CYP2D6","g.2850C>T","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2460","R208","CYP2D6","g.2850C>T","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2461","R208","CYP2D6","g.2850C>T","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2462","R208","CYP2D6","g.2850C>T","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2463","R208","CYP2D6","g.2850C>T","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2464","R208","CYP2D6","g.2850C>T","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2465","R208","CYP2D6","g.2850C>T","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2466","R208","CYP2D6","g.2850C>T","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2467","R208","CYP2D6","g.2850C>T","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2468","R208","CYP2D6","g.2850C>T","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2469","R208","CYP2D6","g.2850C>T","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2470","R208","CYP2D6","g.2850C>T","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2471","R208","CYP2D6","g.2850C>T","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2472","R208","CYP2D6","g.2850C>T","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2473","R208","CYP2D6","g.2850C>T","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2474","R208","CYP2D6","g.2850C>T","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2475","R208","CYP2D6","g.2850C>T","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2476","R208","CYP2D6","g.2850C>T","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2477","R208","CYP2D6","g.2850C>T","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2478","R208","CYP2D6","g.2850C>T","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2479","R208","CYP2D6","g.2850C>T","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2480","R208","CYP2D6","g.2850C>T","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2481","R208","CYP2D6","g.2850C>T","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2482","R208","CYP2D6","g.2850C>T","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2483","R232","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2484","R232","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2485","R232","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2486","R232","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2487","R232","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2488","R232","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2489","R232","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2490","R232","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2491","R232","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2492","R232","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2493","R232","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2494","R232","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2495","R232","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2496","R232","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2497","R232","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2498","R232","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2499","R232","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2500","R232","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2501","R232","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2502","R232","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2503","R232","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2504","R232","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2505","R232","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2506","R232","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2507","R232","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2508","R232","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2509","R232","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2510","R232","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2511","R232","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2512","R232","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2513","R232","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2514","R232","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2515","R232","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2516","R232","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2517","R232","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2518","R232","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2519","R232","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2520","R232","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2521","R232","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2522","R232","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2523","R232","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2524","R232","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2525","R232","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2526","R232","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2527","R232","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2528","R232","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2529","R232","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2530","R232","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2531","R232","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2532","R233","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2533","R233","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2534","R233","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2535","R233","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2536","R233","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2537","R233","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2538","R233","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2539","R233","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2540","R233","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2541","R233","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2542","R233","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2543","R233","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2544","R233","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2545","R233","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2546","R233","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2547","R233","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2548","R233","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2549","R233","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2550","R233","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2551","R233","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2552","R233","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2553","R233","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2554","R233","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2555","R233","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2556","R233","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2557","R233","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2558","R233","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2559","R233","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2560","R233","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2561","R233","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2562","R233","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2563","R233","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2564","R233","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2565","R233","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2566","R233","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2567","R233","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2568","R233","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2569","R233","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2570","R233","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2571","R233","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2572","R233","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2573","R233","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2574","R233","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2575","R233","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2576","R233","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2577","R233","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2578","R233","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2579","R233","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2580","R233","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2581","R70","CYP2D6","g.2850C>T","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2582","R70","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2583","R70","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2584","R70","CYP2D6","g.2850C>T","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2585","R70","CYP2D6","g.2850C>T","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2586","R70","CYP2D6","g.2850C>T","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2587","R70","CYP2D6","g.2850C>T","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2588","R70","CYP2D6","g.2850C>T","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2589","R70","CYP2D6","g.2850C>T","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2590","R70","CYP2D6","g.2850C>T","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2591","R70","CYP2D6","g.2850C>T","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2592","R70","CYP2D6","g.2850C>T","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2593","R70","CYP2D6","g.2850C>T","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2594","R70","CYP2D6","g.2850C>T","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2595","R70","CYP2D6","g.2850C>T","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2596","R70","CYP2D6","g.2850C>T","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2597","R70","CYP2D6","g.2850C>T","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2598","R70","CYP2D6","g.2850C>T","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2599","R70","CYP2D6","g.2850C>T","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2600","R70","CYP2D6","g.2850C>T","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2601","R70","CYP2D6","g.2850C>T","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2602","R70","CYP2D6","g.2850C>T","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2603","R70","CYP2D6","g.2850C>T","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2604","R70","CYP2D6","g.2850C>T","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2605","R70","CYP2D6","g.2850C>T","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2606","R70","CYP2D6","g.2850C>T","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2607","R70","CYP2D6","g.2850C>T","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2608","R70","CYP2D6","g.2850C>T","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2609","R70","CYP2D6","g.2850C>T","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2610","R70","CYP2D6","g.2850C>T","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2611","R70","CYP2D6","g.2850C>T","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2612","R70","CYP2D6","g.2850C>T","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2613","R70","CYP2D6","g.2850C>T","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2614","R70","CYP2D6","g.2850C>T","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2615","R70","CYP2D6","g.2850C>T","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2616","R70","CYP2D6","g.2850C>T","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2617","R70","CYP2D6","g.2850C>T","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2618","R70","CYP2D6","g.2850C>T","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2619","R70","CYP2D6","g.2850C>T","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2620","R70","CYP2D6","g.2850C>T","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2621","R70","CYP2D6","g.2850C>T","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2622","R70","CYP2D6","g.2850C>T","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2623","R70","CYP2D6","g.2850C>T","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2624","R70","CYP2D6","g.2850C>T","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2625","R70","CYP2D6","g.2850C>T","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2626","R70","CYP2D6","g.2850C>T","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2627","R70","CYP2D6","g.2850C>T","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2628","R70","CYP2D6","g.2850C>T","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2629","R70","CYP2D6","g.2850C>T","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2630","R214","CYP2D6","g.2850C>T","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2631","R214","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2632","R214","CYP2D6","g.2850C>T","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2633","R214","CYP2D6","g.2850C>T","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2634","R214","CYP2D6","g.2850C>T","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2635","R214","CYP2D6","g.2850C>T","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2636","R214","CYP2D6","g.2850C>T","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2637","R214","CYP2D6","g.2850C>T","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2638","R214","CYP2D6","g.2850C>T","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2639","R214","CYP2D6","g.2850C>T","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2640","R214","CYP2D6","g.2850C>T","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2641","R214","CYP2D6","g.2850C>T","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2642","R214","CYP2D6","g.2850C>T","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2643","R214","CYP2D6","g.2850C>T","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2644","R214","CYP2D6","g.2850C>T","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2645","R214","CYP2D6","g.2850C>T","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2646","R214","CYP2D6","g.2850C>T","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2647","R214","CYP2D6","g.2850C>T","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2648","R214","CYP2D6","g.2850C>T","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2649","R214","CYP2D6","g.2850C>T","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2650","R214","CYP2D6","g.2850C>T","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2651","R214","CYP2D6","g.2850C>T","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2652","R214","CYP2D6","g.2850C>T","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2653","R214","CYP2D6","g.2850C>T","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2654","R214","CYP2D6","g.2850C>T","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2655","R214","CYP2D6","g.2850C>T","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2656","R214","CYP2D6","g.2850C>T","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2657","R214","CYP2D6","g.2850C>T","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2658","R214","CYP2D6","g.2850C>T","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2659","R214","CYP2D6","g.2850C>T","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2660","R214","CYP2D6","g.2850C>T","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2661","R214","CYP2D6","g.2850C>T","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2662","R214","CYP2D6","g.2850C>T","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2663","R214","CYP2D6","g.2850C>T","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2664","R214","CYP2D6","g.2850C>T","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2665","R214","CYP2D6","g.2850C>T","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2666","R214","CYP2D6","g.2850C>T","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2667","R214","CYP2D6","g.2850C>T","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2668","R214","CYP2D6","g.2850C>T","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2669","R214","CYP2D6","g.2850C>T","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2670","R214","CYP2D6","g.2850C>T","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2671","R214","CYP2D6","g.2850C>T","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2672","R214","CYP2D6","g.2850C>T","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2673","R214","CYP2D6","g.2850C>T","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2674","R214","CYP2D6","g.2850C>T","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2675","R214","CYP2D6","g.2850C>T","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2676","R214","CYP2D6","g.2850C>T","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2677","R214","CYP2D6","g.2850C>T","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2678","R214","CYP2D6","g.2850C>T","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2679","R66","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2680","R66","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2681","R66","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2682","R66","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2683","R66","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2684","R66","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2685","R66","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2686","R66","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2687","R66","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2688","R66","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2689","R66","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2690","R66","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2691","R66","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2692","R66","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2693","R66","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2694","R66","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2695","R66","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2696","R66","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2697","R66","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2698","R66","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2699","R66","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2700","R66","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2701","R66","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2702","R66","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2703","R66","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2704","R66","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2705","R66","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2706","R66","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2707","R66","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2708","R66","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2709","R66","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2710","R66","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2711","R66","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2712","R66","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2713","R66","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2714","R66","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2715","R66","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2716","R66","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2717","R66","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2718","R66","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2719","R66","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2720","R66","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2721","R66","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2722","R66","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2723","R66","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2724","R66","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2725","R66","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2726","R66","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2727","R66","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2728","R75","CYP2D6","g.2850C>T","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2729","R75","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2730","R75","CYP2D6","g.2850C>T","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2731","R75","CYP2D6","g.2850C>T","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2732","R75","CYP2D6","g.2850C>T","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2733","R75","CYP2D6","g.2850C>T","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2734","R75","CYP2D6","g.2850C>T","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2735","R75","CYP2D6","g.2850C>T","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2736","R75","CYP2D6","g.2850C>T","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2737","R75","CYP2D6","g.2850C>T","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2738","R75","CYP2D6","g.2850C>T","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2739","R75","CYP2D6","g.2850C>T","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2740","R75","CYP2D6","g.2850C>T","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2741","R75","CYP2D6","g.2850C>T","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2742","R75","CYP2D6","g.2850C>T","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2743","R75","CYP2D6","g.2850C>T","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2744","R75","CYP2D6","g.2850C>T","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2745","R75","CYP2D6","g.2850C>T","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2746","R75","CYP2D6","g.2850C>T","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2747","R75","CYP2D6","g.2850C>T","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2748","R75","CYP2D6","g.2850C>T","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2749","R75","CYP2D6","g.2850C>T","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2750","R75","CYP2D6","g.2850C>T","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2751","R75","CYP2D6","g.2850C>T","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2752","R75","CYP2D6","g.2850C>T","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2753","R75","CYP2D6","g.2850C>T","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2754","R75","CYP2D6","g.2850C>T","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2755","R75","CYP2D6","g.2850C>T","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2756","R75","CYP2D6","g.2850C>T","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2757","R75","CYP2D6","g.2850C>T","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2758","R75","CYP2D6","g.2850C>T","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2759","R75","CYP2D6","g.2850C>T","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2760","R75","CYP2D6","g.2850C>T","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2761","R75","CYP2D6","g.2850C>T","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2762","R75","CYP2D6","g.2850C>T","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2763","R75","CYP2D6","g.2850C>T","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2764","R75","CYP2D6","g.2850C>T","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2765","R75","CYP2D6","g.2850C>T","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2766","R75","CYP2D6","g.2850C>T","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2767","R75","CYP2D6","g.2850C>T","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2768","R75","CYP2D6","g.2850C>T","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2769","R75","CYP2D6","g.2850C>T","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2770","R75","CYP2D6","g.2850C>T","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2771","R75","CYP2D6","g.2850C>T","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2772","R75","CYP2D6","g.2850C>T","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2773","R75","CYP2D6","g.2850C>T","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2774","R75","CYP2D6","g.2850C>T","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2775","R75","CYP2D6","g.2850C>T","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2776","R75","CYP2D6","g.2850C>T","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2777","R61","CYP2B6","*22","g.-82T>C","0",1,"Efavirenz","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily B member 6","chr19"
"2778","R209","CYP3A5","*6","g.14690G>A","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"2779","R217","CYP3A5","*6","g.14690G>A","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"2780","R57","CYP3A5","*6","g.14690G>A","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"2781","R59","CYP3A5","*6","g.14690G>A","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"2782","R84","CYP3A5","*6","g.14690G>A","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"2783","R231","CYP3A5","*6","g.14690G>A","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"2784","R211","CYP2D6","*4A","g.1846G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2785","R211","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2786","R211","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2787","R211","CYP2D6","*4A","g.1846G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2788","R211","CYP2D6","*4A","g.1846G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2789","R211","CYP2D6","*4A","g.1846G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2790","R211","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2791","R211","CYP2D6","*4A","g.1846G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2792","R211","CYP2D6","*4A","g.1846G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2793","R211","CYP2D6","*4A","g.1846G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2794","R211","CYP2D6","*4A","g.1846G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2795","R211","CYP2D6","*4A","g.1846G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2796","R211","CYP2D6","*4A","g.1846G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2797","R211","CYP2D6","*4A","g.1846G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2798","R211","CYP2D6","*4A","g.1846G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2799","R211","CYP2D6","*4A","g.1846G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2800","R211","CYP2D6","*4A","g.1846G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2801","R211","CYP2D6","*4A","g.1846G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2802","R211","CYP2D6","*4A","g.1846G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2803","R211","CYP2D6","*4A","g.1846G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2804","R211","CYP2D6","*4A","g.1846G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2805","R211","CYP2D6","*4A","g.1846G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2806","R211","CYP2D6","*4A","g.1846G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2807","R211","CYP2D6","*4A","g.1846G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2808","R211","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2809","R211","CYP2D6","*4A","g.1846G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2810","R211","CYP2D6","*4A","g.1846G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2811","R211","CYP2D6","*4A","g.1846G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2812","R211","CYP2D6","*4A","g.1846G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2813","R211","CYP2D6","*4A","g.1846G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2814","R211","CYP2D6","*4A","g.1846G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2815","R211","CYP2D6","*4A","g.1846G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2816","R211","CYP2D6","*4A","g.1846G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2817","R211","CYP2D6","*4A","g.1846G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2818","R211","CYP2D6","*4A","g.1846G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2819","R211","CYP2D6","*4A","g.1846G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2820","R211","CYP2D6","*4A","g.1846G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2821","R211","CYP2D6","*4A","g.1846G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2822","R211","CYP2D6","*4A","g.1846G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2823","R211","CYP2D6","*4A","g.1846G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2824","R211","CYP2D6","*4A","g.1846G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2825","R211","CYP2D6","*4A","g.1846G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2826","R211","CYP2D6","*4A","g.1846G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2827","R211","CYP2D6","*4A","g.1846G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2828","R211","CYP2D6","*4A","g.1846G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2829","R211","CYP2D6","*4A","g.1846G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2830","R211","CYP2D6","*4A","g.1846G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2831","R211","CYP2D6","*4A","g.1846G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2832","R211","CYP2D6","*4A","g.1846G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2833","R212","CYP2D6","*4A","g.1846G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2834","R212","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2835","R212","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2836","R212","CYP2D6","*4A","g.1846G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2837","R212","CYP2D6","*4A","g.1846G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2838","R212","CYP2D6","*4A","g.1846G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2839","R212","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2840","R212","CYP2D6","*4A","g.1846G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2841","R212","CYP2D6","*4A","g.1846G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2842","R212","CYP2D6","*4A","g.1846G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2843","R212","CYP2D6","*4A","g.1846G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2844","R212","CYP2D6","*4A","g.1846G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2845","R212","CYP2D6","*4A","g.1846G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2846","R212","CYP2D6","*4A","g.1846G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2847","R212","CYP2D6","*4A","g.1846G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2848","R212","CYP2D6","*4A","g.1846G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2849","R212","CYP2D6","*4A","g.1846G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2850","R212","CYP2D6","*4A","g.1846G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2851","R212","CYP2D6","*4A","g.1846G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2852","R212","CYP2D6","*4A","g.1846G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2853","R212","CYP2D6","*4A","g.1846G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2854","R212","CYP2D6","*4A","g.1846G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2855","R212","CYP2D6","*4A","g.1846G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2856","R212","CYP2D6","*4A","g.1846G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2857","R212","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2858","R212","CYP2D6","*4A","g.1846G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2859","R212","CYP2D6","*4A","g.1846G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2860","R212","CYP2D6","*4A","g.1846G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2861","R212","CYP2D6","*4A","g.1846G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2862","R212","CYP2D6","*4A","g.1846G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2863","R212","CYP2D6","*4A","g.1846G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2864","R212","CYP2D6","*4A","g.1846G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2865","R212","CYP2D6","*4A","g.1846G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2866","R212","CYP2D6","*4A","g.1846G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2867","R212","CYP2D6","*4A","g.1846G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2868","R212","CYP2D6","*4A","g.1846G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2869","R212","CYP2D6","*4A","g.1846G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2870","R212","CYP2D6","*4A","g.1846G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2871","R212","CYP2D6","*4A","g.1846G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2872","R212","CYP2D6","*4A","g.1846G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2873","R212","CYP2D6","*4A","g.1846G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2874","R212","CYP2D6","*4A","g.1846G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2875","R212","CYP2D6","*4A","g.1846G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2876","R212","CYP2D6","*4A","g.1846G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2877","R212","CYP2D6","*4A","g.1846G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2878","R212","CYP2D6","*4A","g.1846G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2879","R212","CYP2D6","*4A","g.1846G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2880","R212","CYP2D6","*4A","g.1846G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2881","R212","CYP2D6","*4A","g.1846G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2882","R213","CYP2D6","*4A","g.1846G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2883","R213","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2884","R213","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2885","R213","CYP2D6","*4A","g.1846G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2886","R213","CYP2D6","*4A","g.1846G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2887","R213","CYP2D6","*4A","g.1846G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2888","R213","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2889","R213","CYP2D6","*4A","g.1846G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2890","R213","CYP2D6","*4A","g.1846G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2891","R213","CYP2D6","*4A","g.1846G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2892","R213","CYP2D6","*4A","g.1846G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2893","R213","CYP2D6","*4A","g.1846G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2894","R213","CYP2D6","*4A","g.1846G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2895","R213","CYP2D6","*4A","g.1846G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2896","R213","CYP2D6","*4A","g.1846G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2897","R213","CYP2D6","*4A","g.1846G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2898","R213","CYP2D6","*4A","g.1846G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2899","R213","CYP2D6","*4A","g.1846G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2900","R213","CYP2D6","*4A","g.1846G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2901","R213","CYP2D6","*4A","g.1846G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2902","R213","CYP2D6","*4A","g.1846G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2903","R213","CYP2D6","*4A","g.1846G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2904","R213","CYP2D6","*4A","g.1846G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2905","R213","CYP2D6","*4A","g.1846G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2906","R213","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2907","R213","CYP2D6","*4A","g.1846G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2908","R213","CYP2D6","*4A","g.1846G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2909","R213","CYP2D6","*4A","g.1846G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2910","R213","CYP2D6","*4A","g.1846G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2911","R213","CYP2D6","*4A","g.1846G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2912","R213","CYP2D6","*4A","g.1846G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2913","R213","CYP2D6","*4A","g.1846G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2914","R213","CYP2D6","*4A","g.1846G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2915","R213","CYP2D6","*4A","g.1846G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2916","R213","CYP2D6","*4A","g.1846G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2917","R213","CYP2D6","*4A","g.1846G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2918","R213","CYP2D6","*4A","g.1846G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2919","R213","CYP2D6","*4A","g.1846G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2920","R213","CYP2D6","*4A","g.1846G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2921","R213","CYP2D6","*4A","g.1846G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2922","R213","CYP2D6","*4A","g.1846G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2923","R213","CYP2D6","*4A","g.1846G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2924","R213","CYP2D6","*4A","g.1846G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2925","R213","CYP2D6","*4A","g.1846G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2926","R213","CYP2D6","*4A","g.1846G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2927","R213","CYP2D6","*4A","g.1846G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2928","R213","CYP2D6","*4A","g.1846G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2929","R213","CYP2D6","*4A","g.1846G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2930","R213","CYP2D6","*4A","g.1846G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2931","R218","CYP2D6","*4A","g.1846G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2932","R218","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2933","R218","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2934","R218","CYP2D6","*4A","g.1846G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2935","R218","CYP2D6","*4A","g.1846G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2936","R218","CYP2D6","*4A","g.1846G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2937","R218","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2938","R218","CYP2D6","*4A","g.1846G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2939","R218","CYP2D6","*4A","g.1846G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2940","R218","CYP2D6","*4A","g.1846G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2941","R218","CYP2D6","*4A","g.1846G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2942","R218","CYP2D6","*4A","g.1846G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2943","R218","CYP2D6","*4A","g.1846G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2944","R218","CYP2D6","*4A","g.1846G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2945","R218","CYP2D6","*4A","g.1846G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2946","R218","CYP2D6","*4A","g.1846G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2947","R218","CYP2D6","*4A","g.1846G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2948","R218","CYP2D6","*4A","g.1846G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2949","R218","CYP2D6","*4A","g.1846G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2950","R218","CYP2D6","*4A","g.1846G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2951","R218","CYP2D6","*4A","g.1846G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2952","R218","CYP2D6","*4A","g.1846G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2953","R218","CYP2D6","*4A","g.1846G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2954","R218","CYP2D6","*4A","g.1846G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2955","R218","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2956","R218","CYP2D6","*4A","g.1846G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2957","R218","CYP2D6","*4A","g.1846G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2958","R218","CYP2D6","*4A","g.1846G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2959","R218","CYP2D6","*4A","g.1846G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2960","R218","CYP2D6","*4A","g.1846G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2961","R218","CYP2D6","*4A","g.1846G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2962","R218","CYP2D6","*4A","g.1846G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2963","R218","CYP2D6","*4A","g.1846G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2964","R218","CYP2D6","*4A","g.1846G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2965","R218","CYP2D6","*4A","g.1846G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2966","R218","CYP2D6","*4A","g.1846G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2967","R218","CYP2D6","*4A","g.1846G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2968","R218","CYP2D6","*4A","g.1846G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2969","R218","CYP2D6","*4A","g.1846G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2970","R218","CYP2D6","*4A","g.1846G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2971","R218","CYP2D6","*4A","g.1846G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2972","R218","CYP2D6","*4A","g.1846G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2973","R218","CYP2D6","*4A","g.1846G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2974","R218","CYP2D6","*4A","g.1846G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2975","R218","CYP2D6","*4A","g.1846G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2976","R218","CYP2D6","*4A","g.1846G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2977","R218","CYP2D6","*4A","g.1846G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2978","R218","CYP2D6","*4A","g.1846G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2979","R218","CYP2D6","*4A","g.1846G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2980","R68","CYP2D6","*4A","g.1846G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2981","R68","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2982","R68","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2983","R68","CYP2D6","*4A","g.1846G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2984","R68","CYP2D6","*4A","g.1846G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2985","R68","CYP2D6","*4A","g.1846G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2986","R68","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2987","R68","CYP2D6","*4A","g.1846G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"2988","R68","CYP2D6","*4A","g.1846G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2989","R68","CYP2D6","*4A","g.1846G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2990","R68","CYP2D6","*4A","g.1846G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2991","R68","CYP2D6","*4A","g.1846G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2992","R68","CYP2D6","*4A","g.1846G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2993","R68","CYP2D6","*4A","g.1846G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2994","R68","CYP2D6","*4A","g.1846G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2995","R68","CYP2D6","*4A","g.1846G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2996","R68","CYP2D6","*4A","g.1846G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2997","R68","CYP2D6","*4A","g.1846G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2998","R68","CYP2D6","*4A","g.1846G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"2999","R68","CYP2D6","*4A","g.1846G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3000","R68","CYP2D6","*4A","g.1846G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3001","R68","CYP2D6","*4A","g.1846G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3002","R68","CYP2D6","*4A","g.1846G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3003","R68","CYP2D6","*4A","g.1846G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3004","R68","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3005","R68","CYP2D6","*4A","g.1846G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3006","R68","CYP2D6","*4A","g.1846G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3007","R68","CYP2D6","*4A","g.1846G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3008","R68","CYP2D6","*4A","g.1846G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3009","R68","CYP2D6","*4A","g.1846G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3010","R68","CYP2D6","*4A","g.1846G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3011","R68","CYP2D6","*4A","g.1846G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3012","R68","CYP2D6","*4A","g.1846G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3013","R68","CYP2D6","*4A","g.1846G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3014","R68","CYP2D6","*4A","g.1846G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3015","R68","CYP2D6","*4A","g.1846G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3016","R68","CYP2D6","*4A","g.1846G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3017","R68","CYP2D6","*4A","g.1846G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3018","R68","CYP2D6","*4A","g.1846G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3019","R68","CYP2D6","*4A","g.1846G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3020","R68","CYP2D6","*4A","g.1846G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3021","R68","CYP2D6","*4A","g.1846G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3022","R68","CYP2D6","*4A","g.1846G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3023","R68","CYP2D6","*4A","g.1846G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3024","R68","CYP2D6","*4A","g.1846G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3025","R68","CYP2D6","*4A","g.1846G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3026","R68","CYP2D6","*4A","g.1846G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3027","R68","CYP2D6","*4A","g.1846G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3028","R68","CYP2D6","*4A","g.1846G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3029","R81","CYP2D6","*4A","g.1846G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3030","R81","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3031","R81","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3032","R81","CYP2D6","*4A","g.1846G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3033","R81","CYP2D6","*4A","g.1846G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3034","R81","CYP2D6","*4A","g.1846G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3035","R81","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3036","R81","CYP2D6","*4A","g.1846G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3037","R81","CYP2D6","*4A","g.1846G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3038","R81","CYP2D6","*4A","g.1846G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3039","R81","CYP2D6","*4A","g.1846G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3040","R81","CYP2D6","*4A","g.1846G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3041","R81","CYP2D6","*4A","g.1846G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3042","R81","CYP2D6","*4A","g.1846G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3043","R81","CYP2D6","*4A","g.1846G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3044","R81","CYP2D6","*4A","g.1846G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3045","R81","CYP2D6","*4A","g.1846G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3046","R81","CYP2D6","*4A","g.1846G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3047","R81","CYP2D6","*4A","g.1846G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3048","R81","CYP2D6","*4A","g.1846G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3049","R81","CYP2D6","*4A","g.1846G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3050","R81","CYP2D6","*4A","g.1846G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3051","R81","CYP2D6","*4A","g.1846G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3052","R81","CYP2D6","*4A","g.1846G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3053","R81","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3054","R81","CYP2D6","*4A","g.1846G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3055","R81","CYP2D6","*4A","g.1846G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3056","R81","CYP2D6","*4A","g.1846G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3057","R81","CYP2D6","*4A","g.1846G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3058","R81","CYP2D6","*4A","g.1846G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3059","R81","CYP2D6","*4A","g.1846G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3060","R81","CYP2D6","*4A","g.1846G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3061","R81","CYP2D6","*4A","g.1846G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3062","R81","CYP2D6","*4A","g.1846G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3063","R81","CYP2D6","*4A","g.1846G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3064","R81","CYP2D6","*4A","g.1846G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3065","R81","CYP2D6","*4A","g.1846G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3066","R81","CYP2D6","*4A","g.1846G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3067","R81","CYP2D6","*4A","g.1846G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3068","R81","CYP2D6","*4A","g.1846G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3069","R81","CYP2D6","*4A","g.1846G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3070","R81","CYP2D6","*4A","g.1846G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3071","R81","CYP2D6","*4A","g.1846G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3072","R81","CYP2D6","*4A","g.1846G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3073","R81","CYP2D6","*4A","g.1846G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3074","R81","CYP2D6","*4A","g.1846G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3075","R81","CYP2D6","*4A","g.1846G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3076","R81","CYP2D6","*4A","g.1846G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3077","R81","CYP2D6","*4A","g.1846G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3078","V152","CYP2D6","*4A","g.1846G>A","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3079","V152","CYP2D6","*4A","g.1846G>A","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3080","V152","CYP2D6","*4A","g.1846G>A","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3081","V152","CYP2D6","*4A","g.1846G>A","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3082","V152","CYP2D6","*4A","g.1846G>A","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3083","V152","CYP2D6","*4A","g.1846G>A","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3084","V152","CYP2D6","*4A","g.1846G>A","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3085","V152","CYP2D6","*4A","g.1846G>A","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3086","V152","CYP2D6","*4A","g.1846G>A","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3087","V152","CYP2D6","*4A","g.1846G>A","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3088","V152","CYP2D6","*4A","g.1846G>A","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3089","V152","CYP2D6","*4A","g.1846G>A","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3090","V152","CYP2D6","*4A","g.1846G>A","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3091","V152","CYP2D6","*4A","g.1846G>A","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3092","V152","CYP2D6","*4A","g.1846G>A","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3093","V152","CYP2D6","*4A","g.1846G>A","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3094","V152","CYP2D6","*4A","g.1846G>A","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3095","V152","CYP2D6","*4A","g.1846G>A","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3096","V152","CYP2D6","*4A","g.1846G>A","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3097","V152","CYP2D6","*4A","g.1846G>A","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3098","V152","CYP2D6","*4A","g.1846G>A","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3099","V152","CYP2D6","*4A","g.1846G>A","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3100","V152","CYP2D6","*4A","g.1846G>A","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3101","V152","CYP2D6","*4A","g.1846G>A","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3102","V152","CYP2D6","*4A","g.1846G>A","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3103","V152","CYP2D6","*4A","g.1846G>A","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3104","V152","CYP2D6","*4A","g.1846G>A","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3105","V152","CYP2D6","*4A","g.1846G>A","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3106","V152","CYP2D6","*4A","g.1846G>A","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3107","V152","CYP2D6","*4A","g.1846G>A","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3108","V152","CYP2D6","*4A","g.1846G>A","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3109","V152","CYP2D6","*4A","g.1846G>A","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3110","V152","CYP2D6","*4A","g.1846G>A","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3111","V152","CYP2D6","*4A","g.1846G>A","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3112","V152","CYP2D6","*4A","g.1846G>A","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3113","V152","CYP2D6","*4A","g.1846G>A","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3114","V152","CYP2D6","*4A","g.1846G>A","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3115","V152","CYP2D6","*4A","g.1846G>A","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3116","V152","CYP2D6","*4A","g.1846G>A","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3117","V152","CYP2D6","*4A","g.1846G>A","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3118","V152","CYP2D6","*4A","g.1846G>A","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3119","V152","CYP2D6","*4A","g.1846G>A","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3120","V152","CYP2D6","*4A","g.1846G>A","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3121","V152","CYP2D6","*4A","g.1846G>A","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3122","V152","CYP2D6","*4A","g.1846G>A","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3123","V152","CYP2D6","*4A","g.1846G>A","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3124","V152","CYP2D6","*4A","g.1846G>A","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3125","V152","CYP2D6","*4A","g.1846G>A","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3126","V152","CYP2D6","*4A","g.1846G>A","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3127","R208","CYP2D6","*4A","g.1846G>A","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3128","R208","CYP2D6","*4A","g.1846G>A","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3129","R208","CYP2D6","*4A","g.1846G>A","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3130","R208","CYP2D6","*4A","g.1846G>A","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3131","R208","CYP2D6","*4A","g.1846G>A","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3132","R208","CYP2D6","*4A","g.1846G>A","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3133","R208","CYP2D6","*4A","g.1846G>A","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3134","R208","CYP2D6","*4A","g.1846G>A","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3135","R208","CYP2D6","*4A","g.1846G>A","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3136","R208","CYP2D6","*4A","g.1846G>A","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3137","R208","CYP2D6","*4A","g.1846G>A","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3138","R208","CYP2D6","*4A","g.1846G>A","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3139","R208","CYP2D6","*4A","g.1846G>A","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3140","R208","CYP2D6","*4A","g.1846G>A","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3141","R208","CYP2D6","*4A","g.1846G>A","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3142","R208","CYP2D6","*4A","g.1846G>A","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3143","R208","CYP2D6","*4A","g.1846G>A","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3144","R208","CYP2D6","*4A","g.1846G>A","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3145","R208","CYP2D6","*4A","g.1846G>A","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3146","R208","CYP2D6","*4A","g.1846G>A","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3147","R208","CYP2D6","*4A","g.1846G>A","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3148","R208","CYP2D6","*4A","g.1846G>A","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3149","R208","CYP2D6","*4A","g.1846G>A","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3150","R208","CYP2D6","*4A","g.1846G>A","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3151","R208","CYP2D6","*4A","g.1846G>A","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3152","R208","CYP2D6","*4A","g.1846G>A","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3153","R208","CYP2D6","*4A","g.1846G>A","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3154","R208","CYP2D6","*4A","g.1846G>A","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3155","R208","CYP2D6","*4A","g.1846G>A","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3156","R208","CYP2D6","*4A","g.1846G>A","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3157","R208","CYP2D6","*4A","g.1846G>A","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3158","R208","CYP2D6","*4A","g.1846G>A","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3159","R208","CYP2D6","*4A","g.1846G>A","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3160","R208","CYP2D6","*4A","g.1846G>A","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3161","R208","CYP2D6","*4A","g.1846G>A","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3162","R208","CYP2D6","*4A","g.1846G>A","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3163","R208","CYP2D6","*4A","g.1846G>A","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3164","R208","CYP2D6","*4A","g.1846G>A","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3165","R208","CYP2D6","*4A","g.1846G>A","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3166","R208","CYP2D6","*4A","g.1846G>A","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3167","R208","CYP2D6","*4A","g.1846G>A","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3168","R208","CYP2D6","*4A","g.1846G>A","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3169","R208","CYP2D6","*4A","g.1846G>A","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3170","R208","CYP2D6","*4A","g.1846G>A","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3171","R208","CYP2D6","*4A","g.1846G>A","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3172","R208","CYP2D6","*4A","g.1846G>A","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3173","R208","CYP2D6","*4A","g.1846G>A","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3174","R208","CYP2D6","*4A","g.1846G>A","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3175","R208","CYP2D6","*4A","g.1846G>A","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3176","R214","CYP2D6","*4A","g.1846G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3177","R214","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3178","R214","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3179","R214","CYP2D6","*4A","g.1846G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3180","R214","CYP2D6","*4A","g.1846G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3181","R214","CYP2D6","*4A","g.1846G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3182","R214","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3183","R214","CYP2D6","*4A","g.1846G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3184","R214","CYP2D6","*4A","g.1846G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3185","R214","CYP2D6","*4A","g.1846G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3186","R214","CYP2D6","*4A","g.1846G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3187","R214","CYP2D6","*4A","g.1846G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3188","R214","CYP2D6","*4A","g.1846G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3189","R214","CYP2D6","*4A","g.1846G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3190","R214","CYP2D6","*4A","g.1846G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3191","R214","CYP2D6","*4A","g.1846G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3192","R214","CYP2D6","*4A","g.1846G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3193","R214","CYP2D6","*4A","g.1846G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3194","R214","CYP2D6","*4A","g.1846G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3195","R214","CYP2D6","*4A","g.1846G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3196","R214","CYP2D6","*4A","g.1846G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3197","R214","CYP2D6","*4A","g.1846G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3198","R214","CYP2D6","*4A","g.1846G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3199","R214","CYP2D6","*4A","g.1846G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3200","R214","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3201","R214","CYP2D6","*4A","g.1846G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3202","R214","CYP2D6","*4A","g.1846G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3203","R214","CYP2D6","*4A","g.1846G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3204","R214","CYP2D6","*4A","g.1846G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3205","R214","CYP2D6","*4A","g.1846G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3206","R214","CYP2D6","*4A","g.1846G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3207","R214","CYP2D6","*4A","g.1846G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3208","R214","CYP2D6","*4A","g.1846G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3209","R214","CYP2D6","*4A","g.1846G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3210","R214","CYP2D6","*4A","g.1846G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3211","R214","CYP2D6","*4A","g.1846G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3212","R214","CYP2D6","*4A","g.1846G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3213","R214","CYP2D6","*4A","g.1846G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3214","R214","CYP2D6","*4A","g.1846G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3215","R214","CYP2D6","*4A","g.1846G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3216","R214","CYP2D6","*4A","g.1846G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3217","R214","CYP2D6","*4A","g.1846G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3218","R214","CYP2D6","*4A","g.1846G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3219","R214","CYP2D6","*4A","g.1846G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3220","R214","CYP2D6","*4A","g.1846G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3221","R214","CYP2D6","*4A","g.1846G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3222","R214","CYP2D6","*4A","g.1846G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3223","R214","CYP2D6","*4A","g.1846G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3224","R214","CYP2D6","*4A","g.1846G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3225","R65","CYP2D6","*4A","g.1846G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3226","R65","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3227","R65","CYP2D6","*4A","g.1846G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3228","R65","CYP2D6","*4A","g.1846G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3229","R65","CYP2D6","*4A","g.1846G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3230","R65","CYP2D6","*4A","g.1846G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3231","R65","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3232","R65","CYP2D6","*4A","g.1846G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3233","R65","CYP2D6","*4A","g.1846G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3234","R65","CYP2D6","*4A","g.1846G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3235","R65","CYP2D6","*4A","g.1846G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3236","R65","CYP2D6","*4A","g.1846G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3237","R65","CYP2D6","*4A","g.1846G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3238","R65","CYP2D6","*4A","g.1846G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3239","R65","CYP2D6","*4A","g.1846G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3240","R65","CYP2D6","*4A","g.1846G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3241","R65","CYP2D6","*4A","g.1846G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3242","R65","CYP2D6","*4A","g.1846G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3243","R65","CYP2D6","*4A","g.1846G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3244","R65","CYP2D6","*4A","g.1846G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3245","R65","CYP2D6","*4A","g.1846G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3246","R65","CYP2D6","*4A","g.1846G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3247","R65","CYP2D6","*4A","g.1846G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3248","R65","CYP2D6","*4A","g.1846G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3249","R65","CYP2D6","*4A","g.1846G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3250","R65","CYP2D6","*4A","g.1846G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3251","R65","CYP2D6","*4A","g.1846G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3252","R65","CYP2D6","*4A","g.1846G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3253","R65","CYP2D6","*4A","g.1846G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3254","R65","CYP2D6","*4A","g.1846G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3255","R65","CYP2D6","*4A","g.1846G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3256","R65","CYP2D6","*4A","g.1846G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3257","R65","CYP2D6","*4A","g.1846G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3258","R65","CYP2D6","*4A","g.1846G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3259","R65","CYP2D6","*4A","g.1846G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3260","R65","CYP2D6","*4A","g.1846G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3261","R65","CYP2D6","*4A","g.1846G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3262","R65","CYP2D6","*4A","g.1846G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3263","R65","CYP2D6","*4A","g.1846G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3264","R65","CYP2D6","*4A","g.1846G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3265","R65","CYP2D6","*4A","g.1846G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3266","R65","CYP2D6","*4A","g.1846G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3267","R65","CYP2D6","*4A","g.1846G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3268","R65","CYP2D6","*4A","g.1846G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3269","R65","CYP2D6","*4A","g.1846G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3270","R65","CYP2D6","*4A","g.1846G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3271","R65","CYP2D6","*4A","g.1846G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3272","R65","CYP2D6","*4A","g.1846G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3273","R65","CYP2D6","*4A","g.1846G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3274","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3275","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3276","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3277","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3278","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3279","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3280","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3281","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3282","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3283","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3284","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3285","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3286","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3287","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3288","R05","CYP2C19","*2","c.681G>A","g.19154G>A",2,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3289","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3290","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3291","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3292","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3293","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3294","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3295","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3296","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3297","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3298","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3299","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3300","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3301","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3302","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3303","R202","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3304","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3305","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3306","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3307","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3308","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3309","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3310","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3311","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3312","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3313","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3314","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3315","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3316","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3317","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3318","R203","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3319","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3320","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3321","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3322","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3323","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3324","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3325","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3326","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3327","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3328","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3329","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3330","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3331","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3332","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3333","R213","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3334","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3335","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3336","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3337","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3338","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3339","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3340","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3341","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3342","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3343","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3344","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3345","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3346","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3347","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3348","R217","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3349","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3350","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3351","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3352","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3353","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3354","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3355","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3356","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3357","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3358","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3359","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3360","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3361","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3362","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3363","R221","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3364","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3365","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3366","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3367","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3368","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3369","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3370","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3371","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3372","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3373","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3374","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3375","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3376","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3377","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3378","R223","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3379","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3380","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3381","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3382","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3383","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3384","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3385","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3386","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3387","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3388","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3389","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3390","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3391","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3392","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3393","R227","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3394","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3395","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3396","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3397","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3398","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3399","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3400","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3401","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3402","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3403","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3404","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3405","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3406","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3407","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3408","R58","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3409","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3410","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3411","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3412","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3413","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3414","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3415","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3416","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3417","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3418","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3419","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3420","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3421","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3422","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3423","R62","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3424","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3425","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3426","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3427","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3428","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3429","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3430","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3431","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3432","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3433","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3434","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3435","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3436","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3437","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3438","R63","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3439","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3440","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3441","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3442","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3443","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3444","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3445","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3446","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3447","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3448","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3449","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3450","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3451","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3452","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3453","R68","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3454","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3455","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3456","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3457","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3458","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3459","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3460","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3461","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3462","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3463","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3464","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3465","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3466","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3467","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3468","R73","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3469","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3470","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3471","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3472","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3473","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3474","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3475","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3476","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3477","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3478","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3479","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3480","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3481","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3482","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3483","R80","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3484","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3485","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3486","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3487","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3488","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3489","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3490","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3491","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3492","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3493","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3494","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3495","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3496","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3497","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3498","r69","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3499","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3500","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3501","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3502","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3503","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3504","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3505","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3506","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3507","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3508","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3509","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3510","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3511","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3512","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3513","R65","CYP2C19","*2","c.681G>A","g.19154G>A",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3514","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Brivaracetam","intermediate or poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3515","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Citalopram","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3516","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Clobazam","intermediate or poor metabolizers","Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3517","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Clopidogrel","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3518","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Flibanserin","poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3519","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Pantoprazole","poor metabolizers","Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3520","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Carisoprodol","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3521","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Dexlansoprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3522","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Diazepam","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3523","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Doxepin","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3524","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Escitalopram","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3525","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Esomeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3526","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Omeprazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3527","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Rabeprazole","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3528","R233","CYP2C19","*8","c.358T>C","g.12711T>C",1,"Voriconazole","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 19","chr10"
"3529","H47","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3530","R05","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3531","R202","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3532","R203","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3533","R209","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3534","R210","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3535","R211","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3536","R212","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3537","R213","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3538","R215","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3539","R218","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3540","R220","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3541","R221","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3542","R222","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3543","R223","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3544","R224","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3545","R58","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3546","R59","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3547","R60","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3548","R61","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3549","R63","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3550","R68","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3551","R71","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3552","R72","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3553","R73","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3554","R74","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3555","R79","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3556","R80","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3557","R81","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3558","R82","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3559","R84","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3560","R86","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3561","V151","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3562","V152","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3563","V153","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3564","V154","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3565","V155","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3566","R208","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3567","R231","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3568","R232","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3569","R233","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3570","R70","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3571","R214","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3572","R216","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3573","R66","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3574","R76","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3575","R76","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3576","H50","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3577","R207","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3578","R75","CYP1A2","*1F","g.-163C>A","0",1,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3579","R65","CYP1A2","*1F","g.-163C>A","0",2,"0","0","0","cytochrome P450 family 1 subfamily A member 2","chr15"
"3580","R228","CYP2D6","*41","g.2988G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3581","R228","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3582","R228","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3583","R228","CYP2D6","*41","g.2988G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3584","R228","CYP2D6","*41","g.2988G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3585","R228","CYP2D6","*41","g.2988G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3586","R228","CYP2D6","*41","g.2988G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3587","R228","CYP2D6","*41","g.2988G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3588","R228","CYP2D6","*41","g.2988G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3589","R228","CYP2D6","*41","g.2988G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3590","R228","CYP2D6","*41","g.2988G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3591","R228","CYP2D6","*41","g.2988G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3592","R228","CYP2D6","*41","g.2988G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3593","R228","CYP2D6","*41","g.2988G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3594","R228","CYP2D6","*41","g.2988G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3595","R228","CYP2D6","*41","g.2988G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3596","R228","CYP2D6","*41","g.2988G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3597","R228","CYP2D6","*41","g.2988G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3598","R228","CYP2D6","*41","g.2988G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3599","R228","CYP2D6","*41","g.2988G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3600","R228","CYP2D6","*41","g.2988G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3601","R228","CYP2D6","*41","g.2988G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3602","R228","CYP2D6","*41","g.2988G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3603","R228","CYP2D6","*41","g.2988G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3604","R228","CYP2D6","*41","g.2988G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3605","R228","CYP2D6","*41","g.2988G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3606","R228","CYP2D6","*41","g.2988G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3607","R228","CYP2D6","*41","g.2988G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3608","R228","CYP2D6","*41","g.2988G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3609","R228","CYP2D6","*41","g.2988G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3610","R228","CYP2D6","*41","g.2988G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3611","R228","CYP2D6","*41","g.2988G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3612","R228","CYP2D6","*41","g.2988G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3613","R228","CYP2D6","*41","g.2988G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3614","R228","CYP2D6","*41","g.2988G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3615","R228","CYP2D6","*41","g.2988G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3616","R228","CYP2D6","*41","g.2988G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3617","R228","CYP2D6","*41","g.2988G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3618","R228","CYP2D6","*41","g.2988G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3619","R228","CYP2D6","*41","g.2988G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3620","R228","CYP2D6","*41","g.2988G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3621","R228","CYP2D6","*41","g.2988G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3622","R228","CYP2D6","*41","g.2988G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3623","R228","CYP2D6","*41","g.2988G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3624","R228","CYP2D6","*41","g.2988G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3625","R228","CYP2D6","*41","g.2988G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3626","R228","CYP2D6","*41","g.2988G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3627","R228","CYP2D6","*41","g.2988G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3628","R228","CYP2D6","*41","g.2988G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3629","R59","CYP2D6","*41","g.2988G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3630","R59","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3631","R59","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3632","R59","CYP2D6","*41","g.2988G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3633","R59","CYP2D6","*41","g.2988G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3634","R59","CYP2D6","*41","g.2988G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3635","R59","CYP2D6","*41","g.2988G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3636","R59","CYP2D6","*41","g.2988G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3637","R59","CYP2D6","*41","g.2988G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3638","R59","CYP2D6","*41","g.2988G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3639","R59","CYP2D6","*41","g.2988G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3640","R59","CYP2D6","*41","g.2988G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3641","R59","CYP2D6","*41","g.2988G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3642","R59","CYP2D6","*41","g.2988G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3643","R59","CYP2D6","*41","g.2988G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3644","R59","CYP2D6","*41","g.2988G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3645","R59","CYP2D6","*41","g.2988G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3646","R59","CYP2D6","*41","g.2988G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3647","R59","CYP2D6","*41","g.2988G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3648","R59","CYP2D6","*41","g.2988G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3649","R59","CYP2D6","*41","g.2988G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3650","R59","CYP2D6","*41","g.2988G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3651","R59","CYP2D6","*41","g.2988G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3652","R59","CYP2D6","*41","g.2988G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3653","R59","CYP2D6","*41","g.2988G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3654","R59","CYP2D6","*41","g.2988G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3655","R59","CYP2D6","*41","g.2988G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3656","R59","CYP2D6","*41","g.2988G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3657","R59","CYP2D6","*41","g.2988G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3658","R59","CYP2D6","*41","g.2988G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3659","R59","CYP2D6","*41","g.2988G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3660","R59","CYP2D6","*41","g.2988G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3661","R59","CYP2D6","*41","g.2988G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3662","R59","CYP2D6","*41","g.2988G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3663","R59","CYP2D6","*41","g.2988G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3664","R59","CYP2D6","*41","g.2988G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3665","R59","CYP2D6","*41","g.2988G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3666","R59","CYP2D6","*41","g.2988G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3667","R59","CYP2D6","*41","g.2988G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3668","R59","CYP2D6","*41","g.2988G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3669","R59","CYP2D6","*41","g.2988G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3670","R59","CYP2D6","*41","g.2988G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3671","R59","CYP2D6","*41","g.2988G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3672","R59","CYP2D6","*41","g.2988G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3673","R59","CYP2D6","*41","g.2988G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3674","R59","CYP2D6","*41","g.2988G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3675","R59","CYP2D6","*41","g.2988G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3676","R59","CYP2D6","*41","g.2988G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3677","R59","CYP2D6","*41","g.2988G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3678","R60","CYP2D6","*41","g.2988G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3679","R60","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3680","R60","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3681","R60","CYP2D6","*41","g.2988G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3682","R60","CYP2D6","*41","g.2988G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3683","R60","CYP2D6","*41","g.2988G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3684","R60","CYP2D6","*41","g.2988G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3685","R60","CYP2D6","*41","g.2988G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3686","R60","CYP2D6","*41","g.2988G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3687","R60","CYP2D6","*41","g.2988G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3688","R60","CYP2D6","*41","g.2988G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3689","R60","CYP2D6","*41","g.2988G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3690","R60","CYP2D6","*41","g.2988G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3691","R60","CYP2D6","*41","g.2988G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3692","R60","CYP2D6","*41","g.2988G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3693","R60","CYP2D6","*41","g.2988G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3694","R60","CYP2D6","*41","g.2988G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3695","R60","CYP2D6","*41","g.2988G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3696","R60","CYP2D6","*41","g.2988G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3697","R60","CYP2D6","*41","g.2988G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3698","R60","CYP2D6","*41","g.2988G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3699","R60","CYP2D6","*41","g.2988G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3700","R60","CYP2D6","*41","g.2988G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3701","R60","CYP2D6","*41","g.2988G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3702","R60","CYP2D6","*41","g.2988G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3703","R60","CYP2D6","*41","g.2988G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3704","R60","CYP2D6","*41","g.2988G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3705","R60","CYP2D6","*41","g.2988G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3706","R60","CYP2D6","*41","g.2988G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3707","R60","CYP2D6","*41","g.2988G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3708","R60","CYP2D6","*41","g.2988G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3709","R60","CYP2D6","*41","g.2988G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3710","R60","CYP2D6","*41","g.2988G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3711","R60","CYP2D6","*41","g.2988G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3712","R60","CYP2D6","*41","g.2988G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3713","R60","CYP2D6","*41","g.2988G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3714","R60","CYP2D6","*41","g.2988G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3715","R60","CYP2D6","*41","g.2988G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3716","R60","CYP2D6","*41","g.2988G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3717","R60","CYP2D6","*41","g.2988G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3718","R60","CYP2D6","*41","g.2988G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3719","R60","CYP2D6","*41","g.2988G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3720","R60","CYP2D6","*41","g.2988G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3721","R60","CYP2D6","*41","g.2988G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3722","R60","CYP2D6","*41","g.2988G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3723","R60","CYP2D6","*41","g.2988G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3724","R60","CYP2D6","*41","g.2988G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3725","R60","CYP2D6","*41","g.2988G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3726","R60","CYP2D6","*41","g.2988G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3727","R71","CYP2D6","*41","g.2988G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3728","R71","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3729","R71","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3730","R71","CYP2D6","*41","g.2988G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3731","R71","CYP2D6","*41","g.2988G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3732","R71","CYP2D6","*41","g.2988G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3733","R71","CYP2D6","*41","g.2988G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3734","R71","CYP2D6","*41","g.2988G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3735","R71","CYP2D6","*41","g.2988G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3736","R71","CYP2D6","*41","g.2988G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3737","R71","CYP2D6","*41","g.2988G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3738","R71","CYP2D6","*41","g.2988G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3739","R71","CYP2D6","*41","g.2988G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3740","R71","CYP2D6","*41","g.2988G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3741","R71","CYP2D6","*41","g.2988G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3742","R71","CYP2D6","*41","g.2988G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3743","R71","CYP2D6","*41","g.2988G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3744","R71","CYP2D6","*41","g.2988G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3745","R71","CYP2D6","*41","g.2988G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3746","R71","CYP2D6","*41","g.2988G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3747","R71","CYP2D6","*41","g.2988G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3748","R71","CYP2D6","*41","g.2988G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3749","R71","CYP2D6","*41","g.2988G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3750","R71","CYP2D6","*41","g.2988G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3751","R71","CYP2D6","*41","g.2988G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3752","R71","CYP2D6","*41","g.2988G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3753","R71","CYP2D6","*41","g.2988G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3754","R71","CYP2D6","*41","g.2988G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3755","R71","CYP2D6","*41","g.2988G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3756","R71","CYP2D6","*41","g.2988G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3757","R71","CYP2D6","*41","g.2988G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3758","R71","CYP2D6","*41","g.2988G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3759","R71","CYP2D6","*41","g.2988G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3760","R71","CYP2D6","*41","g.2988G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3761","R71","CYP2D6","*41","g.2988G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3762","R71","CYP2D6","*41","g.2988G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3763","R71","CYP2D6","*41","g.2988G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3764","R71","CYP2D6","*41","g.2988G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3765","R71","CYP2D6","*41","g.2988G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3766","R71","CYP2D6","*41","g.2988G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3767","R71","CYP2D6","*41","g.2988G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3768","R71","CYP2D6","*41","g.2988G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3769","R71","CYP2D6","*41","g.2988G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3770","R71","CYP2D6","*41","g.2988G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3771","R71","CYP2D6","*41","g.2988G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3772","R71","CYP2D6","*41","g.2988G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3773","R71","CYP2D6","*41","g.2988G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3774","R71","CYP2D6","*41","g.2988G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3775","R71","CYP2D6","*41","g.2988G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3776","R80","CYP2D6","*41","g.2988G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3777","R80","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3778","R80","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3779","R80","CYP2D6","*41","g.2988G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3780","R80","CYP2D6","*41","g.2988G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3781","R80","CYP2D6","*41","g.2988G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3782","R80","CYP2D6","*41","g.2988G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3783","R80","CYP2D6","*41","g.2988G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3784","R80","CYP2D6","*41","g.2988G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3785","R80","CYP2D6","*41","g.2988G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3786","R80","CYP2D6","*41","g.2988G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3787","R80","CYP2D6","*41","g.2988G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3788","R80","CYP2D6","*41","g.2988G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3789","R80","CYP2D6","*41","g.2988G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3790","R80","CYP2D6","*41","g.2988G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3791","R80","CYP2D6","*41","g.2988G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3792","R80","CYP2D6","*41","g.2988G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3793","R80","CYP2D6","*41","g.2988G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3794","R80","CYP2D6","*41","g.2988G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3795","R80","CYP2D6","*41","g.2988G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3796","R80","CYP2D6","*41","g.2988G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3797","R80","CYP2D6","*41","g.2988G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3798","R80","CYP2D6","*41","g.2988G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3799","R80","CYP2D6","*41","g.2988G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3800","R80","CYP2D6","*41","g.2988G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3801","R80","CYP2D6","*41","g.2988G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3802","R80","CYP2D6","*41","g.2988G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3803","R80","CYP2D6","*41","g.2988G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3804","R80","CYP2D6","*41","g.2988G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3805","R80","CYP2D6","*41","g.2988G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3806","R80","CYP2D6","*41","g.2988G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3807","R80","CYP2D6","*41","g.2988G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3808","R80","CYP2D6","*41","g.2988G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3809","R80","CYP2D6","*41","g.2988G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3810","R80","CYP2D6","*41","g.2988G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3811","R80","CYP2D6","*41","g.2988G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3812","R80","CYP2D6","*41","g.2988G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3813","R80","CYP2D6","*41","g.2988G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3814","R80","CYP2D6","*41","g.2988G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3815","R80","CYP2D6","*41","g.2988G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3816","R80","CYP2D6","*41","g.2988G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3817","R80","CYP2D6","*41","g.2988G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3818","R80","CYP2D6","*41","g.2988G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3819","R80","CYP2D6","*41","g.2988G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3820","R80","CYP2D6","*41","g.2988G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3821","R80","CYP2D6","*41","g.2988G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3822","R80","CYP2D6","*41","g.2988G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3823","R80","CYP2D6","*41","g.2988G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3824","R80","CYP2D6","*41","g.2988G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3825","R82","CYP2D6","*41","g.2988G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3826","R82","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3827","R82","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3828","R82","CYP2D6","*41","g.2988G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3829","R82","CYP2D6","*41","g.2988G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3830","R82","CYP2D6","*41","g.2988G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3831","R82","CYP2D6","*41","g.2988G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3832","R82","CYP2D6","*41","g.2988G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3833","R82","CYP2D6","*41","g.2988G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3834","R82","CYP2D6","*41","g.2988G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3835","R82","CYP2D6","*41","g.2988G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3836","R82","CYP2D6","*41","g.2988G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3837","R82","CYP2D6","*41","g.2988G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3838","R82","CYP2D6","*41","g.2988G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3839","R82","CYP2D6","*41","g.2988G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3840","R82","CYP2D6","*41","g.2988G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3841","R82","CYP2D6","*41","g.2988G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3842","R82","CYP2D6","*41","g.2988G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3843","R82","CYP2D6","*41","g.2988G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3844","R82","CYP2D6","*41","g.2988G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3845","R82","CYP2D6","*41","g.2988G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3846","R82","CYP2D6","*41","g.2988G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3847","R82","CYP2D6","*41","g.2988G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3848","R82","CYP2D6","*41","g.2988G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3849","R82","CYP2D6","*41","g.2988G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3850","R82","CYP2D6","*41","g.2988G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3851","R82","CYP2D6","*41","g.2988G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3852","R82","CYP2D6","*41","g.2988G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3853","R82","CYP2D6","*41","g.2988G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3854","R82","CYP2D6","*41","g.2988G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3855","R82","CYP2D6","*41","g.2988G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3856","R82","CYP2D6","*41","g.2988G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3857","R82","CYP2D6","*41","g.2988G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3858","R82","CYP2D6","*41","g.2988G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3859","R82","CYP2D6","*41","g.2988G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3860","R82","CYP2D6","*41","g.2988G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3861","R82","CYP2D6","*41","g.2988G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3862","R82","CYP2D6","*41","g.2988G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3863","R82","CYP2D6","*41","g.2988G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3864","R82","CYP2D6","*41","g.2988G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3865","R82","CYP2D6","*41","g.2988G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3866","R82","CYP2D6","*41","g.2988G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3867","R82","CYP2D6","*41","g.2988G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3868","R82","CYP2D6","*41","g.2988G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3869","R82","CYP2D6","*41","g.2988G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3870","R82","CYP2D6","*41","g.2988G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3871","R82","CYP2D6","*41","g.2988G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3872","R82","CYP2D6","*41","g.2988G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3873","R82","CYP2D6","*41","g.2988G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3874","R86","CYP2D6","*41","g.2988G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3875","R86","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3876","R86","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3877","R86","CYP2D6","*41","g.2988G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3878","R86","CYP2D6","*41","g.2988G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3879","R86","CYP2D6","*41","g.2988G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3880","R86","CYP2D6","*41","g.2988G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3881","R86","CYP2D6","*41","g.2988G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3882","R86","CYP2D6","*41","g.2988G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3883","R86","CYP2D6","*41","g.2988G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3884","R86","CYP2D6","*41","g.2988G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3885","R86","CYP2D6","*41","g.2988G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3886","R86","CYP2D6","*41","g.2988G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3887","R86","CYP2D6","*41","g.2988G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3888","R86","CYP2D6","*41","g.2988G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3889","R86","CYP2D6","*41","g.2988G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3890","R86","CYP2D6","*41","g.2988G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3891","R86","CYP2D6","*41","g.2988G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3892","R86","CYP2D6","*41","g.2988G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3893","R86","CYP2D6","*41","g.2988G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3894","R86","CYP2D6","*41","g.2988G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3895","R86","CYP2D6","*41","g.2988G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3896","R86","CYP2D6","*41","g.2988G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3897","R86","CYP2D6","*41","g.2988G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3898","R86","CYP2D6","*41","g.2988G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3899","R86","CYP2D6","*41","g.2988G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3900","R86","CYP2D6","*41","g.2988G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3901","R86","CYP2D6","*41","g.2988G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3902","R86","CYP2D6","*41","g.2988G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3903","R86","CYP2D6","*41","g.2988G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3904","R86","CYP2D6","*41","g.2988G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3905","R86","CYP2D6","*41","g.2988G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3906","R86","CYP2D6","*41","g.2988G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3907","R86","CYP2D6","*41","g.2988G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3908","R86","CYP2D6","*41","g.2988G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3909","R86","CYP2D6","*41","g.2988G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3910","R86","CYP2D6","*41","g.2988G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3911","R86","CYP2D6","*41","g.2988G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3912","R86","CYP2D6","*41","g.2988G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3913","R86","CYP2D6","*41","g.2988G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3914","R86","CYP2D6","*41","g.2988G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3915","R86","CYP2D6","*41","g.2988G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3916","R86","CYP2D6","*41","g.2988G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3917","R86","CYP2D6","*41","g.2988G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3918","R86","CYP2D6","*41","g.2988G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3919","R86","CYP2D6","*41","g.2988G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3920","R86","CYP2D6","*41","g.2988G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3921","R86","CYP2D6","*41","g.2988G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3922","R86","CYP2D6","*41","g.2988G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3923","R232","CYP2D6","*41","g.2988G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3924","R232","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3925","R232","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3926","R232","CYP2D6","*41","g.2988G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3927","R232","CYP2D6","*41","g.2988G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3928","R232","CYP2D6","*41","g.2988G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3929","R232","CYP2D6","*41","g.2988G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3930","R232","CYP2D6","*41","g.2988G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3931","R232","CYP2D6","*41","g.2988G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3932","R232","CYP2D6","*41","g.2988G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3933","R232","CYP2D6","*41","g.2988G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3934","R232","CYP2D6","*41","g.2988G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3935","R232","CYP2D6","*41","g.2988G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3936","R232","CYP2D6","*41","g.2988G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3937","R232","CYP2D6","*41","g.2988G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3938","R232","CYP2D6","*41","g.2988G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3939","R232","CYP2D6","*41","g.2988G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3940","R232","CYP2D6","*41","g.2988G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3941","R232","CYP2D6","*41","g.2988G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3942","R232","CYP2D6","*41","g.2988G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3943","R232","CYP2D6","*41","g.2988G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3944","R232","CYP2D6","*41","g.2988G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3945","R232","CYP2D6","*41","g.2988G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3946","R232","CYP2D6","*41","g.2988G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3947","R232","CYP2D6","*41","g.2988G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3948","R232","CYP2D6","*41","g.2988G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3949","R232","CYP2D6","*41","g.2988G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3950","R232","CYP2D6","*41","g.2988G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3951","R232","CYP2D6","*41","g.2988G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3952","R232","CYP2D6","*41","g.2988G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3953","R232","CYP2D6","*41","g.2988G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3954","R232","CYP2D6","*41","g.2988G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3955","R232","CYP2D6","*41","g.2988G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3956","R232","CYP2D6","*41","g.2988G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3957","R232","CYP2D6","*41","g.2988G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3958","R232","CYP2D6","*41","g.2988G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3959","R232","CYP2D6","*41","g.2988G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3960","R232","CYP2D6","*41","g.2988G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3961","R232","CYP2D6","*41","g.2988G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3962","R232","CYP2D6","*41","g.2988G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3963","R232","CYP2D6","*41","g.2988G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3964","R232","CYP2D6","*41","g.2988G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3965","R232","CYP2D6","*41","g.2988G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3966","R232","CYP2D6","*41","g.2988G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3967","R232","CYP2D6","*41","g.2988G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3968","R232","CYP2D6","*41","g.2988G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3969","R232","CYP2D6","*41","g.2988G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3970","R232","CYP2D6","*41","g.2988G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3971","R232","CYP2D6","*41","g.2988G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3972","R76","CYP2D6","*41","g.2988G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3973","R76","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3974","R76","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3975","R76","CYP2D6","*41","g.2988G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3976","R76","CYP2D6","*41","g.2988G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3977","R76","CYP2D6","*41","g.2988G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3978","R76","CYP2D6","*41","g.2988G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3979","R76","CYP2D6","*41","g.2988G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3980","R76","CYP2D6","*41","g.2988G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3981","R76","CYP2D6","*41","g.2988G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3982","R76","CYP2D6","*41","g.2988G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3983","R76","CYP2D6","*41","g.2988G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3984","R76","CYP2D6","*41","g.2988G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3985","R76","CYP2D6","*41","g.2988G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3986","R76","CYP2D6","*41","g.2988G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3987","R76","CYP2D6","*41","g.2988G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3988","R76","CYP2D6","*41","g.2988G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3989","R76","CYP2D6","*41","g.2988G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3990","R76","CYP2D6","*41","g.2988G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3991","R76","CYP2D6","*41","g.2988G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3992","R76","CYP2D6","*41","g.2988G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3993","R76","CYP2D6","*41","g.2988G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3994","R76","CYP2D6","*41","g.2988G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3995","R76","CYP2D6","*41","g.2988G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3996","R76","CYP2D6","*41","g.2988G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3997","R76","CYP2D6","*41","g.2988G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"3998","R76","CYP2D6","*41","g.2988G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"3999","R76","CYP2D6","*41","g.2988G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4000","R76","CYP2D6","*41","g.2988G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4001","R76","CYP2D6","*41","g.2988G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4002","R76","CYP2D6","*41","g.2988G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4003","R76","CYP2D6","*41","g.2988G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4004","R76","CYP2D6","*41","g.2988G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4005","R76","CYP2D6","*41","g.2988G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4006","R76","CYP2D6","*41","g.2988G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4007","R76","CYP2D6","*41","g.2988G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4008","R76","CYP2D6","*41","g.2988G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4009","R76","CYP2D6","*41","g.2988G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4010","R76","CYP2D6","*41","g.2988G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4011","R76","CYP2D6","*41","g.2988G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4012","R76","CYP2D6","*41","g.2988G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4013","R76","CYP2D6","*41","g.2988G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4014","R76","CYP2D6","*41","g.2988G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4015","R76","CYP2D6","*41","g.2988G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4016","R76","CYP2D6","*41","g.2988G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4017","R76","CYP2D6","*41","g.2988G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4018","R76","CYP2D6","*41","g.2988G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4019","R76","CYP2D6","*41","g.2988G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4020","R76","CYP2D6","*41","g.2988G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4021","R76","CYP2D6","*41","g.2988G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4022","R76","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4023","R76","CYP2D6","*41","g.2988G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4024","R76","CYP2D6","*41","g.2988G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4025","R76","CYP2D6","*41","g.2988G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4026","R76","CYP2D6","*41","g.2988G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4027","R76","CYP2D6","*41","g.2988G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4028","R76","CYP2D6","*41","g.2988G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4029","R76","CYP2D6","*41","g.2988G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4030","R76","CYP2D6","*41","g.2988G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4031","R76","CYP2D6","*41","g.2988G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4032","R76","CYP2D6","*41","g.2988G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4033","R76","CYP2D6","*41","g.2988G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4034","R76","CYP2D6","*41","g.2988G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4035","R76","CYP2D6","*41","g.2988G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4036","R76","CYP2D6","*41","g.2988G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4037","R76","CYP2D6","*41","g.2988G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4038","R76","CYP2D6","*41","g.2988G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4039","R76","CYP2D6","*41","g.2988G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4040","R76","CYP2D6","*41","g.2988G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4041","R76","CYP2D6","*41","g.2988G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4042","R76","CYP2D6","*41","g.2988G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4043","R76","CYP2D6","*41","g.2988G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4044","R76","CYP2D6","*41","g.2988G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4045","R76","CYP2D6","*41","g.2988G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4046","R76","CYP2D6","*41","g.2988G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4047","R76","CYP2D6","*41","g.2988G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4048","R76","CYP2D6","*41","g.2988G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4049","R76","CYP2D6","*41","g.2988G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4050","R76","CYP2D6","*41","g.2988G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4051","R76","CYP2D6","*41","g.2988G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4052","R76","CYP2D6","*41","g.2988G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4053","R76","CYP2D6","*41","g.2988G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4054","R76","CYP2D6","*41","g.2988G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4055","R76","CYP2D6","*41","g.2988G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4056","R76","CYP2D6","*41","g.2988G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4057","R76","CYP2D6","*41","g.2988G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4058","R76","CYP2D6","*41","g.2988G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4059","R76","CYP2D6","*41","g.2988G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4060","R76","CYP2D6","*41","g.2988G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4061","R76","CYP2D6","*41","g.2988G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4062","R76","CYP2D6","*41","g.2988G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4063","R76","CYP2D6","*41","g.2988G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4064","R76","CYP2D6","*41","g.2988G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4065","R76","CYP2D6","*41","g.2988G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4066","R76","CYP2D6","*41","g.2988G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4067","R76","CYP2D6","*41","g.2988G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4068","R76","CYP2D6","*41","g.2988G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4069","R76","CYP2D6","*41","g.2988G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4070","H48","CYP2B6","*16/*18","c.983T>C"," g.21011T>C",1,"Efavirenz","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily B member 6","chr19"
"4071","H49","CYP2B6","*16/*18","c.983T>C"," g.21011T>C",1,"Efavirenz","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily B member 6","chr19"
"4072","H47","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4073","R202","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4074","R203","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4075","R206","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4076","R210","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4077","R211","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4078","R212","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4079","R213","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4080","R215","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4081","R220","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4082","R221","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4083","R222","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4084","R223","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4085","R227","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4086","R228","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4087","R58","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4088","R60","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4089","R61","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4090","R68","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4091","R71","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4092","R72","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4093","R73","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4094","R82","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4095","R84","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4096","R86","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4097","V152","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4098","V153","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4099","R208","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4100","R231","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4101","R232","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4102","R233","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4103","R70","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4104","R83","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4105","R214","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4106","R216","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4107","R66","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4108","r69","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4109","R207","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4110","R65","CYP3A5","*3/*10","g.6986A>G","0",1,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4111","R87","CYP3A5","*3/*10","g.6986A>G","0",2,"Tacrolimus","intermediate or normal metabolizers","Results in lower systemic concentrations and lower probability of achieving target concentrations. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.","cytochrome P450 family 3 subfamily A member 5","chr7"
"4112","H48","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4113","H48","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4114","H48","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4115","H48","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4116","H48","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4117","H48","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4118","H48","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4119","H48","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4120","H48","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4121","H48","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4122","H48","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4123","H48","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4124","H48","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4125","H48","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4126","H48","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4127","H48","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4128","H48","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4129","H48","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4130","H48","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4131","H48","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4132","H48","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4133","H48","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4134","H48","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4135","H48","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4136","H48","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4137","H48","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4138","H48","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4139","H48","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4140","H48","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4141","H48","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4142","H48","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4143","H48","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4144","H48","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4145","H48","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4146","H48","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4147","H48","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4148","H48","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4149","H48","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4150","H48","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4151","H48","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4152","H48","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4153","H48","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4154","H48","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4155","H48","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4156","H48","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4157","H48","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4158","H48","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4159","H48","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4160","H48","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4161","H49","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4162","H49","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4163","H49","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4164","H49","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4165","H49","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4166","H49","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4167","H49","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4168","H49","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4169","H49","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4170","H49","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4171","H49","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4172","H49","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4173","H49","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4174","H49","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4175","H49","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4176","H49","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4177","H49","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4178","H49","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4179","H49","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4180","H49","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4181","H49","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4182","H49","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4183","H49","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4184","H49","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4185","H49","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4186","H49","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4187","H49","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4188","H49","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4189","H49","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4190","H49","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4191","H49","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4192","H49","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4193","H49","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4194","H49","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4195","H49","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4196","H49","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4197","H49","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4198","H49","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4199","H49","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4200","H49","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4201","H49","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4202","H49","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4203","H49","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4204","H49","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4205","H49","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4206","H49","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4207","H49","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4208","H49","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4209","H49","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4210","R206","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4211","R206","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4212","R206","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4213","R206","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4214","R206","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4215","R206","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4216","R206","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4217","R206","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4218","R206","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4219","R206","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4220","R206","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4221","R206","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4222","R206","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4223","R206","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4224","R206","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4225","R206","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4226","R206","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4227","R206","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4228","R206","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4229","R206","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4230","R206","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4231","R206","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4232","R206","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4233","R206","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4234","R206","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4235","R206","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4236","R206","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4237","R206","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4238","R206","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4239","R206","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4240","R206","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4241","R206","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4242","R206","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4243","R206","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4244","R206","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4245","R206","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4246","R206","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4247","R206","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4248","R206","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4249","R206","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4250","R206","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4251","R206","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4252","R206","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4253","R206","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4254","R206","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4255","R206","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4256","R206","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4257","R206","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4258","R206","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4259","R209","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4260","R209","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4261","R209","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4262","R209","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4263","R209","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4264","R209","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4265","R209","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4266","R209","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4267","R209","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4268","R209","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4269","R209","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4270","R209","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4271","R209","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4272","R209","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4273","R209","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4274","R209","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4275","R209","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4276","R209","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4277","R209","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4278","R209","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4279","R209","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4280","R209","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4281","R209","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4282","R209","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4283","R209","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4284","R209","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4285","R209","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4286","R209","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4287","R209","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4288","R209","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4289","R209","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4290","R209","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4291","R209","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4292","R209","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4293","R209","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4294","R209","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4295","R209","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4296","R209","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4297","R209","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4298","R209","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4299","R209","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4300","R209","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4301","R209","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4302","R209","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4303","R209","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4304","R209","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4305","R209","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4306","R209","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4307","R209","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4308","R212","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4309","R212","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4310","R212","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4311","R212","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4312","R212","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4313","R212","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4314","R212","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4315","R212","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4316","R212","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4317","R212","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4318","R212","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4319","R212","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4320","R212","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4321","R212","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4322","R212","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4323","R212","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4324","R212","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4325","R212","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4326","R212","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4327","R212","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4328","R212","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4329","R212","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4330","R212","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4331","R212","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4332","R212","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4333","R212","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4334","R212","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4335","R212","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4336","R212","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4337","R212","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4338","R212","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4339","R212","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4340","R212","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4341","R212","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4342","R212","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4343","R212","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4344","R212","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4345","R212","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4346","R212","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4347","R212","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4348","R212","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4349","R212","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4350","R212","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4351","R212","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4352","R212","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4353","R212","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4354","R212","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4355","R212","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4356","R212","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4357","R213","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4358","R213","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4359","R213","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4360","R213","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4361","R213","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4362","R213","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4363","R213","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4364","R213","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4365","R213","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4366","R213","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4367","R213","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4368","R213","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4369","R213","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4370","R213","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4371","R213","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4372","R213","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4373","R213","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4374","R213","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4375","R213","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4376","R213","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4377","R213","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4378","R213","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4379","R213","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4380","R213","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4381","R213","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4382","R213","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4383","R213","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4384","R213","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4385","R213","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4386","R213","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4387","R213","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4388","R213","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4389","R213","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4390","R213","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4391","R213","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4392","R213","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4393","R213","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4394","R213","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4395","R213","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4396","R213","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4397","R213","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4398","R213","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4399","R213","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4400","R213","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4401","R213","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4402","R213","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4403","R213","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4404","R213","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4405","R213","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4406","R215","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4407","R215","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4408","R215","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4409","R215","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4410","R215","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4411","R215","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4412","R215","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4413","R215","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4414","R215","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4415","R215","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4416","R215","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4417","R215","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4418","R215","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4419","R215","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4420","R215","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4421","R215","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4422","R215","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4423","R215","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4424","R215","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4425","R215","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4426","R215","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4427","R215","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4428","R215","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4429","R215","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4430","R215","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4431","R215","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4432","R215","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4433","R215","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4434","R215","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4435","R215","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4436","R215","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4437","R215","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4438","R215","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4439","R215","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4440","R215","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4441","R215","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4442","R215","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4443","R215","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4444","R215","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4445","R215","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4446","R215","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4447","R215","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4448","R215","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4449","R215","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4450","R215","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4451","R215","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4452","R215","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4453","R215","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4454","R215","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4455","R220","CYP2D6","g.4180G>C","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4456","R220","CYP2D6","g.4180G>C","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4457","R220","CYP2D6","g.4180G>C","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4458","R220","CYP2D6","g.4180G>C","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4459","R220","CYP2D6","g.4180G>C","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4460","R220","CYP2D6","g.4180G>C","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4461","R220","CYP2D6","g.4180G>C","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4462","R220","CYP2D6","g.4180G>C","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4463","R220","CYP2D6","g.4180G>C","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4464","R220","CYP2D6","g.4180G>C","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4465","R220","CYP2D6","g.4180G>C","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4466","R220","CYP2D6","g.4180G>C","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4467","R220","CYP2D6","g.4180G>C","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4468","R220","CYP2D6","g.4180G>C","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4469","R220","CYP2D6","g.4180G>C","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4470","R220","CYP2D6","g.4180G>C","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4471","R220","CYP2D6","g.4180G>C","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4472","R220","CYP2D6","g.4180G>C","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4473","R220","CYP2D6","g.4180G>C","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4474","R220","CYP2D6","g.4180G>C","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4475","R220","CYP2D6","g.4180G>C","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4476","R220","CYP2D6","g.4180G>C","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4477","R220","CYP2D6","g.4180G>C","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4478","R220","CYP2D6","g.4180G>C","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4479","R220","CYP2D6","g.4180G>C","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4480","R220","CYP2D6","g.4180G>C","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4481","R220","CYP2D6","g.4180G>C","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4482","R220","CYP2D6","g.4180G>C","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4483","R220","CYP2D6","g.4180G>C","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4484","R220","CYP2D6","g.4180G>C","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4485","R220","CYP2D6","g.4180G>C","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4486","R220","CYP2D6","g.4180G>C","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4487","R220","CYP2D6","g.4180G>C","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4488","R220","CYP2D6","g.4180G>C","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4489","R220","CYP2D6","g.4180G>C","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4490","R220","CYP2D6","g.4180G>C","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4491","R220","CYP2D6","g.4180G>C","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4492","R220","CYP2D6","g.4180G>C","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4493","R220","CYP2D6","g.4180G>C","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4494","R220","CYP2D6","g.4180G>C","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4495","R220","CYP2D6","g.4180G>C","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4496","R220","CYP2D6","g.4180G>C","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4497","R220","CYP2D6","g.4180G>C","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4498","R220","CYP2D6","g.4180G>C","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4499","R220","CYP2D6","g.4180G>C","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4500","R220","CYP2D6","g.4180G>C","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4501","R220","CYP2D6","g.4180G>C","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4502","R220","CYP2D6","g.4180G>C","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4503","R220","CYP2D6","g.4180G>C","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4504","R221","CYP2D6","g.4180G>C","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4505","R221","CYP2D6","g.4180G>C","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4506","R221","CYP2D6","g.4180G>C","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4507","R221","CYP2D6","g.4180G>C","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4508","R221","CYP2D6","g.4180G>C","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4509","R221","CYP2D6","g.4180G>C","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4510","R221","CYP2D6","g.4180G>C","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4511","R221","CYP2D6","g.4180G>C","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4512","R221","CYP2D6","g.4180G>C","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4513","R221","CYP2D6","g.4180G>C","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4514","R221","CYP2D6","g.4180G>C","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4515","R221","CYP2D6","g.4180G>C","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4516","R221","CYP2D6","g.4180G>C","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4517","R221","CYP2D6","g.4180G>C","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4518","R221","CYP2D6","g.4180G>C","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4519","R221","CYP2D6","g.4180G>C","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4520","R221","CYP2D6","g.4180G>C","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4521","R221","CYP2D6","g.4180G>C","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4522","R221","CYP2D6","g.4180G>C","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4523","R221","CYP2D6","g.4180G>C","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4524","R221","CYP2D6","g.4180G>C","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4525","R221","CYP2D6","g.4180G>C","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4526","R221","CYP2D6","g.4180G>C","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4527","R221","CYP2D6","g.4180G>C","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4528","R221","CYP2D6","g.4180G>C","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4529","R221","CYP2D6","g.4180G>C","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4530","R221","CYP2D6","g.4180G>C","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4531","R221","CYP2D6","g.4180G>C","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4532","R221","CYP2D6","g.4180G>C","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4533","R221","CYP2D6","g.4180G>C","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4534","R221","CYP2D6","g.4180G>C","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4535","R221","CYP2D6","g.4180G>C","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4536","R221","CYP2D6","g.4180G>C","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4537","R221","CYP2D6","g.4180G>C","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4538","R221","CYP2D6","g.4180G>C","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4539","R221","CYP2D6","g.4180G>C","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4540","R221","CYP2D6","g.4180G>C","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4541","R221","CYP2D6","g.4180G>C","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4542","R221","CYP2D6","g.4180G>C","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4543","R221","CYP2D6","g.4180G>C","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4544","R221","CYP2D6","g.4180G>C","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4545","R221","CYP2D6","g.4180G>C","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4546","R221","CYP2D6","g.4180G>C","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4547","R221","CYP2D6","g.4180G>C","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4548","R221","CYP2D6","g.4180G>C","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4549","R221","CYP2D6","g.4180G>C","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4550","R221","CYP2D6","g.4180G>C","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4551","R221","CYP2D6","g.4180G>C","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4552","R221","CYP2D6","g.4180G>C","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4553","R222","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4554","R222","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4555","R222","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4556","R222","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4557","R222","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4558","R222","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4559","R222","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4560","R222","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4561","R222","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4562","R222","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4563","R222","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4564","R222","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4565","R222","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4566","R222","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4567","R222","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4568","R222","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4569","R222","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4570","R222","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4571","R222","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4572","R222","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4573","R222","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4574","R222","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4575","R222","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4576","R222","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4577","R222","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4578","R222","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4579","R222","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4580","R222","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4581","R222","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4582","R222","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4583","R222","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4584","R222","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4585","R222","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4586","R222","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4587","R222","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4588","R222","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4589","R222","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4590","R222","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4591","R222","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4592","R222","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4593","R222","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4594","R222","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4595","R222","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4596","R222","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4597","R222","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4598","R222","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4599","R222","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4600","R222","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4601","R222","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4602","R57","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4603","R57","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4604","R57","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4605","R57","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4606","R57","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4607","R57","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4608","R57","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4609","R57","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4610","R57","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4611","R57","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4612","R57","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4613","R57","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4614","R57","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4615","R57","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4616","R57","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4617","R57","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4618","R57","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4619","R57","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4620","R57","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4621","R57","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4622","R57","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4623","R57","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4624","R57","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4625","R57","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4626","R57","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4627","R57","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4628","R57","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4629","R57","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4630","R57","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4631","R57","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4632","R57","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4633","R57","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4634","R57","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4635","R57","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4636","R57","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4637","R57","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4638","R57","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4639","R57","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4640","R57","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4641","R57","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4642","R57","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4643","R57","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4644","R57","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4645","R57","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4646","R57","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4647","R57","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4648","R57","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4649","R57","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4650","R57","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4651","R60","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4652","R60","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4653","R60","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4654","R60","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4655","R60","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4656","R60","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4657","R60","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4658","R60","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4659","R60","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4660","R60","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4661","R60","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4662","R60","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4663","R60","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4664","R60","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4665","R60","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4666","R60","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4667","R60","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4668","R60","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4669","R60","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4670","R60","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4671","R60","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4672","R60","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4673","R60","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4674","R60","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4675","R60","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4676","R60","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4677","R60","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4678","R60","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4679","R60","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4680","R60","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4681","R60","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4682","R60","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4683","R60","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4684","R60","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4685","R60","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4686","R60","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4687","R60","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4688","R60","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4689","R60","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4690","R60","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4691","R60","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4692","R60","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4693","R60","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4694","R60","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4695","R60","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4696","R60","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4697","R60","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4698","R60","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4699","R60","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4700","R61","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4701","R61","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4702","R61","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4703","R61","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4704","R61","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4705","R61","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4706","R61","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4707","R61","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4708","R61","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4709","R61","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4710","R61","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4711","R61","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4712","R61","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4713","R61","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4714","R61","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4715","R61","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4716","R61","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4717","R61","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4718","R61","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4719","R61","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4720","R61","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4721","R61","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4722","R61","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4723","R61","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4724","R61","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4725","R61","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4726","R61","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4727","R61","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4728","R61","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4729","R61","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4730","R61","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4731","R61","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4732","R61","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4733","R61","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4734","R61","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4735","R61","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4736","R61","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4737","R61","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4738","R61","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4739","R61","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4740","R61","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4741","R61","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4742","R61","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4743","R61","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4744","R61","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4745","R61","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4746","R61","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4747","R61","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4748","R61","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4749","R63","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4750","R63","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4751","R63","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4752","R63","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4753","R63","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4754","R63","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4755","R63","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4756","R63","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4757","R63","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4758","R63","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4759","R63","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4760","R63","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4761","R63","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4762","R63","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4763","R63","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4764","R63","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4765","R63","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4766","R63","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4767","R63","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4768","R63","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4769","R63","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4770","R63","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4771","R63","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4772","R63","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4773","R63","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4774","R63","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4775","R63","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4776","R63","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4777","R63","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4778","R63","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4779","R63","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4780","R63","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4781","R63","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4782","R63","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4783","R63","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4784","R63","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4785","R63","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4786","R63","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4787","R63","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4788","R63","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4789","R63","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4790","R63","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4791","R63","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4792","R63","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4793","R63","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4794","R63","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4795","R63","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4796","R63","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4797","R63","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4798","R68","CYP2D6","g.4180G>C","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4799","R68","CYP2D6","g.4180G>C","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4800","R68","CYP2D6","g.4180G>C","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4801","R68","CYP2D6","g.4180G>C","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4802","R68","CYP2D6","g.4180G>C","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4803","R68","CYP2D6","g.4180G>C","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4804","R68","CYP2D6","g.4180G>C","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4805","R68","CYP2D6","g.4180G>C","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4806","R68","CYP2D6","g.4180G>C","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4807","R68","CYP2D6","g.4180G>C","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4808","R68","CYP2D6","g.4180G>C","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4809","R68","CYP2D6","g.4180G>C","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4810","R68","CYP2D6","g.4180G>C","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4811","R68","CYP2D6","g.4180G>C","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4812","R68","CYP2D6","g.4180G>C","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4813","R68","CYP2D6","g.4180G>C","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4814","R68","CYP2D6","g.4180G>C","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4815","R68","CYP2D6","g.4180G>C","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4816","R68","CYP2D6","g.4180G>C","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4817","R68","CYP2D6","g.4180G>C","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4818","R68","CYP2D6","g.4180G>C","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4819","R68","CYP2D6","g.4180G>C","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4820","R68","CYP2D6","g.4180G>C","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4821","R68","CYP2D6","g.4180G>C","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4822","R68","CYP2D6","g.4180G>C","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4823","R68","CYP2D6","g.4180G>C","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4824","R68","CYP2D6","g.4180G>C","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4825","R68","CYP2D6","g.4180G>C","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4826","R68","CYP2D6","g.4180G>C","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4827","R68","CYP2D6","g.4180G>C","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4828","R68","CYP2D6","g.4180G>C","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4829","R68","CYP2D6","g.4180G>C","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4830","R68","CYP2D6","g.4180G>C","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4831","R68","CYP2D6","g.4180G>C","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4832","R68","CYP2D6","g.4180G>C","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4833","R68","CYP2D6","g.4180G>C","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4834","R68","CYP2D6","g.4180G>C","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4835","R68","CYP2D6","g.4180G>C","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4836","R68","CYP2D6","g.4180G>C","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4837","R68","CYP2D6","g.4180G>C","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4838","R68","CYP2D6","g.4180G>C","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4839","R68","CYP2D6","g.4180G>C","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4840","R68","CYP2D6","g.4180G>C","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4841","R68","CYP2D6","g.4180G>C","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4842","R68","CYP2D6","g.4180G>C","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4843","R68","CYP2D6","g.4180G>C","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4844","R68","CYP2D6","g.4180G>C","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4845","R68","CYP2D6","g.4180G>C","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4846","R68","CYP2D6","g.4180G>C","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4847","R71","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4848","R71","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4849","R71","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4850","R71","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4851","R71","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4852","R71","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4853","R71","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4854","R71","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4855","R71","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4856","R71","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4857","R71","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4858","R71","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4859","R71","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4860","R71","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4861","R71","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4862","R71","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4863","R71","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4864","R71","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4865","R71","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4866","R71","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4867","R71","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4868","R71","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4869","R71","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4870","R71","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4871","R71","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4872","R71","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4873","R71","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4874","R71","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4875","R71","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4876","R71","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4877","R71","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4878","R71","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4879","R71","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4880","R71","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4881","R71","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4882","R71","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4883","R71","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4884","R71","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4885","R71","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4886","R71","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4887","R71","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4888","R71","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4889","R71","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4890","R71","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4891","R71","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4892","R71","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4893","R71","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4894","R71","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4895","R71","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4896","R72","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4897","R72","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4898","R72","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4899","R72","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4900","R72","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4901","R72","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4902","R72","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4903","R72","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4904","R72","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4905","R72","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4906","R72","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4907","R72","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4908","R72","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4909","R72","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4910","R72","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4911","R72","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4912","R72","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4913","R72","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4914","R72","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4915","R72","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4916","R72","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4917","R72","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4918","R72","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4919","R72","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4920","R72","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4921","R72","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4922","R72","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4923","R72","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4924","R72","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4925","R72","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4926","R72","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4927","R72","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4928","R72","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4929","R72","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4930","R72","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4931","R72","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4932","R72","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4933","R72","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4934","R72","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4935","R72","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4936","R72","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4937","R72","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4938","R72","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4939","R72","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4940","R72","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4941","R72","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4942","R72","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4943","R72","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4944","R72","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4945","R79","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4946","R79","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4947","R79","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4948","R79","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4949","R79","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4950","R79","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4951","R79","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4952","R79","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4953","R79","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4954","R79","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4955","R79","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4956","R79","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4957","R79","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4958","R79","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4959","R79","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4960","R79","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4961","R79","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4962","R79","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4963","R79","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4964","R79","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4965","R79","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4966","R79","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4967","R79","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4968","R79","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4969","R79","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4970","R79","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4971","R79","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"4972","R79","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4973","R79","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4974","R79","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4975","R79","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4976","R79","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4977","R79","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4978","R79","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4979","R79","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4980","R79","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4981","R79","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4982","R79","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4983","R79","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4984","R79","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4985","R79","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4986","R79","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4987","R79","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4988","R79","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4989","R79","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4990","R79","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4991","R79","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4992","R79","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4993","R79","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4994","R80","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4995","R80","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4996","R80","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4997","R80","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4998","R80","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"4999","R80","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5000","R80","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5001","R80","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5002","R80","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5003","R80","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5004","R80","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5005","R80","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5006","R80","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5007","R80","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5008","R80","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5009","R80","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5010","R80","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5011","R80","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5012","R80","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5013","R80","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5014","R80","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5015","R80","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5016","R80","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5017","R80","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5018","R80","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5019","R80","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5020","R80","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5021","R80","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5022","R80","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5023","R80","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5024","R80","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5025","R80","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5026","R80","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5027","R80","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5028","R80","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5029","R80","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5030","R80","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5031","R80","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5032","R80","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5033","R80","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5034","R80","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5035","R80","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5036","R80","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5037","R80","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5038","R80","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5039","R80","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5040","R80","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5041","R80","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5042","R80","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5043","R82","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5044","R82","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5045","R82","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5046","R82","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5047","R82","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5048","R82","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5049","R82","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5050","R82","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5051","R82","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5052","R82","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5053","R82","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5054","R82","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5055","R82","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5056","R82","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5057","R82","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5058","R82","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5059","R82","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5060","R82","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5061","R82","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5062","R82","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5063","R82","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5064","R82","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5065","R82","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5066","R82","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5067","R82","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5068","R82","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5069","R82","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5070","R82","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5071","R82","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5072","R82","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5073","R82","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5074","R82","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5075","R82","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5076","R82","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5077","R82","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5078","R82","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5079","R82","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5080","R82","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5081","R82","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5082","R82","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5083","R82","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5084","R82","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5085","R82","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5086","R82","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5087","R82","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5088","R82","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5089","R82","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5090","R82","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5091","R82","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5092","R84","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5093","R84","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5094","R84","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5095","R84","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5096","R84","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5097","R84","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5098","R84","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5099","R84","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5100","R84","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5101","R84","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5102","R84","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5103","R84","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5104","R84","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5105","R84","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5106","R84","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5107","R84","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5108","R84","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5109","R84","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5110","R84","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5111","R84","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5112","R84","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5113","R84","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5114","R84","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5115","R84","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5116","R84","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5117","R84","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5118","R84","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5119","R84","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5120","R84","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5121","R84","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5122","R84","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5123","R84","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5124","R84","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5125","R84","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5126","R84","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5127","R84","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5128","R84","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5129","R84","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5130","R84","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5131","R84","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5132","R84","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5133","R84","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5134","R84","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5135","R84","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5136","R84","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5137","R84","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5138","R84","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5139","R84","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5140","R84","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5141","R231","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5142","R231","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5143","R231","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5144","R231","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5145","R231","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5146","R231","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5147","R231","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5148","R231","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5149","R231","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5150","R231","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5151","R231","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5152","R231","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5153","R231","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5154","R231","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5155","R231","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5156","R231","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5157","R231","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5158","R231","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5159","R231","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5160","R231","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5161","R231","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5162","R231","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5163","R231","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5164","R231","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5165","R231","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5166","R231","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5167","R231","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5168","R231","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5169","R231","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5170","R231","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5171","R231","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5172","R231","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5173","R231","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5174","R231","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5175","R231","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5176","R231","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5177","R231","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5178","R231","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5179","R231","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5180","R231","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5181","R231","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5182","R231","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5183","R231","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5184","R231","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5185","R231","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5186","R231","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5187","R231","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5188","R231","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5189","R231","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5190","R232","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5191","R232","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5192","R232","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5193","R232","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5194","R232","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5195","R232","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5196","R232","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5197","R232","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5198","R232","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5199","R232","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5200","R232","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5201","R232","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5202","R232","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5203","R232","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5204","R232","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5205","R232","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5206","R232","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5207","R232","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5208","R232","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5209","R232","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5210","R232","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5211","R232","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5212","R232","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5213","R232","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5214","R232","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5215","R232","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5216","R232","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5217","R232","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5218","R232","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5219","R232","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5220","R232","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5221","R232","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5222","R232","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5223","R232","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5224","R232","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5225","R232","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5226","R232","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5227","R232","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5228","R232","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5229","R232","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5230","R232","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5231","R232","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5232","R232","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5233","R232","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5234","R232","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5235","R232","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5236","R232","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5237","R232","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5238","R232","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5239","R233","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5240","R233","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5241","R233","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5242","R233","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5243","R233","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5244","R233","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5245","R233","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5246","R233","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5247","R233","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5248","R233","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5249","R233","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5250","R233","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5251","R233","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5252","R233","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5253","R233","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5254","R233","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5255","R233","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5256","R233","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5257","R233","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5258","R233","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5259","R233","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5260","R233","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5261","R233","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5262","R233","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5263","R233","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5264","R233","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5265","R233","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5266","R233","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5267","R233","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5268","R233","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5269","R233","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5270","R233","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5271","R233","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5272","R233","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5273","R233","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5274","R233","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5275","R233","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5276","R233","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5277","R233","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5278","R233","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5279","R233","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5280","R233","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5281","R233","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5282","R233","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5283","R233","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5284","R233","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5285","R233","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5286","R233","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5287","R233","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5288","R70","CYP2D6","g.4180G>C","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5289","R70","CYP2D6","g.4180G>C","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5290","R70","CYP2D6","g.4180G>C","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5291","R70","CYP2D6","g.4180G>C","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5292","R70","CYP2D6","g.4180G>C","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5293","R70","CYP2D6","g.4180G>C","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5294","R70","CYP2D6","g.4180G>C","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5295","R70","CYP2D6","g.4180G>C","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5296","R70","CYP2D6","g.4180G>C","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5297","R70","CYP2D6","g.4180G>C","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5298","R70","CYP2D6","g.4180G>C","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5299","R70","CYP2D6","g.4180G>C","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5300","R70","CYP2D6","g.4180G>C","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5301","R70","CYP2D6","g.4180G>C","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5302","R70","CYP2D6","g.4180G>C","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5303","R70","CYP2D6","g.4180G>C","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5304","R70","CYP2D6","g.4180G>C","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5305","R70","CYP2D6","g.4180G>C","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5306","R70","CYP2D6","g.4180G>C","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5307","R70","CYP2D6","g.4180G>C","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5308","R70","CYP2D6","g.4180G>C","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5309","R70","CYP2D6","g.4180G>C","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5310","R70","CYP2D6","g.4180G>C","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5311","R70","CYP2D6","g.4180G>C","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5312","R70","CYP2D6","g.4180G>C","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5313","R70","CYP2D6","g.4180G>C","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5314","R70","CYP2D6","g.4180G>C","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5315","R70","CYP2D6","g.4180G>C","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5316","R70","CYP2D6","g.4180G>C","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5317","R70","CYP2D6","g.4180G>C","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5318","R70","CYP2D6","g.4180G>C","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5319","R70","CYP2D6","g.4180G>C","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5320","R70","CYP2D6","g.4180G>C","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5321","R70","CYP2D6","g.4180G>C","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5322","R70","CYP2D6","g.4180G>C","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5323","R70","CYP2D6","g.4180G>C","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5324","R70","CYP2D6","g.4180G>C","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5325","R70","CYP2D6","g.4180G>C","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5326","R70","CYP2D6","g.4180G>C","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5327","R70","CYP2D6","g.4180G>C","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5328","R70","CYP2D6","g.4180G>C","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5329","R70","CYP2D6","g.4180G>C","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5330","R70","CYP2D6","g.4180G>C","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5331","R70","CYP2D6","g.4180G>C","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5332","R70","CYP2D6","g.4180G>C","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5333","R70","CYP2D6","g.4180G>C","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5334","R70","CYP2D6","g.4180G>C","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5335","R70","CYP2D6","g.4180G>C","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5336","R70","CYP2D6","g.4180G>C","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5337","R214","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5338","R214","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5339","R214","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5340","R214","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5341","R214","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5342","R214","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5343","R214","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5344","R214","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5345","R214","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5346","R214","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5347","R214","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5348","R214","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5349","R214","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5350","R214","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5351","R214","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5352","R214","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5353","R214","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5354","R214","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5355","R214","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5356","R214","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5357","R214","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5358","R214","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5359","R214","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5360","R214","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5361","R214","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5362","R214","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5363","R214","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5364","R214","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5365","R214","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5366","R214","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5367","R214","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5368","R214","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5369","R214","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5370","R214","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5371","R214","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5372","R214","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5373","R214","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5374","R214","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5375","R214","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5376","R214","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5377","R214","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5378","R214","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5379","R214","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5380","R214","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5381","R214","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5382","R214","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5383","R214","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5384","R214","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5385","R214","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5386","R66","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5387","R66","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5388","R66","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5389","R66","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5390","R66","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5391","R66","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5392","R66","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5393","R66","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5394","R66","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5395","R66","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5396","R66","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5397","R66","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5398","R66","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5399","R66","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5400","R66","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5401","R66","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5402","R66","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5403","R66","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5404","R66","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5405","R66","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5406","R66","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5407","R66","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5408","R66","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5409","R66","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5410","R66","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5411","R66","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5412","R66","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5413","R66","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5414","R66","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5415","R66","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5416","R66","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5417","R66","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5418","R66","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5419","R66","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5420","R66","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5421","R66","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5422","R66","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5423","R66","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5424","R66","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5425","R66","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5426","R66","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5427","R66","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5428","R66","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5429","R66","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5430","R66","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5431","R66","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5432","R66","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5433","R66","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5434","R66","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5435","r69","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5436","r69","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5437","r69","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5438","r69","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5439","r69","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5440","r69","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5441","r69","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5442","r69","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5443","r69","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5444","r69","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5445","r69","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5446","r69","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5447","r69","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5448","r69","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5449","r69","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5450","r69","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5451","r69","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5452","r69","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5453","r69","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5454","r69","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5455","r69","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5456","r69","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5457","r69","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5458","r69","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5459","r69","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5460","r69","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5461","r69","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5462","r69","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5463","r69","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5464","r69","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5465","r69","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5466","r69","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5467","r69","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5468","r69","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5469","r69","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5470","r69","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5471","r69","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5472","r69","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5473","r69","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5474","r69","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5475","r69","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5476","r69","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5477","r69","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5478","r69","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5479","r69","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5480","r69","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5481","r69","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5482","r69","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5483","r69","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5484","H50","CYP2D6","g.4180G>C","0","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5485","H50","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5486","H50","CYP2D6","g.4180G>C","0","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5487","H50","CYP2D6","g.4180G>C","0","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5488","H50","CYP2D6","g.4180G>C","0","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5489","H50","CYP2D6","g.4180G>C","0","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5490","H50","CYP2D6","g.4180G>C","0","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5491","H50","CYP2D6","g.4180G>C","0","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5492","H50","CYP2D6","g.4180G>C","0","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5493","H50","CYP2D6","g.4180G>C","0","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5494","H50","CYP2D6","g.4180G>C","0","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5495","H50","CYP2D6","g.4180G>C","0","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5496","H50","CYP2D6","g.4180G>C","0","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5497","H50","CYP2D6","g.4180G>C","0","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5498","H50","CYP2D6","g.4180G>C","0","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5499","H50","CYP2D6","g.4180G>C","0","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5500","H50","CYP2D6","g.4180G>C","0","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5501","H50","CYP2D6","g.4180G>C","0","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5502","H50","CYP2D6","g.4180G>C","0","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5503","H50","CYP2D6","g.4180G>C","0","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5504","H50","CYP2D6","g.4180G>C","0","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5505","H50","CYP2D6","g.4180G>C","0","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5506","H50","CYP2D6","g.4180G>C","0","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5507","H50","CYP2D6","g.4180G>C","0","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5508","H50","CYP2D6","g.4180G>C","0","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5509","H50","CYP2D6","g.4180G>C","0","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5510","H50","CYP2D6","g.4180G>C","0","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5511","H50","CYP2D6","g.4180G>C","0","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5512","H50","CYP2D6","g.4180G>C","0","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5513","H50","CYP2D6","g.4180G>C","0","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5514","H50","CYP2D6","g.4180G>C","0","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5515","H50","CYP2D6","g.4180G>C","0","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5516","H50","CYP2D6","g.4180G>C","0","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5517","H50","CYP2D6","g.4180G>C","0","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5518","H50","CYP2D6","g.4180G>C","0","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5519","H50","CYP2D6","g.4180G>C","0","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5520","H50","CYP2D6","g.4180G>C","0","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5521","H50","CYP2D6","g.4180G>C","0","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5522","H50","CYP2D6","g.4180G>C","0","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5523","H50","CYP2D6","g.4180G>C","0","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5524","H50","CYP2D6","g.4180G>C","0","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5525","H50","CYP2D6","g.4180G>C","0","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5526","H50","CYP2D6","g.4180G>C","0","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5527","H50","CYP2D6","g.4180G>C","0","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5528","H50","CYP2D6","g.4180G>C","0","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5529","H50","CYP2D6","g.4180G>C","0","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5530","H50","CYP2D6","g.4180G>C","0","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5531","H50","CYP2D6","g.4180G>C","0","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5532","H50","CYP2D6","g.4180G>C","0","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5533","R75","CYP2D6","g.4180G>C","0","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5534","R75","CYP2D6","g.4180G>C","0","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5535","R75","CYP2D6","g.4180G>C","0","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5536","R75","CYP2D6","g.4180G>C","0","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5537","R75","CYP2D6","g.4180G>C","0","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5538","R75","CYP2D6","g.4180G>C","0","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5539","R75","CYP2D6","g.4180G>C","0","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5540","R75","CYP2D6","g.4180G>C","0","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5541","R75","CYP2D6","g.4180G>C","0","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5542","R75","CYP2D6","g.4180G>C","0","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5543","R75","CYP2D6","g.4180G>C","0","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5544","R75","CYP2D6","g.4180G>C","0","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5545","R75","CYP2D6","g.4180G>C","0","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5546","R75","CYP2D6","g.4180G>C","0","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5547","R75","CYP2D6","g.4180G>C","0","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5548","R75","CYP2D6","g.4180G>C","0","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5549","R75","CYP2D6","g.4180G>C","0","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5550","R75","CYP2D6","g.4180G>C","0","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5551","R75","CYP2D6","g.4180G>C","0","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5552","R75","CYP2D6","g.4180G>C","0","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5553","R75","CYP2D6","g.4180G>C","0","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5554","R75","CYP2D6","g.4180G>C","0","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5555","R75","CYP2D6","g.4180G>C","0","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5556","R75","CYP2D6","g.4180G>C","0","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5557","R75","CYP2D6","g.4180G>C","0","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5558","R75","CYP2D6","g.4180G>C","0","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5559","R75","CYP2D6","g.4180G>C","0","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5560","R75","CYP2D6","g.4180G>C","0","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5561","R75","CYP2D6","g.4180G>C","0","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5562","R75","CYP2D6","g.4180G>C","0","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5563","R75","CYP2D6","g.4180G>C","0","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5564","R75","CYP2D6","g.4180G>C","0","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5565","R75","CYP2D6","g.4180G>C","0","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5566","R75","CYP2D6","g.4180G>C","0","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5567","R75","CYP2D6","g.4180G>C","0","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5568","R75","CYP2D6","g.4180G>C","0","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5569","R75","CYP2D6","g.4180G>C","0","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5570","R75","CYP2D6","g.4180G>C","0","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5571","R75","CYP2D6","g.4180G>C","0","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5572","R75","CYP2D6","g.4180G>C","0","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5573","R75","CYP2D6","g.4180G>C","0","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5574","R75","CYP2D6","g.4180G>C","0","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5575","R75","CYP2D6","g.4180G>C","0","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5576","R75","CYP2D6","g.4180G>C","0","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5577","R75","CYP2D6","g.4180G>C","0","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5578","R75","CYP2D6","g.4180G>C","0","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5579","R75","CYP2D6","g.4180G>C","0","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5580","R75","CYP2D6","g.4180G>C","0","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5581","R75","CYP2D6","g.4180G>C","0","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5582","R212","CYP2B6","*5/*7","c.1459C>T","0",1,"Efavirenz","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily B member 6","chr19"
"5583","R223","CYP2B6","*5/*7","c.1459C>T","0",1,"Efavirenz","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily B member 6","chr19"
"5584","R80","CYP2B6","*5/*7","c.1459C>T","0",1,"Efavirenz","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily B member 6","chr19"
"5585","R231","CYP2B6","*5/*7","c.1459C>T","0",1,"Efavirenz","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily B member 6","chr19"
"5586","R233","CYP2B6","*5/*7","c.1459C>T","0",1,"Efavirenz","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily B member 6","chr19"
"5587","R211","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5588","R211","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5589","R211","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5590","R211","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5591","R211","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5592","R211","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5593","R211","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5594","R211","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5595","R66","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5596","R66","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5597","R66","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5598","R66","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5599","R66","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5600","R66","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5601","R66","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5602","R66","CYP2C9","*3/*18","c.1075A>C","g.42614A>C",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"5603","R217","CYP2D6","*29","g.3183G>A","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5604","R217","CYP2D6","*29","g.3183G>A","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5605","R217","CYP2D6","*29","g.3183G>A","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5606","R217","CYP2D6","*29","g.3183G>A","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5607","R217","CYP2D6","*29","g.3183G>A","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5608","R217","CYP2D6","*29","g.3183G>A","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5609","R217","CYP2D6","*29","g.3183G>A","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5610","R217","CYP2D6","*29","g.3183G>A","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5611","R217","CYP2D6","*29","g.3183G>A","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5612","R217","CYP2D6","*29","g.3183G>A","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5613","R217","CYP2D6","*29","g.3183G>A","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5614","R217","CYP2D6","*29","g.3183G>A","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5615","R217","CYP2D6","*29","g.3183G>A","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5616","R217","CYP2D6","*29","g.3183G>A","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5617","R217","CYP2D6","*29","g.3183G>A","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5618","R217","CYP2D6","*29","g.3183G>A","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5619","R217","CYP2D6","*29","g.3183G>A","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5620","R217","CYP2D6","*29","g.3183G>A","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5621","R217","CYP2D6","*29","g.3183G>A","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5622","R217","CYP2D6","*29","g.3183G>A","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5623","R217","CYP2D6","*29","g.3183G>A","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5624","R217","CYP2D6","*29","g.3183G>A","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5625","R217","CYP2D6","*29","g.3183G>A","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5626","R217","CYP2D6","*29","g.3183G>A","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5627","R217","CYP2D6","*29","g.3183G>A","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5628","R217","CYP2D6","*29","g.3183G>A","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5629","R217","CYP2D6","*29","g.3183G>A","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5630","R217","CYP2D6","*29","g.3183G>A","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5631","R217","CYP2D6","*29","g.3183G>A","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5632","R217","CYP2D6","*29","g.3183G>A","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5633","R217","CYP2D6","*29","g.3183G>A","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5634","R217","CYP2D6","*29","g.3183G>A","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5635","R217","CYP2D6","*29","g.3183G>A","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5636","R217","CYP2D6","*29","g.3183G>A","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5637","R217","CYP2D6","*29","g.3183G>A","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5638","R217","CYP2D6","*29","g.3183G>A","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5639","R217","CYP2D6","*29","g.3183G>A","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5640","R217","CYP2D6","*29","g.3183G>A","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5641","R217","CYP2D6","*29","g.3183G>A","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5642","R217","CYP2D6","*29","g.3183G>A","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5643","R217","CYP2D6","*29","g.3183G>A","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5644","R217","CYP2D6","*29","g.3183G>A","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5645","R217","CYP2D6","*29","g.3183G>A","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5646","R217","CYP2D6","*29","g.3183G>A","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5647","R217","CYP2D6","*29","g.3183G>A","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5648","R217","CYP2D6","*29","g.3183G>A","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5649","R217","CYP2D6","*29","g.3183G>A","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5650","R217","CYP2D6","*29","g.3183G>A","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5651","R217","CYP2D6","*29","g.3183G>A","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5652","R227","CYP2D6","*29","g.3183G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5653","R227","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5654","R227","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5655","R227","CYP2D6","*29","g.3183G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5656","R227","CYP2D6","*29","g.3183G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5657","R227","CYP2D6","*29","g.3183G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5658","R227","CYP2D6","*29","g.3183G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5659","R227","CYP2D6","*29","g.3183G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5660","R227","CYP2D6","*29","g.3183G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5661","R227","CYP2D6","*29","g.3183G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5662","R227","CYP2D6","*29","g.3183G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5663","R227","CYP2D6","*29","g.3183G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5664","R227","CYP2D6","*29","g.3183G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5665","R227","CYP2D6","*29","g.3183G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5666","R227","CYP2D6","*29","g.3183G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5667","R227","CYP2D6","*29","g.3183G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5668","R227","CYP2D6","*29","g.3183G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5669","R227","CYP2D6","*29","g.3183G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5670","R227","CYP2D6","*29","g.3183G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5671","R227","CYP2D6","*29","g.3183G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5672","R227","CYP2D6","*29","g.3183G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5673","R227","CYP2D6","*29","g.3183G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5674","R227","CYP2D6","*29","g.3183G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5675","R227","CYP2D6","*29","g.3183G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5676","R227","CYP2D6","*29","g.3183G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5677","R227","CYP2D6","*29","g.3183G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5678","R227","CYP2D6","*29","g.3183G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5679","R227","CYP2D6","*29","g.3183G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5680","R227","CYP2D6","*29","g.3183G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5681","R227","CYP2D6","*29","g.3183G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5682","R227","CYP2D6","*29","g.3183G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5683","R227","CYP2D6","*29","g.3183G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5684","R227","CYP2D6","*29","g.3183G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5685","R227","CYP2D6","*29","g.3183G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5686","R227","CYP2D6","*29","g.3183G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5687","R227","CYP2D6","*29","g.3183G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5688","R227","CYP2D6","*29","g.3183G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5689","R227","CYP2D6","*29","g.3183G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5690","R227","CYP2D6","*29","g.3183G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5691","R227","CYP2D6","*29","g.3183G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5692","R227","CYP2D6","*29","g.3183G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5693","R227","CYP2D6","*29","g.3183G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5694","R227","CYP2D6","*29","g.3183G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5695","R227","CYP2D6","*29","g.3183G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5696","R227","CYP2D6","*29","g.3183G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5697","R227","CYP2D6","*29","g.3183G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5698","R227","CYP2D6","*29","g.3183G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5699","R227","CYP2D6","*29","g.3183G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5700","R227","CYP2D6","*29","g.3183G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5701","R63","CYP2D6","*29","g.3183G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5702","R63","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5703","R63","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5704","R63","CYP2D6","*29","g.3183G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5705","R63","CYP2D6","*29","g.3183G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5706","R63","CYP2D6","*29","g.3183G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5707","R63","CYP2D6","*29","g.3183G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5708","R63","CYP2D6","*29","g.3183G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5709","R63","CYP2D6","*29","g.3183G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5710","R63","CYP2D6","*29","g.3183G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5711","R63","CYP2D6","*29","g.3183G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5712","R63","CYP2D6","*29","g.3183G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5713","R63","CYP2D6","*29","g.3183G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5714","R63","CYP2D6","*29","g.3183G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5715","R63","CYP2D6","*29","g.3183G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5716","R63","CYP2D6","*29","g.3183G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5717","R63","CYP2D6","*29","g.3183G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5718","R63","CYP2D6","*29","g.3183G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5719","R63","CYP2D6","*29","g.3183G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5720","R63","CYP2D6","*29","g.3183G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5721","R63","CYP2D6","*29","g.3183G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5722","R63","CYP2D6","*29","g.3183G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5723","R63","CYP2D6","*29","g.3183G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5724","R63","CYP2D6","*29","g.3183G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5725","R63","CYP2D6","*29","g.3183G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5726","R63","CYP2D6","*29","g.3183G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5727","R63","CYP2D6","*29","g.3183G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5728","R63","CYP2D6","*29","g.3183G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5729","R63","CYP2D6","*29","g.3183G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5730","R63","CYP2D6","*29","g.3183G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5731","R63","CYP2D6","*29","g.3183G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5732","R63","CYP2D6","*29","g.3183G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5733","R63","CYP2D6","*29","g.3183G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5734","R63","CYP2D6","*29","g.3183G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5735","R63","CYP2D6","*29","g.3183G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5736","R63","CYP2D6","*29","g.3183G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5737","R63","CYP2D6","*29","g.3183G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5738","R63","CYP2D6","*29","g.3183G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5739","R63","CYP2D6","*29","g.3183G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5740","R63","CYP2D6","*29","g.3183G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5741","R63","CYP2D6","*29","g.3183G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5742","R63","CYP2D6","*29","g.3183G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5743","R63","CYP2D6","*29","g.3183G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5744","R63","CYP2D6","*29","g.3183G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5745","R63","CYP2D6","*29","g.3183G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5746","R63","CYP2D6","*29","g.3183G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5747","R63","CYP2D6","*29","g.3183G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5748","R63","CYP2D6","*29","g.3183G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5749","R63","CYP2D6","*29","g.3183G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5750","R64","CYP2D6","*29","g.3183G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5751","R64","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5752","R64","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5753","R64","CYP2D6","*29","g.3183G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5754","R64","CYP2D6","*29","g.3183G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5755","R64","CYP2D6","*29","g.3183G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5756","R64","CYP2D6","*29","g.3183G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5757","R64","CYP2D6","*29","g.3183G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5758","R64","CYP2D6","*29","g.3183G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5759","R64","CYP2D6","*29","g.3183G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5760","R64","CYP2D6","*29","g.3183G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5761","R64","CYP2D6","*29","g.3183G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5762","R64","CYP2D6","*29","g.3183G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5763","R64","CYP2D6","*29","g.3183G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5764","R64","CYP2D6","*29","g.3183G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5765","R64","CYP2D6","*29","g.3183G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5766","R64","CYP2D6","*29","g.3183G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5767","R64","CYP2D6","*29","g.3183G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5768","R64","CYP2D6","*29","g.3183G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5769","R64","CYP2D6","*29","g.3183G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5770","R64","CYP2D6","*29","g.3183G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5771","R64","CYP2D6","*29","g.3183G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5772","R64","CYP2D6","*29","g.3183G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5773","R64","CYP2D6","*29","g.3183G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5774","R64","CYP2D6","*29","g.3183G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5775","R64","CYP2D6","*29","g.3183G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5776","R64","CYP2D6","*29","g.3183G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5777","R64","CYP2D6","*29","g.3183G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5778","R64","CYP2D6","*29","g.3183G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5779","R64","CYP2D6","*29","g.3183G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5780","R64","CYP2D6","*29","g.3183G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5781","R64","CYP2D6","*29","g.3183G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5782","R64","CYP2D6","*29","g.3183G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5783","R64","CYP2D6","*29","g.3183G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5784","R64","CYP2D6","*29","g.3183G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5785","R64","CYP2D6","*29","g.3183G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5786","R64","CYP2D6","*29","g.3183G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5787","R64","CYP2D6","*29","g.3183G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5788","R64","CYP2D6","*29","g.3183G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5789","R64","CYP2D6","*29","g.3183G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5790","R64","CYP2D6","*29","g.3183G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5791","R64","CYP2D6","*29","g.3183G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5792","R64","CYP2D6","*29","g.3183G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5793","R64","CYP2D6","*29","g.3183G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5794","R64","CYP2D6","*29","g.3183G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5795","R64","CYP2D6","*29","g.3183G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5796","R64","CYP2D6","*29","g.3183G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5797","R64","CYP2D6","*29","g.3183G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5798","R64","CYP2D6","*29","g.3183G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5799","R73","CYP2D6","*29","g.3183G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5800","R73","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5801","R73","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5802","R73","CYP2D6","*29","g.3183G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5803","R73","CYP2D6","*29","g.3183G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5804","R73","CYP2D6","*29","g.3183G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5805","R73","CYP2D6","*29","g.3183G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5806","R73","CYP2D6","*29","g.3183G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5807","R73","CYP2D6","*29","g.3183G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5808","R73","CYP2D6","*29","g.3183G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5809","R73","CYP2D6","*29","g.3183G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5810","R73","CYP2D6","*29","g.3183G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5811","R73","CYP2D6","*29","g.3183G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5812","R73","CYP2D6","*29","g.3183G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5813","R73","CYP2D6","*29","g.3183G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5814","R73","CYP2D6","*29","g.3183G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5815","R73","CYP2D6","*29","g.3183G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5816","R73","CYP2D6","*29","g.3183G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5817","R73","CYP2D6","*29","g.3183G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5818","R73","CYP2D6","*29","g.3183G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5819","R73","CYP2D6","*29","g.3183G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5820","R73","CYP2D6","*29","g.3183G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5821","R73","CYP2D6","*29","g.3183G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5822","R73","CYP2D6","*29","g.3183G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5823","R73","CYP2D6","*29","g.3183G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5824","R73","CYP2D6","*29","g.3183G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5825","R73","CYP2D6","*29","g.3183G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5826","R73","CYP2D6","*29","g.3183G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5827","R73","CYP2D6","*29","g.3183G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5828","R73","CYP2D6","*29","g.3183G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5829","R73","CYP2D6","*29","g.3183G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5830","R73","CYP2D6","*29","g.3183G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5831","R73","CYP2D6","*29","g.3183G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5832","R73","CYP2D6","*29","g.3183G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5833","R73","CYP2D6","*29","g.3183G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5834","R73","CYP2D6","*29","g.3183G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5835","R73","CYP2D6","*29","g.3183G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5836","R73","CYP2D6","*29","g.3183G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5837","R73","CYP2D6","*29","g.3183G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5838","R73","CYP2D6","*29","g.3183G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5839","R73","CYP2D6","*29","g.3183G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5840","R73","CYP2D6","*29","g.3183G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5841","R73","CYP2D6","*29","g.3183G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5842","R73","CYP2D6","*29","g.3183G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5843","R73","CYP2D6","*29","g.3183G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5844","R73","CYP2D6","*29","g.3183G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5845","R73","CYP2D6","*29","g.3183G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5846","R73","CYP2D6","*29","g.3183G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5847","R73","CYP2D6","*29","g.3183G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5848","V151","CYP2D6","*29","g.3183G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5849","V151","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5850","V151","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5851","V151","CYP2D6","*29","g.3183G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5852","V151","CYP2D6","*29","g.3183G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5853","V151","CYP2D6","*29","g.3183G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5854","V151","CYP2D6","*29","g.3183G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5855","V151","CYP2D6","*29","g.3183G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5856","V151","CYP2D6","*29","g.3183G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5857","V151","CYP2D6","*29","g.3183G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5858","V151","CYP2D6","*29","g.3183G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5859","V151","CYP2D6","*29","g.3183G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5860","V151","CYP2D6","*29","g.3183G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5861","V151","CYP2D6","*29","g.3183G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5862","V151","CYP2D6","*29","g.3183G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5863","V151","CYP2D6","*29","g.3183G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5864","V151","CYP2D6","*29","g.3183G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5865","V151","CYP2D6","*29","g.3183G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5866","V151","CYP2D6","*29","g.3183G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5867","V151","CYP2D6","*29","g.3183G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5868","V151","CYP2D6","*29","g.3183G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5869","V151","CYP2D6","*29","g.3183G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5870","V151","CYP2D6","*29","g.3183G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5871","V151","CYP2D6","*29","g.3183G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5872","V151","CYP2D6","*29","g.3183G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5873","V151","CYP2D6","*29","g.3183G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5874","V151","CYP2D6","*29","g.3183G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5875","V151","CYP2D6","*29","g.3183G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5876","V151","CYP2D6","*29","g.3183G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5877","V151","CYP2D6","*29","g.3183G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5878","V151","CYP2D6","*29","g.3183G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5879","V151","CYP2D6","*29","g.3183G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5880","V151","CYP2D6","*29","g.3183G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5881","V151","CYP2D6","*29","g.3183G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5882","V151","CYP2D6","*29","g.3183G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5883","V151","CYP2D6","*29","g.3183G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5884","V151","CYP2D6","*29","g.3183G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5885","V151","CYP2D6","*29","g.3183G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5886","V151","CYP2D6","*29","g.3183G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5887","V151","CYP2D6","*29","g.3183G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5888","V151","CYP2D6","*29","g.3183G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5889","V151","CYP2D6","*29","g.3183G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5890","V151","CYP2D6","*29","g.3183G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5891","V151","CYP2D6","*29","g.3183G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5892","V151","CYP2D6","*29","g.3183G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5893","V151","CYP2D6","*29","g.3183G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5894","V151","CYP2D6","*29","g.3183G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5895","V151","CYP2D6","*29","g.3183G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5896","V151","CYP2D6","*29","g.3183G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5897","V154","CYP2D6","*29","g.3183G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5898","V154","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5899","V154","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5900","V154","CYP2D6","*29","g.3183G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5901","V154","CYP2D6","*29","g.3183G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5902","V154","CYP2D6","*29","g.3183G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5903","V154","CYP2D6","*29","g.3183G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5904","V154","CYP2D6","*29","g.3183G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5905","V154","CYP2D6","*29","g.3183G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5906","V154","CYP2D6","*29","g.3183G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5907","V154","CYP2D6","*29","g.3183G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5908","V154","CYP2D6","*29","g.3183G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5909","V154","CYP2D6","*29","g.3183G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5910","V154","CYP2D6","*29","g.3183G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5911","V154","CYP2D6","*29","g.3183G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5912","V154","CYP2D6","*29","g.3183G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5913","V154","CYP2D6","*29","g.3183G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5914","V154","CYP2D6","*29","g.3183G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5915","V154","CYP2D6","*29","g.3183G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5916","V154","CYP2D6","*29","g.3183G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5917","V154","CYP2D6","*29","g.3183G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5918","V154","CYP2D6","*29","g.3183G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5919","V154","CYP2D6","*29","g.3183G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5920","V154","CYP2D6","*29","g.3183G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5921","V154","CYP2D6","*29","g.3183G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5922","V154","CYP2D6","*29","g.3183G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5923","V154","CYP2D6","*29","g.3183G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5924","V154","CYP2D6","*29","g.3183G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5925","V154","CYP2D6","*29","g.3183G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5926","V154","CYP2D6","*29","g.3183G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5927","V154","CYP2D6","*29","g.3183G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5928","V154","CYP2D6","*29","g.3183G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5929","V154","CYP2D6","*29","g.3183G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5930","V154","CYP2D6","*29","g.3183G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5931","V154","CYP2D6","*29","g.3183G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5932","V154","CYP2D6","*29","g.3183G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5933","V154","CYP2D6","*29","g.3183G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5934","V154","CYP2D6","*29","g.3183G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5935","V154","CYP2D6","*29","g.3183G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5936","V154","CYP2D6","*29","g.3183G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5937","V154","CYP2D6","*29","g.3183G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5938","V154","CYP2D6","*29","g.3183G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5939","V154","CYP2D6","*29","g.3183G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5940","V154","CYP2D6","*29","g.3183G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5941","V154","CYP2D6","*29","g.3183G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5942","V154","CYP2D6","*29","g.3183G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5943","V154","CYP2D6","*29","g.3183G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5944","V154","CYP2D6","*29","g.3183G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5945","V154","CYP2D6","*29","g.3183G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5946","R65","CYP2D6","*29","g.3183G>A","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5947","R65","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5948","R65","CYP2D6","*29","g.3183G>A","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5949","R65","CYP2D6","*29","g.3183G>A","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5950","R65","CYP2D6","*29","g.3183G>A","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5951","R65","CYP2D6","*29","g.3183G>A","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5952","R65","CYP2D6","*29","g.3183G>A","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5953","R65","CYP2D6","*29","g.3183G>A","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5954","R65","CYP2D6","*29","g.3183G>A","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5955","R65","CYP2D6","*29","g.3183G>A","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5956","R65","CYP2D6","*29","g.3183G>A","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5957","R65","CYP2D6","*29","g.3183G>A","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5958","R65","CYP2D6","*29","g.3183G>A","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5959","R65","CYP2D6","*29","g.3183G>A","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5960","R65","CYP2D6","*29","g.3183G>A","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5961","R65","CYP2D6","*29","g.3183G>A","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5962","R65","CYP2D6","*29","g.3183G>A","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5963","R65","CYP2D6","*29","g.3183G>A","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5964","R65","CYP2D6","*29","g.3183G>A","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5965","R65","CYP2D6","*29","g.3183G>A","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5966","R65","CYP2D6","*29","g.3183G>A","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5967","R65","CYP2D6","*29","g.3183G>A","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5968","R65","CYP2D6","*29","g.3183G>A","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5969","R65","CYP2D6","*29","g.3183G>A","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5970","R65","CYP2D6","*29","g.3183G>A","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5971","R65","CYP2D6","*29","g.3183G>A","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5972","R65","CYP2D6","*29","g.3183G>A","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"5973","R65","CYP2D6","*29","g.3183G>A","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5974","R65","CYP2D6","*29","g.3183G>A","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5975","R65","CYP2D6","*29","g.3183G>A","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5976","R65","CYP2D6","*29","g.3183G>A","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5977","R65","CYP2D6","*29","g.3183G>A","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5978","R65","CYP2D6","*29","g.3183G>A","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5979","R65","CYP2D6","*29","g.3183G>A","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5980","R65","CYP2D6","*29","g.3183G>A","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5981","R65","CYP2D6","*29","g.3183G>A","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5982","R65","CYP2D6","*29","g.3183G>A","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5983","R65","CYP2D6","*29","g.3183G>A","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5984","R65","CYP2D6","*29","g.3183G>A","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5985","R65","CYP2D6","*29","g.3183G>A","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5986","R65","CYP2D6","*29","g.3183G>A","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5987","R65","CYP2D6","*29","g.3183G>A","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5988","R65","CYP2D6","*29","g.3183G>A","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5989","R65","CYP2D6","*29","g.3183G>A","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5990","R65","CYP2D6","*29","g.3183G>A","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5991","R65","CYP2D6","*29","g.3183G>A","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5992","R65","CYP2D6","*29","g.3183G>A","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5993","R65","CYP2D6","*29","g.3183G>A","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5994","R65","CYP2D6","*29","g.3183G>A","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5995","H47","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5996","H47","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5997","H47","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5998","H47","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"5999","H47","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6000","H47","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6001","H47","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6002","H47","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6003","H47","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6004","H47","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6005","H47","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6006","H47","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6007","H47","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6008","H47","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6009","H47","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6010","H47","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6011","H47","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6012","H47","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6013","H47","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6014","H47","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6015","H47","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6016","H47","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6017","H47","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6018","H47","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6019","H47","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6020","H47","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6021","H47","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6022","H47","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6023","H47","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6024","H47","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6025","H47","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6026","H47","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6027","H47","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6028","H47","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6029","H47","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6030","H47","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6031","H47","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6032","H47","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6033","H47","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6034","H47","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6035","H47","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6036","H47","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6037","H47","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6038","H47","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6039","H47","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6040","H47","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6041","H47","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6042","H47","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6043","H47","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6044","H48","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6045","H48","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6046","H48","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6047","H48","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6048","H48","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6049","H48","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6050","H48","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6051","H48","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6052","H48","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6053","H48","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6054","H48","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6055","H48","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6056","H48","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6057","H48","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6058","H48","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6059","H48","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6060","H48","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6061","H48","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6062","H48","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6063","H48","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6064","H48","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6065","H48","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6066","H48","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6067","H48","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6068","H48","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6069","H48","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6070","H48","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6071","H48","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6072","H48","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6073","H48","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6074","H48","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6075","H48","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6076","H48","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6077","H48","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6078","H48","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6079","H48","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6080","H48","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6081","H48","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6082","H48","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6083","H48","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6084","H48","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6085","H48","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6086","H48","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6087","H48","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6088","H48","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6089","H48","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6090","H48","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6091","H48","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6092","H48","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6093","H49","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6094","H49","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6095","H49","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6096","H49","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6097","H49","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6098","H49","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6099","H49","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6100","H49","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6101","H49","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6102","H49","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6103","H49","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6104","H49","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6105","H49","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6106","H49","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6107","H49","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6108","H49","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6109","H49","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6110","H49","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6111","H49","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6112","H49","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6113","H49","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6114","H49","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6115","H49","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6116","H49","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6117","H49","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6118","H49","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6119","H49","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6120","H49","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6121","H49","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6122","H49","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6123","H49","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6124","H49","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6125","H49","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6126","H49","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6127","H49","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6128","H49","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6129","H49","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6130","H49","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6131","H49","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6132","H49","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6133","H49","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6134","H49","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6135","H49","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6136","H49","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6137","H49","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6138","H49","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6139","H49","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6140","H49","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6141","H49","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6142","R210","CYP2D6","*17","g.1023C>T","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6143","R210","CYP2D6","*17","g.1023C>T","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6144","R210","CYP2D6","*17","g.1023C>T","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6145","R210","CYP2D6","*17","g.1023C>T","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6146","R210","CYP2D6","*17","g.1023C>T","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6147","R210","CYP2D6","*17","g.1023C>T","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6148","R210","CYP2D6","*17","g.1023C>T","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6149","R210","CYP2D6","*17","g.1023C>T","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6150","R210","CYP2D6","*17","g.1023C>T","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6151","R210","CYP2D6","*17","g.1023C>T","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6152","R210","CYP2D6","*17","g.1023C>T","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6153","R210","CYP2D6","*17","g.1023C>T","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6154","R210","CYP2D6","*17","g.1023C>T","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6155","R210","CYP2D6","*17","g.1023C>T","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6156","R210","CYP2D6","*17","g.1023C>T","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6157","R210","CYP2D6","*17","g.1023C>T","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6158","R210","CYP2D6","*17","g.1023C>T","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6159","R210","CYP2D6","*17","g.1023C>T","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6160","R210","CYP2D6","*17","g.1023C>T","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6161","R210","CYP2D6","*17","g.1023C>T","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6162","R210","CYP2D6","*17","g.1023C>T","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6163","R210","CYP2D6","*17","g.1023C>T","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6164","R210","CYP2D6","*17","g.1023C>T","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6165","R210","CYP2D6","*17","g.1023C>T","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6166","R210","CYP2D6","*17","g.1023C>T","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6167","R210","CYP2D6","*17","g.1023C>T","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6168","R210","CYP2D6","*17","g.1023C>T","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6169","R210","CYP2D6","*17","g.1023C>T","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6170","R210","CYP2D6","*17","g.1023C>T","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6171","R210","CYP2D6","*17","g.1023C>T","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6172","R210","CYP2D6","*17","g.1023C>T","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6173","R210","CYP2D6","*17","g.1023C>T","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6174","R210","CYP2D6","*17","g.1023C>T","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6175","R210","CYP2D6","*17","g.1023C>T","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6176","R210","CYP2D6","*17","g.1023C>T","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6177","R210","CYP2D6","*17","g.1023C>T","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6178","R210","CYP2D6","*17","g.1023C>T","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6179","R210","CYP2D6","*17","g.1023C>T","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6180","R210","CYP2D6","*17","g.1023C>T","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6181","R210","CYP2D6","*17","g.1023C>T","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6182","R210","CYP2D6","*17","g.1023C>T","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6183","R210","CYP2D6","*17","g.1023C>T","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6184","R210","CYP2D6","*17","g.1023C>T","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6185","R210","CYP2D6","*17","g.1023C>T","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6186","R210","CYP2D6","*17","g.1023C>T","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6187","R210","CYP2D6","*17","g.1023C>T","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6188","R210","CYP2D6","*17","g.1023C>T","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6189","R210","CYP2D6","*17","g.1023C>T","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6190","R210","CYP2D6","*17","g.1023C>T","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6191","R215","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6192","R215","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6193","R215","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6194","R215","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6195","R215","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6196","R215","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6197","R215","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6198","R215","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6199","R215","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6200","R215","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6201","R215","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6202","R215","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6203","R215","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6204","R215","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6205","R215","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6206","R215","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6207","R215","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6208","R215","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6209","R215","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6210","R215","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6211","R215","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6212","R215","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6213","R215","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6214","R215","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6215","R215","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6216","R215","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6217","R215","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6218","R215","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6219","R215","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6220","R215","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6221","R215","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6222","R215","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6223","R215","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6224","R215","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6225","R215","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6226","R215","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6227","R215","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6228","R215","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6229","R215","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6230","R215","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6231","R215","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6232","R215","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6233","R215","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6234","R215","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6235","R215","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6236","R215","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6237","R215","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6238","R215","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6239","R215","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6240","R222","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6241","R222","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6242","R222","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6243","R222","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6244","R222","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6245","R222","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6246","R222","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6247","R222","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6248","R222","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6249","R222","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6250","R222","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6251","R222","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6252","R222","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6253","R222","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6254","R222","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6255","R222","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6256","R222","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6257","R222","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6258","R222","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6259","R222","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6260","R222","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6261","R222","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6262","R222","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6263","R222","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6264","R222","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6265","R222","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6266","R222","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6267","R222","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6268","R222","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6269","R222","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6270","R222","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6271","R222","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6272","R222","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6273","R222","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6274","R222","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6275","R222","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6276","R222","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6277","R222","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6278","R222","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6279","R222","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6280","R222","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6281","R222","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6282","R222","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6283","R222","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6284","R222","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6285","R222","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6286","R222","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6287","R222","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6288","R222","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6289","R223","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6290","R223","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6291","R223","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6292","R223","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6293","R223","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6294","R223","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6295","R223","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6296","R223","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6297","R223","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6298","R223","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6299","R223","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6300","R223","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6301","R223","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6302","R223","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6303","R223","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6304","R223","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6305","R223","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6306","R223","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6307","R223","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6308","R223","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6309","R223","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6310","R223","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6311","R223","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6312","R223","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6313","R223","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6314","R223","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6315","R223","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6316","R223","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6317","R223","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6318","R223","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6319","R223","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6320","R223","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6321","R223","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6322","R223","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6323","R223","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6324","R223","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6325","R223","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6326","R223","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6327","R223","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6328","R223","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6329","R223","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6330","R223","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6331","R223","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6332","R223","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6333","R223","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6334","R223","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6335","R223","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6336","R223","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6337","R223","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6338","R57","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6339","R57","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6340","R57","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6341","R57","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6342","R57","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6343","R57","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6344","R57","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6345","R57","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6346","R57","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6347","R57","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6348","R57","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6349","R57","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6350","R57","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6351","R57","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6352","R57","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6353","R57","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6354","R57","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6355","R57","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6356","R57","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6357","R57","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6358","R57","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6359","R57","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6360","R57","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6361","R57","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6362","R57","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6363","R57","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6364","R57","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6365","R57","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6366","R57","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6367","R57","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6368","R57","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6369","R57","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6370","R57","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6371","R57","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6372","R57","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6373","R57","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6374","R57","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6375","R57","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6376","R57","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6377","R57","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6378","R57","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6379","R57","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6380","R57","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6381","R57","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6382","R57","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6383","R57","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6384","R57","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6385","R57","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6386","R57","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6387","R64","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6388","R64","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6389","R64","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6390","R64","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6391","R64","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6392","R64","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6393","R64","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6394","R64","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6395","R64","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6396","R64","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6397","R64","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6398","R64","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6399","R64","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6400","R64","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6401","R64","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6402","R64","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6403","R64","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6404","R64","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6405","R64","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6406","R64","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6407","R64","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6408","R64","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6409","R64","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6410","R64","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6411","R64","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6412","R64","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6413","R64","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6414","R64","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6415","R64","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6416","R64","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6417","R64","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6418","R64","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6419","R64","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6420","R64","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6421","R64","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6422","R64","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6423","R64","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6424","R64","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6425","R64","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6426","R64","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6427","R64","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6428","R64","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6429","R64","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6430","R64","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6431","R64","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6432","R64","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6433","R64","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6434","R64","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6435","R64","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6436","R72","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6437","R72","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6438","R72","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6439","R72","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6440","R72","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6441","R72","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6442","R72","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6443","R72","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6444","R72","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6445","R72","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6446","R72","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6447","R72","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6448","R72","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6449","R72","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6450","R72","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6451","R72","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6452","R72","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6453","R72","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6454","R72","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6455","R72","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6456","R72","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6457","R72","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6458","R72","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6459","R72","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6460","R72","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6461","R72","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6462","R72","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6463","R72","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6464","R72","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6465","R72","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6466","R72","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6467","R72","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6468","R72","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6469","R72","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6470","R72","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6471","R72","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6472","R72","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6473","R72","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6474","R72","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6475","R72","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6476","R72","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6477","R72","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6478","R72","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6479","R72","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6480","R72","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6481","R72","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6482","R72","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6483","R72","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6484","R72","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6485","R84","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6486","R84","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6487","R84","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6488","R84","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6489","R84","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6490","R84","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6491","R84","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6492","R84","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6493","R84","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6494","R84","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6495","R84","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6496","R84","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6497","R84","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6498","R84","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6499","R84","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6500","R84","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6501","R84","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6502","R84","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6503","R84","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6504","R84","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6505","R84","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6506","R84","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6507","R84","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6508","R84","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6509","R84","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6510","R84","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6511","R84","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6512","R84","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6513","R84","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6514","R84","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6515","R84","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6516","R84","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6517","R84","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6518","R84","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6519","R84","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6520","R84","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6521","R84","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6522","R84","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6523","R84","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6524","R84","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6525","R84","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6526","R84","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6527","R84","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6528","R84","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6529","R84","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6530","R84","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6531","R84","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6532","R84","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6533","R84","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6534","R86","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6535","R86","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6536","R86","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6537","R86","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6538","R86","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6539","R86","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6540","R86","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6541","R86","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6542","R86","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6543","R86","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6544","R86","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6545","R86","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6546","R86","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6547","R86","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6548","R86","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6549","R86","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6550","R86","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6551","R86","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6552","R86","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6553","R86","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6554","R86","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6555","R86","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6556","R86","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6557","R86","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6558","R86","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6559","R86","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6560","R86","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6561","R86","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6562","R86","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6563","R86","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6564","R86","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6565","R86","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6566","R86","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6567","R86","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6568","R86","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6569","R86","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6570","R86","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6571","R86","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6572","R86","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6573","R86","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6574","R86","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6575","R86","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6576","R86","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6577","R86","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6578","R86","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6579","R86","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6580","R86","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6581","R86","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6582","R86","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6583","V153","CYP2D6","*17","g.1023C>T","0",1,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6584","V153","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6585","V153","CYP2D6","*17","g.1023C>T","0",1,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6586","V153","CYP2D6","*17","g.1023C>T","0",1,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6587","V153","CYP2D6","*17","g.1023C>T","0",1,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6588","V153","CYP2D6","*17","g.1023C>T","0",1,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6589","V153","CYP2D6","*17","g.1023C>T","0",1,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6590","V153","CYP2D6","*17","g.1023C>T","0",1,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6591","V153","CYP2D6","*17","g.1023C>T","0",1,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6592","V153","CYP2D6","*17","g.1023C>T","0",1,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6593","V153","CYP2D6","*17","g.1023C>T","0",1,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6594","V153","CYP2D6","*17","g.1023C>T","0",1,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6595","V153","CYP2D6","*17","g.1023C>T","0",1,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6596","V153","CYP2D6","*17","g.1023C>T","0",1,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6597","V153","CYP2D6","*17","g.1023C>T","0",1,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6598","V153","CYP2D6","*17","g.1023C>T","0",1,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6599","V153","CYP2D6","*17","g.1023C>T","0",1,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6600","V153","CYP2D6","*17","g.1023C>T","0",1,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6601","V153","CYP2D6","*17","g.1023C>T","0",1,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6602","V153","CYP2D6","*17","g.1023C>T","0",1,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6603","V153","CYP2D6","*17","g.1023C>T","0",1,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6604","V153","CYP2D6","*17","g.1023C>T","0",1,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6605","V153","CYP2D6","*17","g.1023C>T","0",1,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6606","V153","CYP2D6","*17","g.1023C>T","0",1,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6607","V153","CYP2D6","*17","g.1023C>T","0",1,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6608","V153","CYP2D6","*17","g.1023C>T","0",1,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6609","V153","CYP2D6","*17","g.1023C>T","0",1,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6610","V153","CYP2D6","*17","g.1023C>T","0",1,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6611","V153","CYP2D6","*17","g.1023C>T","0",1,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6612","V153","CYP2D6","*17","g.1023C>T","0",1,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6613","V153","CYP2D6","*17","g.1023C>T","0",1,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6614","V153","CYP2D6","*17","g.1023C>T","0",1,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6615","V153","CYP2D6","*17","g.1023C>T","0",1,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6616","V153","CYP2D6","*17","g.1023C>T","0",1,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6617","V153","CYP2D6","*17","g.1023C>T","0",1,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6618","V153","CYP2D6","*17","g.1023C>T","0",1,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6619","V153","CYP2D6","*17","g.1023C>T","0",1,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6620","V153","CYP2D6","*17","g.1023C>T","0",1,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6621","V153","CYP2D6","*17","g.1023C>T","0",1,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6622","V153","CYP2D6","*17","g.1023C>T","0",1,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6623","V153","CYP2D6","*17","g.1023C>T","0",1,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6624","V153","CYP2D6","*17","g.1023C>T","0",1,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6625","V153","CYP2D6","*17","g.1023C>T","0",1,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6626","V153","CYP2D6","*17","g.1023C>T","0",1,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6627","V153","CYP2D6","*17","g.1023C>T","0",1,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6628","V153","CYP2D6","*17","g.1023C>T","0",1,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6629","V153","CYP2D6","*17","g.1023C>T","0",1,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6630","V153","CYP2D6","*17","g.1023C>T","0",1,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6631","V153","CYP2D6","*17","g.1023C>T","0",1,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6632","R216","CYP2D6","*17","g.1023C>T","0",2,"Amphetamine","poor metabolizers","May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6633","R216","CYP2D6","*17","g.1023C>T","0",2,"Aripiprazole","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6634","R216","CYP2D6","*17","g.1023C>T","0",2,"Aripiprazole Lauroxil","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6635","R216","CYP2D6","*17","g.1023C>T","0",2,"Atomoxetine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6636","R216","CYP2D6","*17","g.1023C>T","0",2,"Brexpiprazole","poor metabolizers","Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6637","R216","CYP2D6","*17","g.1023C>T","0",2,"Clozapine","poor metabolizers","Results in higher systemic concentrations. Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6638","R216","CYP2D6","*17","g.1023C>T","0",2,"Codeine","ultrarapid metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6639","R216","CYP2D6","*17","g.1023C>T","0",2,"Deutetrabenazine","poor metabolizers","Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6640","R216","CYP2D6","*17","g.1023C>T","0",2,"Eliglustat","ultrarapid, normal, intermediate, or poor metabolizers","Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6641","R216","CYP2D6","*17","g.1023C>T","0",2,"Gefitinib","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6642","R216","CYP2D6","*17","g.1023C>T","0",2,"Iloperidone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6643","R216","CYP2D6","*17","g.1023C>T","0",2,"Lofexidine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6644","R216","CYP2D6","*17","g.1023C>T","0",2,"Meclizine","ultrarapid, intermediate, or poor metabolizers","May affect systemic concentrations. Monitor for adverse reactions and clinical effect.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6645","R216","CYP2D6","*17","g.1023C>T","0",2,"Metoclopramide","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6646","R216","CYP2D6","*17","g.1023C>T","0",2,"Pimozide","poor metabolizers","Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6647","R216","CYP2D6","*17","g.1023C>T","0",2,"Propafenone","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6648","R216","CYP2D6","*17","g.1023C>T","0",2,"Tetrabenazine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6649","R216","CYP2D6","*17","g.1023C>T","0",2,"Thioridazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6650","R216","CYP2D6","*17","g.1023C>T","0",2,"Tramadol","Ultrarapid metabolizers3","Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6651","R216","CYP2D6","*17","g.1023C>T","0",2,"Valbenazine","poor metabolizers","Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6652","R216","CYP2D6","*17","g.1023C>T","0",2,"Venlafaxine","poor metabolizers","Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6653","R216","CYP2D6","*17","g.1023C>T","0",2,"Vortioxetine","poor metabolizers","Results in higher systemic concentrations. The maximum recommended dose is 10 mg.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6654","R216","CYP2D6","*17","g.1023C>T","0",2,"Carvedilol","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (dizziness).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6655","R216","CYP2D6","*17","g.1023C>T","0",2,"Cevimeline","poor metabolizers","May result in higher adverse reaction risk. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6656","R216","CYP2D6","*17","g.1023C>T","0",2,"Codeine","poor metabolizers","Results in lower systemic active metabolite concentrations and may result in reduced efficacy.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6657","R216","CYP2D6","*17","g.1023C>T","0",2,"Perphenazine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6658","R216","CYP2D6","*17","g.1023C>T","0",2,"Tolterodine","poor metabolizers","Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).","cytochrome P450 family 2 subfamily D member 6","chr22"
"6659","R216","CYP2D6","*17","g.1023C>T","0",2,"Amitriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6660","R216","CYP2D6","*17","g.1023C>T","0",2,"Amoxapine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6661","R216","CYP2D6","*17","g.1023C>T","0",2,"Clomipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6662","R216","CYP2D6","*17","g.1023C>T","0",2,"Darifenacin","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6663","R216","CYP2D6","*17","g.1023C>T","0",2,"Desipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6664","R216","CYP2D6","*17","g.1023C>T","0",2,"Donepezil","ultrarapid or poor metabolizers","Alters systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6665","R216","CYP2D6","*17","g.1023C>T","0",2,"Doxepin","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6666","R216","CYP2D6","*17","g.1023C>T","0",2,"Fesoterodine","poor metabolizers","Results in higher systemic active metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6667","R216","CYP2D6","*17","g.1023C>T","0",2,"Fluvoxamine","poor metabolizers","Results in higher systemic concentrations. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6668","R216","CYP2D6","*17","g.1023C>T","0",2,"Galantamine","poor metabolizers","Results in higher systemic concentrations. Titrate dosage based on tolerability.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6669","R216","CYP2D6","*17","g.1023C>T","0",2,"Imipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6670","R216","CYP2D6","*17","g.1023C>T","0",2,"Metoprolol","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6671","R216","CYP2D6","*17","g.1023C>T","0",2,"Mirabegron","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6672","R216","CYP2D6","*17","g.1023C>T","0",2,"Nebivolol","poor metabolizers","May result in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6673","R216","CYP2D6","*17","g.1023C>T","0",2,"Nortriptyline","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6674","R216","CYP2D6","*17","g.1023C>T","0",2,"Paroxetine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6675","R216","CYP2D6","*17","g.1023C>T","0",2,"Propranolol","poor metabolizers","May affect systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6676","R216","CYP2D6","*17","g.1023C>T","0",2,"Protriptyline","poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6677","R216","CYP2D6","*17","g.1023C>T","0",2,"Risperidone","poor metabolizers","Alters systemic parent drug and metabolite concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6678","R216","CYP2D6","*17","g.1023C>T","0",2,"Tamoxifen","intermediate or poor metabolizers","Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6679","R216","CYP2D6","*17","g.1023C>T","0",2,"Tamsulosin","poor metabolizers","Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6680","R216","CYP2D6","*17","g.1023C>T","0",2,"Trimipramine","ultrarapid, intermediate, or poor metabolizers","May alter systemic concentrations.","cytochrome P450 family 2 subfamily D member 6","chr22"
"6681","R70","CYP3A4","*3","c.1334T>C","0",2,"0","0","0","cytochrome P450 family 3 subfamily A member 4","chr7"
"6682","H47","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6683","H47","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6684","H47","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6685","H47","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6686","H47","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6687","H47","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6688","H47","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6689","H47","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6690","R71","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6691","R71","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6692","R71","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6693","R71","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6694","R71","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6695","R71","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6696","R71","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6697","R71","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6698","R82","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6699","R82","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6700","R82","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6701","R82","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6702","R82","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6703","R82","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6704","R82","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6705","R82","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6706","V152","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6707","V152","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6708","V152","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6709","V152","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6710","V152","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6711","V152","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6712","V152","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6713","V152","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6714","R233","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6715","R233","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6716","R233","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6717","R233","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6718","R233","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6719","R233","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6720","R233","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6721","R233","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6722","R214","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Celecoxib","poor metabolizers","Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6723","R214","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Dronabinol","intermediate or poor metabolizers","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6724","R214","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Erdafitinib","*3/*3 (poor metabolizers)","May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6725","R214","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Flurbiprofen","poor metabolizers","Results in higher systemic concentrations. Use a reduced dosage.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6726","R214","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Piroxicam","intermediate or poor metabolizers","Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6727","R214","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Siponimod","intermediate or poor metabolizers","Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6728","R214","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Warfarin","intermediate or poor metabolizers","Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.","cytochrome P450 family 2 subfamily C member 9","chr10"
"6729","R214","CYP2C9","*2","c.430C>T",".g.3608C>T",1,"Avatrombopag","intermediate or poor metabolizers","Results in higher systemic concentrations.","cytochrome P450 family 2 subfamily C member 9","chr10"
